{"timestamp": "2026-01-19T08:07:06.808115", "question": "{\"CASE_CORE\":{\"ADJUVANT_TREATMENT\":{\"cycles_or_courses\":\"6 cycles\",\"given\":\"Yes\",\"regimens\":[\"白紫+卡铂\"]},\"BIOMARKERS\":{\"AFP\":\"<0.91 ng/ml (2022-10-12)\",\"CA125\":\"933.00 U/ml (2022-12-29)\",\"HER2\":\"Unknown\",\"MSI\":\"Unknown\",\"PDL1_CPS\":\"Unknown\",\"TMB\":\"Unknown\"},\"BRCA1\":\"Unknown\",\"BRCA2\":\"Unknown\",\"CURRENT_STATUS\":\"Recurrent ovarian carcinoma with hepatic and pelvic metastatic disease\",\"DIAGNOSIS\":{\"components\":[\"高级别腺癌\"],\"histology\":\"首先考虑为透明细胞癌\",\"laterality\":\"Unknown\",\"primary\":\"卵巢癌复发\",\"site\":\"卵巢\"},\"HRD\":\"Unknown\",\"INITIAL_TREATMENT\":\"Yes\",\"LINE_OF_THERAPY\":[{\"cycles\":\"6\",\"end_date\":\"2022-08-17\",\"intent\":\"Adjuvant\",\"line\":\"1L\",\"regimen\":\"白紫+卡铂\",\"start_date\":\"Unknown\"}],\"MAINTENANCE\":\"Unknown\",\"MAINTENANCE_DETAIL\":{\"end_date\":\"Unknown\",\"given\":\"Unknown\",\"regimens\":[],\"start_date\":\"Unknown\"},\"NEOADJUVANT\":\"Unknown\",\"PFI_days\":\"56\",\"PLATINUM_HISTORY\":[{\"PFI_days\":\"56\",\"end_date\":\"2022-08-17\",\"evidence\":\"CA125:89.60U/ml (2022-10-12)\",\"evidence_type\":\"Biochemical\",\"first_relapse_date\":\"2022-10-12\",\"line\":\"1L\",\"start_date\":\"Unknown\",\"status\":\"Resistant\"}],\"PLATINUM_PFI_CURRENT\":\"56\",\"PLATINUM_STATUS\":\"Resistant\",\"PLATINUM_STATUS_CURRENT\":\"Resistant\",\"RELAPSE\":\"Yes\",\"RELAPSE_DATE\":{\"date\":\"2022-10-12\",\"evidence\":\"CA125:89.60U/ml\",\"type\":\"Biochemical\"},\"SCENE\":\"Platinum_resistant_relapse\",\"STAGE\":{\"stage_basis\":\"Unknown\",\"stage_system\":\"Unknown\",\"stage_text\":\"Unknown\"},\"SURGERY_DONE\":{\"date\":\"2022-03-28\",\"performed\":\"Yes\",\"procedure\":\"Debulking surgery + partial rectosigmoid resection + partial vaginectomy + retroperitoneal lesion resection + complex adhesiolysis + left ureteral stent placement + bladder repair\"},\"TIMELINE\":{\"constraints\":{\"max_events\":30,\"min_events\":3,\"must_include\":[\"first diagnostic imaging or pathology confirmation (if available)\"],\"ordering_rules\":{\"prioritize_last_event\":true}},\"events\":[{\"date\":\"2022-03-28\",\"description\":\"Debulking surgery with multiple procedures (partial rectosigmoid resection, partial vaginectomy, retroperitoneal lesion resection, left ureteral stent, bladder repair)\",\"event_type\":\"Surgery\",\"key_result\":\"Tumor ~7*4*2.5cm; full-thickness intestinal wall high-grade adenocarcinoma; consider clear cell carcinoma\",\"regimen_or_test\":\"Surgery\"},{\"date\":\"2022-08-17\",\"description\":\"Postoperative chemotherapy completed: 白紫+卡铂, 6 cycles\",\"event_type\":\"Chemo\",\"key_result\":\"Last administration recorded 2022-08-17\",\"regimen_or_test\":\"白紫+卡铂\"},{\"date\":\"2022-10-12\",\"description\":\"Tumor markers rising after chemotherapy\",\"event_type\":\"Lab\",\"key_result\":\"CA19-9:77.20U/ml; CA125:89.60U/ml; AFP:<0.91ng/ml\",\"regimen_or_test\":\"CA125, CA19-9, HE4, AFP\"},{\"date\":\"2022-10-24\",\"description\":\"MRI: pelvic post-op, presacral mass increased; pelvic mesenteric enhancing nodules\",\"event_type\":\"Imaging\",\"key_result\":\"Consider recurrence with adjacent sacral involvement; pelvic mesenteric nodules suggest metastases\",\"regimen_or_test\":\"MRI pelvis\"},{\"date\":\"2022-10-25\",\"description\":\"CT: multiple hepatic nodules, some new, likely metastases\",\"event_type\":\"Imaging\",\"key_result\":\"Multiple liver lesions, consider metastases\",\"regimen_or_test\":\"CT abdomen\"},{\"date\":\"2022-12-29\",\"description\":\"Tumor markers markedly elevated\",\"event_type\":\"Lab\",\"key_result\":\"CA19-9:229.00U/ml; CA125:933.00U/ml; HE4:111.00pmol/L\",\"regimen_or_test\":\"CA125, CA19-9, HE4, CA15-3\"},{\"date\":\"2022-12-30\",\"description\":\"MRI and CT show progression: increased presacral mass, new right iliac bone lesion, more hepatic metastases\",\"event_type\":\"Imaging\",\"key_result\":\"Pelvic presacral mass increased; right iliac bone enhancing nodule; hepatic metastases increased\",\"regimen_or_test\":\"MRI pelvis, CT abdomen\"}]},\"VISIT_DATE\":\"2023-01-03\",\"first_relapse_date\":\"2022-10-12\",\"last_platinum_end_date\":\"2022-08-17\"},\"LAB_TRENDS\":{\"labs\":[{\"analyte\":\"CA125\",\"history\":[{\"date\":\"Unknown\",\"flag\":\"Unknown\",\"value\":\"45.7\"},{\"date\":\"2022-08-15\",\"flag\":\"Unknown\",\"value\":\"14.90\"},{\"date\":\"2022-10-12\",\"flag\":\"↑\",\"value\":\"89.60\"},{\"date\":\"2022-11-17\",\"flag\":\"Unknown\",\"value\":\"403\"},{\"date\":\"2022-12-29\",\"flag\":\"↑\",\"value\":\"933.00\"}],\"latest\":{\"date\":\"2022-12-29\",\"flag\":\"↑\",\"value\":\"933.00\"},\"reference_range\":\"Unknown\",\"unit\":\"U/ml\"},{\"analyte\":\"CA19-9\",\"history\":[{\"date\":\"Unknown\",\"flag\":\"Unknown\",\"value\":\"161\"},{\"date\":\"2022-08-15\",\"flag\":\"Unknown\",\"value\":\"7.16\"},{\"date\":\"2022-10-12\",\"flag\":\"↑\",\"value\":\"77.20\"},{\"date\":\"2022-12-29\",\"flag\":\"↑\",\"value\":\"229.00\"}],\"latest\":{\"date\":\"2022-12-29\",\"flag\":\"↑\",\"value\":\"229.00\"},\"reference_range\":\"Unknown\",\"unit\":\"U/ml\"},{\"analyte\":\"HE4\",\"history\":[{\"date\":\"Unknown\",\"flag\":\"Unknown\",\"value\":\"562\"},{\"date\":\"2022-08-15\",\"flag\":\"↑\",\"value\":\"87.90\"},{\"date\":\"2022-10-12\",\"flag\":\"Unknown\",\"value\":\"59.70\"},{\"date\":\"2022-12-29\",\"flag\":\"↑\",\"value\":\"111.00\"}],\"latest\":{\"date\":\"2022-12-29\",\"flag\":\"↑\",\"value\":\"111.00\"},\"reference_range\":\"Unknown\",\"unit\":\"pmol/L\"},{\"analyte\":\"AFP\",\"history\":[{\"date\":\"2022-10-12\",\"flag\":\"Unknown\",\"value\":\"<0.91\"}],\"latest\":{\"date\":\"2022-10-12\",\"flag\":\"Unknown\",\"value\":\"<0.91\"},\"reference_range\":\"Unknown\",\"unit\":\"ng/ml\"},{\"analyte\":\"Hb\",\"history\":[{\"date\":\"2022-11-10\",\"flag\":\"Unknown\",\"value\":\"97\"},{\"date\":\"2022-11-30\",\"flag\":\"Unknown\",\"value\":\"94\"}],\"latest\":{\"date\":\"2022-11-30\",\"flag\":\"Unknown\",\"value\":\"94\"},\"reference_range\":\"Unknown\",\"unit\":\"g/L\"}],\"milestones\":[{\"date\":\"2022-03-28\",\"description\":\"Primary debulking surgery\",\"type\":\"Surgery\"},{\"date\":\"2022-08-17\",\"description\":\"Completed 6 cycles of 白紫+卡铂\",\"type\":\"ChemoEnd\"},{\"date\":\"2022-10-12\",\"description\":\"Biochemical relapse with rising CA125\",\"type\":\"Relapse\"}]},\"MED_ONC\":{\"current_regimen\":{\"cycle_info\":\"Unknown\",\"last_admin_date\":\"Unknown\",\"name\":\"Unknown\"},\"genetic_testing\":{\"germline\":[],\"somatic\":[]},\"monitoring_points\":[],\"planned_next_regimen\":\"Unknown\",\"prior_systemic_therapies\":[\"白紫+卡铂 (6 cycles)\"]},\"NUC_MED\":{\"studies\":[]},\"PATHOLOGY\":{\"specimens\":[{\"components\":[\"高级别腺癌\"],\"date\":\"2022-03-28\",\"diagnosis\":\"部分直乙结肠+左侧腹膜后肿瘤+部分阴道: 肠壁全层见高级别腺癌，结合T2022-04771首先考虑为透明细胞癌；可符合卵巢透明细胞癌累及。\",\"grade\":\"Unknown\",\"ihc\":[{\"marker\":\"MLH1\",\"result\":\"(+)\"},{\"marker\":\"MSH6\",\"result\":\"(+)\"},{\"marker\":\"MSH2\",\"result\":\"(+)\"},{\"marker\":\"PMS2\",\"result\":\"(+)\"},{\"marker\":\"ER\",\"result\":\"(部分+)\"},{\"marker\":\"PR\",\"result\":\"(少弱+)\"},{\"marker\":\"P53\",\"result\":\"(+/-)\"},{\"marker\":\"WT1\",\"result\":\"(-)\"},{\"marker\":\"Ki-67\",\"result\":\"(60%+)\"},{\"marker\":\"HNF1B\",\"result\":\"(+)\"},{\"marker\":\"NapsinA\",\"result\":\"(灶+)\"},{\"marker\":\"P16\",\"result\":\"(+)\"},{\"marker\":\"PAX8\",\"result\":\"(+)\"},{\"marker\":\"SALL4\",\"result\":\"(-)\"},{\"marker\":\"ZBTB16\",\"result\":\"(-)\"}],\"involvement_sites\":[\"intestinal wall full thickness\",\"peritoneum (left retroperitoneal tumor)\",\"vagina (partial)\"],\"laterality\":\"Unknown\",\"molecular\":[],\"raw_text\":\"2022.03.28在全麻下行“瘤体减灭术+直肠乙状结肠部分切除术+阴道部分切除术+腹膜后病损切除术+复杂肠粘连松解术+左输尿管支架置管术+膀胱修补术。（部分直乙结肠+左侧腹膜后肿瘤+部分阴道）肠壁全层见高级别腺癌，结合T2022-04771首先考虑为透明细胞癌，正在加做免疫组化进一步明确。肿块大小约7*4*2.5cm。双侧切缘阴性，肠周淋巴结（4/15）见癌转移，伴癌结节1枚。（膀胱后壁肿瘤）纤维脂肪组织，局灶纤维组织增生、含铁血黄素沉积、泡沫样组织反应，未见癌累及。补充诊断1：【补充报告】（部分直乙结肠+左侧腹膜后肿瘤+部分阴道）可符合卵巢透明细胞癌累及。免疫组化（HI22-06789）瘤细胞：MLH1(ES05)（+），MSH6（+），MSH2（+），PMS2（+），ER（部分+），PR（少弱+），P53（+/-），WT1（-），Ki-67（60%+），HNF1B（+），NapsinA（灶+），P16（+），PAX8（+），SALL4（-），ZBTB16（-）\",\"sample_type\":\"Surgical resection\",\"site\":\"partial rectosigmoid + left retroperitoneal tumor + partial vagina\",\"tumor_size\":\"7*4*2.5cm\",\"uncertainty_or_missing\":[\"Molecular/genetic testing not reported\",\"Definitive origin laterality not specified\"]}]},\"RADIOLOGY\":{\"next_imaging_plan\":{\"modality\":\"Unknown\",\"timing\":\"Unknown\"},\"studies\":[{\"anatomic_sites\":[\"pelvis\",\"sacrum\"],\"date\":\"2022-10-24\",\"findings\":[\"Pelvis post-op changes\",\"presacral mass, consider recurrence with adjacent sacral involvement\",\"multiple enhancing small mesenteric nodules in pelvis, suggest metastases\"],\"impression\":\"Recurrence with possible sacral involvement and pelvic mesenteric metastases\",\"modality\":\"MRI\",\"trend_vs_prior\":\"Worse\"},{\"anatomic_sites\":[\"liver\"],\"date\":\"2022-10-25\",\"findings\":[\"Multiple hepatic nodules, some new compared to prior\",\"hepatic cysts unchanged\"],\"impression\":\"Multiple liver lesions, consider metastases\",\"modality\":\"CT\",\"trend_vs_prior\":\"Worse\"},{\"anatomic_sites\":[\"pelvis\",\"right iliac bone\",\"sacrum\",\"rectum\"],\"date\":\"2022-12-30\",\"findings\":[\"Presacral mass increased in range with heterogeneous enhancement\",\"new enhancing nodule in right iliac bone\",\"multiple pelvic mesenteric enhancing nodules\",\"rectal local bowel wall thickening with enhancement\"],\"impression\":\"Progressive pelvic recurrence with possible peritoneal and sacral involvement; new right iliac bone lesion\",\"modality\":\"MRI\",\"trend_vs_prior\":\"Worse\"},{\"anatomic_sites\":[\"liver\",\"spleen\"],\"date\":\"2022-12-30\",\"findings\":[\"Multiple hepatic metastatic nodules increased in number and size\",\"patchy splenic shadow, possible splenic infarct\"],\"impression\":\"Progressive hepatic metastases; splenic abnormality noted, follow-up suggested\",\"modality\":\"CT\",\"trend_vs_prior\":\"Worse\"}]},\"TIMELINE\":{\"constraints\":{\"max_events\":30,\"min_events\":3,\"must_include\":[\"first diagnostic imaging or pathology confirmation (if available)\"],\"ordering_rules\":{\"prioritize_last_event\":true}},\"events\":[{\"date\":\"2022-03-28\",\"description\":\"Debulking surgery with multiple procedures (partial rectosigmoid resection, partial vaginectomy, retroperitoneal lesion resection, left ureteral stent, bladder repair)\",\"event_type\":\"Surgery\",\"key_result\":\"Tumor ~7*4*2.5cm; full-thickness intestinal wall high-grade adenocarcinoma; consider clear cell carcinoma\",\"regimen_or_test\":\"Surgery\"},{\"date\":\"2022-08-17\",\"description\":\"Postoperative chemotherapy completed: 白紫+卡铂, 6 cycles\",\"event_type\":\"Chemo\",\"key_result\":\"Last administration recorded 2022-08-17\",\"regimen_or_test\":\"白紫+卡铂\"},{\"date\":\"2022-10-12\",\"description\":\"Tumor markers rising after chemotherapy\",\"event_type\":\"Lab\",\"key_result\":\"CA19-9:77.20U/ml; CA125:89.60U/ml; AFP:<0.91ng/ml\",\"regimen_or_test\":\"CA125, CA19-9, HE4, AFP\"},{\"date\":\"2022-10-24\",\"description\":\"MRI: pelvic post-op, presacral mass increased; pelvic mesenteric enhancing nodules\",\"event_type\":\"Imaging\",\"key_result\":\"Consider recurrence with adjacent sacral involvement; pelvic mesenteric nodules suggest metastases\",\"regimen_or_test\":\"MRI pelvis\"},{\"date\":\"2022-10-25\",\"description\":\"CT: multiple hepatic nodules, some new, likely metastases\",\"event_type\":\"Imaging\",\"key_result\":\"Multiple liver lesions, consider metastases\",\"regimen_or_test\":\"CT abdomen\"},{\"date\":\"2022-12-29\",\"description\":\"Tumor markers markedly elevated\",\"event_type\":\"Lab\",\"key_result\":\"CA19-9:229.00U/ml; CA125:933.00U/ml; HE4:111.00pmol/L\",\"regimen_or_test\":\"CA125, CA19-9, HE4, CA15-3\"},{\"date\":\"2022-12-30\",\"description\":\"MRI and CT show progression: increased presacral mass, new right iliac bone lesion, more hepatic metastases\",\"event_type\":\"Imaging\",\"key_result\":\"Pelvic presacral mass increased; right iliac bone enhancing nodule; hepatic metastases increased\",\"regimen_or_test\":\"MRI pelvis, CT abdomen\"}]}}", "final_output": "- Confirm ECOG status, symptoms, goals; if ECOG ≥3 or patient declines systemic therapy, then adjust management from active treatment to best supportive care. [@guideline:nccn_ovariancancer_v3_2025__v00000000|22]\n\n- Clarify current bleeding, pain, anemia and HGB 74 g/L; if symptomatic or hemodynamically unstable, then adjust management from outpatient planning to urgent transfusion/stabilization. [@20230103|5600862]\n\n- Obtain full molecular/biomarker profile and trial options; if actionable alteration or suitable trial available, then adjust management from standard empiric therapy to biomarker- or trial-driven strategy.", "initial_ops": {"chair": "- Confirm performance status, symptom burden, and goals of care, then prioritize systemic therapy for platinum‑resistant clear‑cell ovarian carcinoma with rapid progression [@guideline:nccn_ovariancancer_v3_2025__v00000000|22; @pubmed:33758607].  \n\n- Obtain updated labs (including iron studies, renal/hepatic function), address severe anemia (Hgb 74 g/L) and bone/sacral pain, and arrange palliative radiation consult for symptomatic pelvic/osseous disease [@20230103|5600862; @2022-12-29|MR].  \n\n- Ensure comprehensive molecular profiling using recent tumor (beyond current HRD‑negative, BRCA‑wildtype report) to identify trial/targeted options, and discuss enrollment in studies tailored to clear‑cell, platinum‑resistant ovarian cancer [@OH2203828|2022-04-18; @guideline:nccn_ovariancancer_v3_2025__v00000000|15; @pubmed:33758607].", "oncologist": "- Early biochemical and radiologic relapse (<6 months) after adjuvant platinum suggests platinum-resistant clear cell ovarian carcinoma; consider non‑platinum systemic approach [@guideline:nccn_ovariancancer_v3_2025__v00000000|14].  \n\n- Current severe anemia (Hgb 74 g/L) may limit therapy intensity; optimize transfusion/iron and clarify performance status, symptoms, comorbidities [@20230103|2023-01-03].  \n\n- HRD negative, BRCA1/2 wild-type; need updated imaging for disease burden, ECOG, renal function, and prior maintenance/biologic exposure to choose regimen [@OH2203828|2022-04-18].", "radiologist": "- Progressive presacral pelvic mass with sacral and right iliac bone involvement, plus multiple pelvic mesenteric nodules consistent with recurrent/metastatic disease [@2022-12-29|MR].  \n\n- Increasing number and size of multiple hepatic metastatic nodules; stable hepatic cysts [@2022-12-29|CT].  \n\n- Splenic patchy low-density lesion suspicious for infarct; recommend imaging follow‑up for evolution and complications [@2022-12-29|CT][@pubmed:33758607].", "pathologist": "- Histology and IHC support diagnosis of ovarian clear cell carcinoma involving rectosigmoid, retroperitoneum, and vagina; grade not specified [@HISTOLOGY_AND_IHC|2022-03-28].  \n\n- MMR proteins intact; HRD and BRCA1/2 pathogenic variants not detected; germline ATM p.Y316C reported, clinical significance unclear [@OH2203828|2022-04-18].  \n\n- For future care, comprehensive tumor profiling (MSI, TMB, PD-L1, broader somatic panel) is missing and should be updated [@guideline:nccn_ovariancancer_v3_2025__v00000000|15].", "nuclear": "- No PET/CT available; metabolic burden, sacral/right iliac bone involvement, and splenic lesion characterization remain unknown/needs update.  \n\n- Prior CT/MR show progressive pelvic, hepatic, and possible sacral/right iliac bone metastases, high suspicion for widespread recurrence [@2022-12-29|MR][@2022-12-29|CT].  \n\n- PET/CT could refine current staging, assess extrahepatic/peritoneal/bone disease, and guide radiotherapy or surgery decisions [@guideline:nccn_ovariancancer_v3_2025__v00000000|22]."}, "merged_summary": "Key Knowledge:\n- Platinum‑resistant clear cell ovarian carcinoma with rapid progression and widespread involvement (pelvis, liver, sacrum/right iliac bone); surgery and radiation regarded as palliative only.\n- High symptom burden from painful pelvic/bony disease and severe anemia (Hgb 74 g/L), constraining systemic therapy intensity.\n- Pathology: ovarian clear cell carcinoma; MMR intact; HRD‑negative; BRCA1/2 wild‑type; germline ATM p.Y316C VUS; comprehensive somatic profiling (MSI, TMB, PD‑L1, broad panel) still pending.\n- Last imaging (Dec 2022 CT/MR) shows progressive pelvic/hepatic disease, sacral/right iliac involvement, and a splenic lesion suspicious for infarct; restaging CT planned as primary imaging tool.\n\nControversies:\n- Need for PET/CT beyond contrast CT, with consensus leaning to limit PET/CT to CT‑equivocal lesions that would change radiation fields/local interventions, as PET/CT is unlikely to alter systemic therapy.\n- Optimal selection and sequencing of non‑platinum systemic therapy (including potential anti‑angiogenic/immunotherapy and trials) given severe anemia and yet‑uncertain ECOG and comorbidities.\n- Clinical relevance of the ATM VUS for targeted approaches and clinical trial eligibility.\n\nMissing Info:\n- ECOG performance status, detailed symptom and pain profile, comorbidities, thromboembolism status, and patient goals of care.\n- Updated comprehensive labs: CBC, iron/B12, renal, hepatic, coagulation profile.\n- New contrast CT chest/abdomen/pelvis to define current disease extent, including splenic lesion evolution; documentation of prior maintenance/biologic therapies.\n- Completed comprehensive tumor profiling (MSI, TMB, PD‑L1, broad somatic panel/ctDNA).\n- Confirmation of palliative care involvement and a structured survivorship/symptom management plan.\n\nWorking Plan:\n- Urgently optimize supportive care: investigate and correct severe anemia (transfusion, iron/B12 workup), obtain full labs, document ECOG, symptoms, comorbidities, thromboembolism status, and clarify goals of care.\n- Restage with contrast-enhanced CT chest/abdomen/pelvis to reassess pelvic, hepatic, bone, and splenic disease; use CT as the primary tool for planning palliative radiation to presacral/sacral/right iliac lesions.\n- Reserve PET/CT for CT‑equivocal bone or splenic sites where metabolic data would change radiation fields or other local interventions.\n- Arrange palliative radiation oncology review for symptomatic pelvic/bony disease and integrate formal palliative care.\n- Proceed with comprehensive molecular profiling (MSI, TMB, PD‑L1, broad somatic panel on recent tissue/ctDNA) and multidisciplinary review of HRD‑negative/BRCA‑WT/ATM VUS status.\n- After clinical optimization and restaging, prioritize an evidence‑based non‑platinum systemic/second‑line strategy and evaluate eligibility for clinical trials in platinum‑resistant clear cell ovarian carcinoma, including anti‑angiogenic and immunotherapy options as appropriate.", "final_round_ops": {"Round 1": {"chair": "- Confirm performance status, symptom burden, and discuss goals; prioritize systemic therapy for platinum‑resistant clear cell histology and rapid metastatic progression [@report_id:2022-12-29|MR; @report_id:2022-12-29|CT; @guideline:nccn_ovariancancer_v3_2025__v00000000|22].  \n\n- Obtain updated comprehensive labs (including iron/B12, renal, hepatic, coagulation), manage significant anemia urgently, and rule out contraindications before starting next‑line systemic and bone‑directed/palliative local treatments [@report_id:2023-01-03|5600862].  \n\n- Arrange multidisciplinary review of molecular profile (HRD‑negative, BRCA‑WT, ATM variant) and consider repeat/expanded profiling on recent tissue, then prioritize evidence‑based non‑platinum systemic options and clinical trial enrollment for platinum‑resistant ovarian clear cell carcinoma [@report_id:OH2203828|2022-04-18; @pubmed:33758607].", "oncologist": "- Urgently optimize supportive care: investigate/transfuse severe anemia [@20230103|2023-01-03], assess ECOG, pain, comorbidities, and clarify goals of care.  \n\n- Obtain updated contrast CT chest/abdomen/pelvis for current extent, then plan palliative radiation to sacral/right iliac lesions and systemic strategy. [@guideline:nccn_ovariancancer_v3_2025__v00000000|15]  \n\n- Arrange comprehensive tumor profiling (MSI, TMB, PD‑L1, broad somatic panel) on recent tissue/ctDNA to inform non‑platinum and trial options.", "radiologist": "- Obtain updated contrast CT chest/abdomen/pelvis to reassess burden since progression on 2022-12-29/30 imaging [@2022-12-29|CT][@2022-12-29|MR].  \n\n- Reserve PET/CT for unresolved questions about sacral/right iliac bone or splenic involvement that would directly modify radiation fields [@2022-12-29|CT].  \n\n- Use updated imaging to guide palliative RT planning for painful presacral/sacral/right iliac lesions, aligning with symptom-directed management in recurrence [@guideline:nccn_ovariancancer_v3_2025__v00000000|22].", "pathologist": "- Urgently document ECOG, detailed symptoms, comorbidities, and evaluate/transfuse for severe anemia before defining any new systemic strategy [@guideline:nccn_ovariancancer_v3_2025__v00000000|14].  \n\n- Obtain updated contrast CT chest/abdomen/pelvis to reassess pelvic, hepatic, bone, and splenic disease before radiation or systemic decisions [@report_id_unknown|unknown].  \n\n- Arrange comprehensive tumor profiling on recent tissue or ctDNA (MSI, TMB, PD-L1, broad somatic panel) to inform future options [@OH2203828|2022-04-18].", "nuclear": "- Prioritize supportive care: document ECOG, symptoms, comorbidities; investigate/transfuse for severe anemia before systemic decisions (Hgb 74 g/L, labs otherwise unknown).  \n\n- Obtain updated contrast CT chest/abdomen/pelvis to reassess pelvic, hepatic, sacral/right iliac, and splenic disease before radiation planning [@2022-12-29|MR][@2022-12-29|CT].  \n\n- Reserve PET/CT for situations where CT leaves uncertainty that would meaningfully alter radiation fields or local interventions [@guideline:nccn_ovariancancer_v3_2025__v00000000|22]."}, "Round 2": {"chair": "- Prioritize second-line systemic therapy for platinum-resistant clear cell ovarian carcinoma with visceral and bone metastases; deem surgery/radiation palliative only [@guideline:nccn_ovariancancer_v3_2025__v00000000|14; @report_id:2022-12-29|CT].  \n\n- Before finalizing regimen, urgently optimize anemia, assess ECOG, symptoms, and clarify goals; obtain full chemistry, coagulation, and updated pain/thromboembolism status [@report_id:20230103|5600862].  \n\n- Arrange comprehensive survivorship and trial-focused review including prior HRD-negative, BRCA‑wildtype status to consider non‑platinum, anti‑angiogenic, immunotherapy, or trial options in sequencing [@guideline:esmo_cpg_epithelialovarian_2023__v00000000|10; @report_id:OH2203828].", "oncologist": "- Urgently correct anemia (transfusion, iron/B12 workup), complete full labs, document ECOG, symptoms, comorbidities, and goals of care. [@20230103|2023-01-03]  \n\n- Restage with contrast CT chest/abdomen/pelvis, then coordinate palliative radiation for painful pelvic/sacral/right iliac disease and integrate palliative care. [@guideline:nccn_ovariancancer_v3_2025__v00000000|15]  \n\n- Send comprehensive molecular profiling (MSI, TMB, PD‑L1, broad panel/ctDNA); after optimization, select non‑platinum systemic/clinical‑trial strategy for platinum‑resistant clear cell disease. [@pubmed:33758607]", "radiologist": "- Obtain updated contrast-enhanced CT chest/abdomen/pelvis to restage since documented progression on Dec 2022 imaging [@2022-12-29|CT][@2022-12-29|MR].  \n\n- Use CT as primary tool for palliative RT planning to presacral/sacral/right iliac lesions; reserve PET/CT for equivocal sites [@guideline:nccn_ovariancancer_v3_2025__v00000000|22].  \n\n- Reassess splenic low-density lesion on new CT to distinguish evolving infarct from alternative pathology and guide need for further imaging [@2022-12-29|CT].", "pathologist": "- Proceed with comprehensive tumor profiling (MSI, TMB, PD‑L1, broad somatic panel) on recent tissue/ctDNA to expand options [@guideline:nccn_ovariancancer_v3_2025__v00000000|15].  \n\n- Maintain diagnosis of ovarian clear cell carcinoma with intact MMR and HRD-/BRCA1/2‑wild type status; ATM p.Y316C remains VUS [@HISTOLOGY_AND_IHC|2022-03-28].  \n\n- Ensure pathology–radiology correlation on new contrast CT (pelvis, sacrum/right iliac, spleen) to confirm sites for palliative radiation (report_id unknown|unknown).", "nuclear": "- Continue with updated contrast CT chest/abdomen/pelvis as primary restaging tool to guide palliative radiation planning [@2022-12-29|CT][@2022-12-29|MR].  \n\n- Reserve PET/CT for CT‑equivocal bone or splenic lesions where metabolic clarification would change radiation fields or local procedures [@guideline:nccn_ovariancancer_v3_2025__v00000000|22].  \n\n- No current evidence that PET/CT would alter systemic therapy choice in this established platinum‑resistant, widely metastatic setting [@guideline:nccn_ovariancancer_v3_2025__v00000000|22]."}}, "interaction_log": {"Round 1": {"Turn 1": {"chair": {"chair": null, "oncologist": null, "radiologist": null, "pathologist": null, "nuclear": null}, "oncologist": {"chair": "Before committing to a new systemic line, we must urgently document ECOG, detailed symptoms, comorbidities, and transfuse/clarify cause of severe anemia, as these may preclude intensive chemotherapy options.", "oncologist": null, "radiologist": null, "pathologist": null, "nuclear": null}, "radiologist": {"chair": null, "oncologist": "Most recent cross-sectional imaging is from 2022-12-29/30 and already shows clear systemic progression; updated contrast CT (chest/abdomen/pelvis) is needed before further systemic or radiation decisions.", "radiologist": null, "pathologist": null, "nuclear": null}, "pathologist": {"chair": null, "oncologist": null, "radiologist": null, "pathologist": null, "nuclear": null}, "nuclear": {"chair": null, "oncologist": null, "radiologist": null, "pathologist": null, "nuclear": null}}, "Turn 2": {"chair": {"chair": null, "oncologist": null, "radiologist": null, "pathologist": null, "nuclear": null}, "oncologist": {"chair": null, "oncologist": null, "radiologist": null, "pathologist": null, "nuclear": null}, "radiologist": {"chair": null, "oncologist": null, "radiologist": null, "pathologist": null, "nuclear": null}, "pathologist": {"chair": null, "oncologist": "From a pathology standpoint, comprehensive tumor profiling (MSI, TMB, PD-L1, broad somatic panel) remains outstanding and is important for future options.", "radiologist": null, "pathologist": null, "nuclear": null}, "nuclear": {"chair": null, "oncologist": "Given rapid progression and planned local interventions, clarify whether PET/CT is intended to change radiation fields or only confirm known lesions.", "radiologist": "If PET/CT is considered, please specify whether CT findings leave uncertainty about sacral/right iliac or splenic involvement that would alter management.", "pathologist": null, "nuclear": null}}}, "Round 2": {"Turn 1": {"chair": {"chair": null, "oncologist": null, "radiologist": null, "pathologist": null, "nuclear": null}, "oncologist": {"chair": null, "oncologist": null, "radiologist": null, "pathologist": null, "nuclear": null}, "radiologist": {"chair": null, "oncologist": null, "radiologist": null, "pathologist": null, "nuclear": null}, "pathologist": {"chair": null, "oncologist": null, "radiologist": null, "pathologist": null, "nuclear": null}, "nuclear": {"chair": null, "oncologist": null, "radiologist": null, "pathologist": null, "nuclear": null}}, "Turn 2": {"chair": {"chair": null, "oncologist": null, "radiologist": null, "pathologist": null, "nuclear": null}, "oncologist": {"chair": null, "oncologist": null, "radiologist": null, "pathologist": null, "nuclear": null}, "radiologist": {"chair": null, "oncologist": null, "radiologist": null, "pathologist": null, "nuclear": null}, "pathologist": {"chair": null, "oncologist": null, "radiologist": null, "pathologist": null, "nuclear": null}, "nuclear": {"chair": null, "oncologist": null, "radiologist": null, "pathologist": null, "nuclear": null}}}}, "agent_logs": {"chair": [{"role": "chair", "user_message": "Give INITIAL opinion (use ONLY your system-provided patient facts).\nReturn up to 3 bullets, each ≤20 words.\nIf key data missing, say exactly what needs updating.\nAt least ONE bullet must be evidence-based and include [@guideline:doc_id|page] or [@pubmed:PMID].\nIf you reference treatment strategy categories, guidelines, trials, or literature evidence, include tags [@guideline:doc_id|page] or [@pubmed:PMID].", "assistant_reply": "- Confirm performance status, symptom burden, and goals of care, then prioritize systemic therapy for platinum‑resistant clear‑cell ovarian carcinoma with rapid progression [@guideline:nccn_ovariancancer_v3_2025__v00000000|22; @pubmed:33758607].  \n\n- Obtain updated labs (including iron studies, renal/hepatic function), address severe anemia (Hgb 74 g/L) and bone/sacral pain, and arrange palliative radiation consult for symptomatic pelvic/osseous disease [@20230103|5600862; @2022-12-29|MR].  \n\n- Ensure comprehensive molecular profiling using recent tumor (beyond current HRD‑negative, BRCA‑wildtype report) to identify trial/targeted options, and discuss enrollment in studies tailored to clear‑cell, platinum‑resistant ovarian cancer [@OH2203828|2022-04-18; @guideline:nccn_ovariancancer_v3_2025__v00000000|15; @pubmed:33758607].", "timestamp": "2026-01-19T08:02:57.137204"}, {"role": "chair", "user_message": "ROLE: chair. VISIT: 2023-01-03 08:53:29.260000\nDefault is NOT to speak. Speak ONLY if: conflict | safety | missing-critical | new-critical.\n\nCONTEXT (latest):\n[MDT_GLOBAL_KNOWLEDGE]\nKey Knowledge:\n- Platinum‑resistant clear cell ovarian carcinoma with rapid systemic progression (pelvis, liver, bone/sacrum) and likely widespread disease.\n- High symptom burden: painful presacral/bony disease and severe anemia (Hgb 74 g/L) limiting treatment options.\n- Pathology: clear cell carcinoma; MMR intact; HRD‑negative; BRCA1/2 wild‑type; germline ATM VUS; no comprehensive somatic profiling.\n- Imaging shows progressive pelvic/hepatic metastases; splenic lesion suspicious for infarct.\n\nControversies:\n- Added value of PET/CT for staging versus limited impact on systemic management in established platinum‑resistant disease.\n- Choice and intensity of non‑platinum systemic therapy given severe anemia and unknown performance status.\n- Significance of germline ATM VUS for trial eligibility/targeted approaches.\n\nMissing Info:\n- ECOG performance status, detailed symptom burden, and patient goals of care.\n- Updated labs (CBC, iron studies, renal/hepatic function) and comorbidities.\n- Most recent imaging overview and prior exposure to maintenance/biologic therapy.\n- Full tumor profiling (MSI, TMB, PD‑L1, broad somatic panel) and palliative care involvement.\n\nWorking Plan:\n- Clarify ECOG, symptoms, and goals; optimize supportive care (transfusion/iron, pain control).\n- Arrange palliative radiation oncology review for pelvic/sacral/right iliac bone disease.\n- Update staging with contrast CT; consider PET/CT if it will guide local interventions.\n- Plan non‑platinum systemic strategy appropriate to status and prior treatments.\n- Obtain comprehensive molecular profiling (tissue or ctDNA) to guide targeted/clinical trial options.\n\nAllowed targets: [oncologist,radiologist,pathologist,nuclear]\nReturn ONE-LINE JSON only:{\"speak\":\"yes/no\",\"messages\":[{\"target\":\"<role>\",\"message\":\"<1-2 sentences>\",\"why\":\"conflict|safety|missing|new\"}]}", "assistant_reply": "- Platinum-resistant clear cell ovarian carcinoma with rapid systemic progression and severe anemia; admit/optimize performance status and correct HGB before systemic therapy intensification [@20230103|5600862].  \n- Plan non‑platinum systemic therapy with early palliative radiotherapy/symptom control input; prioritize clinical trial options given clear cell histology and chemoresistance [@guideline:nccn_ovariancancer_v3_2025__v00000000|14][@pubmed:33758607].  \n- Missing: current ECOG, organ function (renal/hepatic, coagulation), pain status, patient goals; confirm HRD/PD‑L1 not re-testable or already definitively negative beyond existing germline panel [@OH2203828|2022-04-18].", "timestamp": "2026-01-19T08:03:24.830694"}, {"role": "chair", "user_message": "ROLE: chair. VISIT: 2023-01-03 08:53:29.260000\nDefault is NOT to speak. Speak ONLY if: conflict | safety | missing-critical | new-critical.\n\nCONTEXT (latest):\n[MDT_GLOBAL_KNOWLEDGE]\nKey Knowledge:\n- Platinum‑resistant clear cell ovarian carcinoma with rapid systemic progression (pelvis, liver, bone/sacrum) and likely widespread disease.\n- High symptom burden: painful presacral/bony disease and severe anemia (Hgb 74 g/L) limiting treatment options.\n- Pathology: clear cell carcinoma; MMR intact; HRD‑negative; BRCA1/2 wild‑type; germline ATM VUS; no comprehensive somatic profiling.\n- Imaging shows progressive pelvic/hepatic metastases; splenic lesion suspicious for infarct.\n\nControversies:\n- Added value of PET/CT for staging versus limited impact on systemic management in established platinum‑resistant disease.\n- Choice and intensity of non‑platinum systemic therapy given severe anemia and unknown performance status.\n- Significance of germline ATM VUS for trial eligibility/targeted approaches.\n\nMissing Info:\n- ECOG performance status, detailed symptom burden, and patient goals of care.\n- Updated labs (CBC, iron studies, renal/hepatic function) and comorbidities.\n- Most recent imaging overview and prior exposure to maintenance/biologic therapy.\n- Full tumor profiling (MSI, TMB, PD‑L1, broad somatic panel) and palliative care involvement.\n\nWorking Plan:\n- Clarify ECOG, symptoms, and goals; optimize supportive care (transfusion/iron, pain control).\n- Arrange palliative radiation oncology review for pelvic/sacral/right iliac bone disease.\n- Update staging with contrast CT; consider PET/CT if it will guide local interventions.\n- Plan non‑platinum systemic strategy appropriate to status and prior treatments.\n- Obtain comprehensive molecular profiling (tissue or ctDNA) to guide targeted/clinical trial options.\n\n[RECENT_DELTAS]\n[R1T1 DELTA] oncologist->chair(missing): Before committing to a new systemic line, we must urgently document ECOG, detailed symptoms, comorbidities, and transfuse/clarify cause of severe anemia, as these may preclude intensive chemotherapy options. | radiologist->oncologist(missing): Most recent cross-sectional imaging is from 2022-12-29/30 and already shows clear systemic progression; updated contrast CT (chest/abdomen/pelvis) is needed before further systemic or radiation decisions.\n\nAllowed targets: [oncologist,radiologist,pathologist,nuclear]\nReturn ONE-LINE JSON only:{\"speak\":\"yes/no\",\"messages\":[{\"target\":\"<role>\",\"message\":\"<1-2 sentences>\",\"why\":\"conflict|safety|missing|new\"}]}", "assistant_reply": "- Missing: ECOG status, pain/bleeding, patient goals, prior maintenance, and eligibility/interest for clinical trials before finalizing systemic plan.  \n\n- Intent: shift from curative to palliative systemic therapy plus best supportive care, as platinum-resistant clear cell relapse with liver/bone spread [@guideline:nccn_ovariancancer_v3_2025__v00000000|22].  \n\n- Sequence today: stabilize anemia (Hb 74 g/L) and assess organ function, then select non‑platinum systemic strategy; involve palliative care early [@report_id:20230103|2023-01-03].", "timestamp": "2026-01-19T08:03:33.392830"}, {"role": "chair", "user_message": "Given MDT context:\n[MDT_GLOBAL_KNOWLEDGE]\nKey Knowledge:\n- Platinum‑resistant clear cell ovarian carcinoma with rapid systemic progression (pelvis, liver, bone/sacrum) and likely widespread disease.\n- High symptom burden: painful presacral/bony disease and severe anemia (Hgb 74 g/L) limiting treatment options.\n- Pathology: clear cell carcinoma; MMR intact; HRD‑negative; BRCA1/2 wild‑type; germline ATM VUS; no comprehensive somatic profiling.\n- Imaging shows progressive pelvic/hepatic metastases; splenic lesion suspicious for infarct.\n\nControversies:\n- Added value of PET/CT for staging versus limited impact on systemic management in established platinum‑resistant disease.\n- Choice and intensity of non‑platinum systemic therapy given severe anemia and unknown performance status.\n- Significance of germline ATM VUS for trial eligibility/targeted approaches.\n\nMissing Info:\n- ECOG performance status, detailed symptom burden, and patient goals of care.\n- Updated labs (CBC, iron studies, renal/hepatic function) and comorbidities.\n- Most recent imaging overview and prior exposure to maintenance/biologic therapy.\n- Full tumor profiling (MSI, TMB, PD‑L1, broad somatic panel) and palliative care involvement.\n\nWorking Plan:\n- Clarify ECOG, symptoms, and goals; optimize supportive care (transfusion/iron, pain control).\n- Arrange palliative radiation oncology review for pelvic/sacral/right iliac bone disease.\n- Update staging with contrast CT; consider PET/CT if it will guide local interventions.\n- Plan non‑platinum systemic strategy appropriate to status and prior treatments.\n- Obtain comprehensive molecular profiling (tissue or ctDNA) to guide targeted/clinical trial options.\n\n[RECENT_DELTAS]\n[R1T1 DELTA] oncologist->chair(missing): Before committing to a new systemic line, we must urgently document ECOG, detailed symptoms, comorbidities, and transfuse/clarify cause of severe anemia, as these may preclude intensive chemotherapy options. | radiologist->oncologist(missing): Most recent cross-sectional imaging is from 2022-12-29/30 and already shows clear systemic progression; updated contrast CT (chest/abdomen/pelvis) is needed before further systemic or radiation decisions.\n[R1T2 DELTA] pathologist->oncologist(unspecified): From a pathology standpoint, comprehensive tumor profiling (MSI, TMB, PD-L1, broad somatic panel) remains outstanding and is important for future options. | nuclear->oncologist(missing): Given rapid progression and planned local interventions, clarify whether PET/CT is intended to change radiation fields or only confirm known lesions. | nuclear->radiologist(missing): If PET/CT is considered, please specify whether CT findings leave uncertainty about sacral/right iliac or splenic involvement that would alter management.\n\nDISCUSSION HISTORY (this round):\nTurn 1: oncologist→chair: Before committing to a new systemic line, we must urgently document ECOG, detailed symptoms, comorbidities, and transfuse/clarify cause of severe anemia, as these may preclude intensive chemotherapy options. | radiologist→oncologist: Most recent cross-sectional imaging is from 2022-12-29/30 and already shows clear systemic progression; updated contrast CT (chest/abdomen/pelvis) is needed before further systemic or radiation decisions.\nTurn 2: pathologist→oncologist: From a pathology standpoint, comprehensive tumor profiling (MSI, TMB, PD-L1, broad somatic panel) remains outstanding and is important for future options. | nuclear→oncologist: Given rapid progression and planned local interventions, clarify whether PET/CT is intended to change radiation fields or only confirm known lesions. | nuclear→radiologist: If PET/CT is considered, please specify whether CT findings leave uncertainty about sacral/right iliac or splenic involvement that would alter management.\n\nProvide FINAL refined plan based on the above context and discussions.\nUp to 3 bullets, each ≤20 words.\nAny factual claim must include [@report_id|date] or say unknown.\nAt least ONE bullet must be evidence-based and include [@guideline:doc_id|page] or [@pubmed:PMID].\nIf you reference treatment strategy categories, guidelines, trials, or literature evidence, include tags [@guideline:doc_id|page] or [@pubmed:PMID].\nIf discussions mentioned specific evidence, you may reference it with appropriate tags.", "assistant_reply": "- Confirm performance status, symptom burden, and discuss goals; prioritize systemic therapy for platinum‑resistant clear cell histology and rapid metastatic progression [@report_id:2022-12-29|MR; @report_id:2022-12-29|CT; @guideline:nccn_ovariancancer_v3_2025__v00000000|22].  \n\n- Obtain updated comprehensive labs (including iron/B12, renal, hepatic, coagulation), manage significant anemia urgently, and rule out contraindications before starting next‑line systemic and bone‑directed/palliative local treatments [@report_id:2023-01-03|5600862].  \n\n- Arrange multidisciplinary review of molecular profile (HRD‑negative, BRCA‑WT, ATM variant) and consider repeat/expanded profiling on recent tissue, then prioritize evidence‑based non‑platinum systemic options and clinical trial enrollment for platinum‑resistant ovarian clear cell carcinoma [@report_id:OH2203828|2022-04-18; @pubmed:33758607].", "timestamp": "2026-01-19T08:04:08.354385"}, {"role": "chair", "user_message": "ROLE: chair. VISIT: 2023-01-03 08:53:29.260000\nDefault is NOT to speak. Speak ONLY if: conflict | safety | missing-critical | new-critical.\n\nCONTEXT (latest):\n[MDT_GLOBAL_KNOWLEDGE]\nKey Knowledge:\n- Platinum‑resistant clear cell ovarian carcinoma with rapid progression and widespread involvement (pelvis, liver, sacrum/right iliac bone).\n- High symptom burden: painful pelvic/bony disease and severe anemia (Hgb 74 g/L) restricting systemic options.\n- Pathology: clear cell carcinoma; MMR intact; HRD‑negative; BRCA1/2 wild‑type; germline ATM VUS; comprehensive somatic profiling not yet completed.\n- Last imaging (Dec 2022 CT/MR) shows progressive pelvic/hepatic disease, sacral/right iliac involvement, and splenic lesion suspicious for infarct.\n\nControversies:\n- Need for PET/CT beyond contrast CT, given likely limited impact on systemic therapy and its role mainly in refining radiation fields.\n- Optimal non‑platinum systemic regimen and intensity in the context of severe anemia and yet‑uncertain ECOG/comorbidities.\n- Relevance of ATM VUS for targeted therapy or trial eligibility.\n\nMissing Info:\n- ECOG performance status, detailed symptoms (including pain control), comorbidities, and patient goals of care.\n- Updated comprehensive labs (CBC, iron/B12, renal, hepatic, coagulation).\n- New contrast CT chest/abdomen/pelvis and record of prior maintenance/biologic treatments.\n- Completed comprehensive tumor profiling (MSI, TMB, PD‑L1, broad somatic panel).\n- Confirmation of palliative care involvement and a formal symptom management plan.\n\nWorking Plan:\n- Optimize supportive care urgently: investigate/manage severe anemia, obtain full labs, document ECOG, symptoms, comorbidities, and clarify goals of care.\n- Obtain updated contrast CT chest/abdomen/pelvis to reassess disease and plan palliative radiation to presacral/sacral/right iliac lesions.\n- Reserve PET/CT for CT‑equivocal bone/splenic findings that would alter radiation fields/local interventions.\n- Arrange palliative radiation oncology review for symptomatic pelvic/bone disease.\n- Perform multidisciplinary review of existing molecular data and send comprehensive profiling (MSI, TMB, PD‑L1, broad somatic panel) on recent tissue/ctDNA.\n- After optimization and restaging, select an evidence‑based non‑platinum systemic approach and assess eligibility for clear‑cell, platinum‑resistant clinical trials.\n\nAllowed targets: [oncologist,radiologist,pathologist,nuclear]\nReturn ONE-LINE JSON only:{\"speak\":\"yes/no\",\"messages\":[{\"target\":\"<role>\",\"message\":\"<1-2 sentences>\",\"why\":\"conflict|safety|missing|new\"}]}", "assistant_reply": "- Missing: ECOG status, symptoms, and patient goals; these must guide whether to prioritize disease control, quality of life, or both.  \n- Platinum‑resistant clear cell relapse with liver/bone disease: prioritize non‑platinum systemic therapy ± trial enrollment; avoid futile aggressive local surgery [@guideline:nccn_ovariancancer_v3_2025__v00000000|22][@pubmed:33758607].  \n- Immediately correct severe anemia (Hgb 74 g/L) and reassess organ function before starting next‑line therapy or trial [@20230103|5600862].", "timestamp": "2026-01-19T08:04:55.059290"}, {"role": "chair", "user_message": "Given MDT context:\n[MDT_GLOBAL_KNOWLEDGE]\nKey Knowledge:\n- Platinum‑resistant clear cell ovarian carcinoma with rapid progression and widespread involvement (pelvis, liver, sacrum/right iliac bone).\n- High symptom burden: painful pelvic/bony disease and severe anemia (Hgb 74 g/L) restricting systemic options.\n- Pathology: clear cell carcinoma; MMR intact; HRD‑negative; BRCA1/2 wild‑type; germline ATM VUS; comprehensive somatic profiling not yet completed.\n- Last imaging (Dec 2022 CT/MR) shows progressive pelvic/hepatic disease, sacral/right iliac involvement, and splenic lesion suspicious for infarct.\n\nControversies:\n- Need for PET/CT beyond contrast CT, given likely limited impact on systemic therapy and its role mainly in refining radiation fields.\n- Optimal non‑platinum systemic regimen and intensity in the context of severe anemia and yet‑uncertain ECOG/comorbidities.\n- Relevance of ATM VUS for targeted therapy or trial eligibility.\n\nMissing Info:\n- ECOG performance status, detailed symptoms (including pain control), comorbidities, and patient goals of care.\n- Updated comprehensive labs (CBC, iron/B12, renal, hepatic, coagulation).\n- New contrast CT chest/abdomen/pelvis and record of prior maintenance/biologic treatments.\n- Completed comprehensive tumor profiling (MSI, TMB, PD‑L1, broad somatic panel).\n- Confirmation of palliative care involvement and a formal symptom management plan.\n\nWorking Plan:\n- Optimize supportive care urgently: investigate/manage severe anemia, obtain full labs, document ECOG, symptoms, comorbidities, and clarify goals of care.\n- Obtain updated contrast CT chest/abdomen/pelvis to reassess disease and plan palliative radiation to presacral/sacral/right iliac lesions.\n- Reserve PET/CT for CT‑equivocal bone/splenic findings that would alter radiation fields/local interventions.\n- Arrange palliative radiation oncology review for symptomatic pelvic/bone disease.\n- Perform multidisciplinary review of existing molecular data and send comprehensive profiling (MSI, TMB, PD‑L1, broad somatic panel) on recent tissue/ctDNA.\n- After optimization and restaging, select an evidence‑based non‑platinum systemic approach and assess eligibility for clear‑cell, platinum‑resistant clinical trials.\n\nDISCUSSION HISTORY (this round):\nNo direct discussions in this round.\n\nProvide FINAL refined plan based on the above context and discussions.\nUp to 3 bullets, each ≤20 words.\nAny factual claim must include [@report_id|date] or say unknown.\nAt least ONE bullet must be evidence-based and include [@guideline:doc_id|page] or [@pubmed:PMID].\nIf you reference treatment strategy categories, guidelines, trials, or literature evidence, include tags [@guideline:doc_id|page] or [@pubmed:PMID].\nIf discussions mentioned specific evidence, you may reference it with appropriate tags.", "assistant_reply": "- Prioritize second-line systemic therapy for platinum-resistant clear cell ovarian carcinoma with visceral and bone metastases; deem surgery/radiation palliative only [@guideline:nccn_ovariancancer_v3_2025__v00000000|14; @report_id:2022-12-29|CT].  \n\n- Before finalizing regimen, urgently optimize anemia, assess ECOG, symptoms, and clarify goals; obtain full chemistry, coagulation, and updated pain/thromboembolism status [@report_id:20230103|5600862].  \n\n- Arrange comprehensive survivorship and trial-focused review including prior HRD-negative, BRCA‑wildtype status to consider non‑platinum, anti‑angiogenic, immunotherapy, or trial options in sequencing [@guideline:esmo_cpg_epithelialovarian_2023__v00000000|10; @report_id:OH2203828].", "timestamp": "2026-01-19T08:06:04.033897"}, {"role": "chair", "user_message": "\nAs the MDT chair for gynecologic oncology, you are seeing the patient at OUTPATIENT TIME: 2023-01-03 08:53:29.260000.\nBased on PATIENT FACTS + MDT discussion + FINAL refined plans from all experts, determine the CURRENT best management plan for this visit.\n\n# MDT DISCUSSION SUMMARY\nKey Knowledge:\n- Platinum‑resistant clear cell ovarian carcinoma with rapid progression and widespread involvement (pelvis, liver, sacrum/right iliac bone); surgery and radiation regarded as palliative only.\n- High symptom burden from painful pelvic/bony disease and severe anemia (Hgb 74 g/L), constraining systemic therapy intensity.\n- Pathology: ovarian clear cell carcinoma; MMR intact; HRD‑negative; BRCA1/2 wild‑type; germline ATM p.Y316C VUS; comprehensive somatic profiling (MSI, TMB, PD‑L1, broad panel) still pending.\n- Last imaging (Dec 2022 CT/MR) shows progressive pelvic/hepatic disease, sacral/right iliac involvement, and a splenic lesion suspicious for infarct; restaging CT planned as primary imaging tool.\n\nControversies:\n- Need for PET/CT beyond contrast CT, with consensus leaning to limit PET/CT to CT‑equivocal lesions that would change radiation fields/local interventions, as PET/CT is unlikely to alter systemic therapy.\n- Optimal selection and sequencing of non‑platinum systemic therapy (including potential anti‑angiogenic/immunotherapy and trials) given severe anemia and yet‑uncertain ECOG and comorbidities.\n- Clinical relevance of the ATM VUS for targeted approaches and clinical trial eligibility.\n\nMissing Info:\n- ECOG performance status, detailed symptom and pain profile, comorbidities, thromboembolism status, and patient goals of care.\n- Updated comprehensive labs: CBC, iron/B12, renal, hepatic, coagulation profile.\n- New contrast CT chest/abdomen/pelvis to define current disease extent, including splenic lesion evolution; documentation of prior maintenance/biologic therapies.\n- Completed comprehensive tumor profiling (MSI, TMB, PD‑L1, broad somatic panel/ctDNA).\n- Confirmation of palliative care involvement and a structured survivorship/symptom management plan.\n\nWorking Plan:\n- Urgently optimize supportive care: investigate and correct severe anemia (transfusion, iron/B12 workup), obtain full labs, document ECOG, symptoms, comorbidities, thromboembolism status, and clarify goals of care.\n- Restage with contrast-enhanced CT chest/abdomen/pelvis to reassess pelvic, hepatic, bone, and splenic disease; use CT as the primary tool for planning palliative radiation to presacral/sacral/right iliac lesions.\n- Reserve PET/CT for CT‑equivocal bone or splenic sites where metabolic data would change radiation fields or other local interventions.\n- Arrange palliative radiation oncology review for symptomatic pelvic/bony disease and integrate formal palliative care.\n- Proceed with comprehensive molecular profiling (MSI, TMB, PD‑L1, broad somatic panel on recent tissue/ctDNA) and multidisciplinary review of HRD‑negative/BRCA‑WT/ATM VUS status.\n- After clinical optimization and restaging, prioritize an evidence‑based non‑platinum systemic/second‑line strategy and evaluate eligibility for clinical trials in platinum‑resistant clear cell ovarian carcinoma, including anti‑angiogenic and immunotherapy options as appropriate.\n\n# INITIAL EXPERT OPINIONS\n- chair: - Confirm performance status, symptom burden, and goals of care, then prioritize systemic therapy for platinum‑resistant clear‑cell ovarian carcinoma with rapid progression [@guideline:nccn_ovariancan\n- oncologist: - Early biochemical and radiologic relapse (<6 months) after adjuvant platinum suggests platinum-resistant clear cell ovarian carcinoma; consider non‑platinum systemic approach [@guideline:nccn_ovaria\n- radiologist: - Progressive presacral pelvic mass with sacral and right iliac bone involvement, plus multiple pelvic mesenteric nodules consistent with recurrent/metastatic disease [@2022-12-29|MR].  \n\n- Increasing\n- pathologist: - Histology and IHC support diagnosis of ovarian clear cell carcinoma involving rectosigmoid, retroperitoneum, and vagina; grade not specified [@HISTOLOGY_AND_IHC|2022-03-28].  \n\n- MMR proteins intact\n- nuclear: - No PET/CT available; metabolic burden, sacral/right iliac bone involvement, and splenic lesion characterization remain unknown/needs update.  \n\n- Prior CT/MR show progressive pelvic, hepatic, and po\n\n# DISCUSSION INTERACTIONS\nRound 1: R1T1: oncologist→chair: Before committing to a new systemic line, we must urgently document ECOG, detailed symptoms, comorbi | R1T1: radiologist→oncologist: Most recent cross-sectional imaging is from 2022-12-29/30 and already shows clear systemic progressi | R1T2: pathologist→oncologist: From a pathology standpoint, comprehensive tumor profiling (MSI, TMB, PD-L1, broad somatic panel) re | R1T2: nuclear→oncologist: Given rapid progression and planned local interventions, clarify whether PET/CT is intended to chang | R1T2: nuclear→radiologist: If PET/CT is considered, please specify whether CT findings leave uncertainty about sacral/right ili\n\n\n\n# FINAL REFINED PLANS (All experts, all rounds)\n{\n  \"Round 1\": {\n    \"chair\": \"- Confirm performance status, symptom burden, and discuss goals; prioritize systemic therapy for platinum‑resistant clear cell histology and rapid metastatic progression [@report_id:2022-12-29|MR; @report_id:2022-12-29|CT; @guideline:nccn_ovariancancer_v3_2025__v00000000|22].  \\n\\n- Obtain updated comprehensive labs (including iron/B12, renal, hepatic, coagulation), manage significant anemia urgently, and rule out contraindications before starting next‑line systemic and bone‑directed/palliative local treatments [@report_id:2023-01-03|5600862].  \\n\\n- Arrange multidisciplinary review of molecular profile (HRD‑negative, BRCA‑WT, ATM variant) and consider repeat/expanded profiling on recent tissue, then prioritize evidence‑based non‑platinum systemic options and clinical trial enrollment for platinum‑resistant ovarian clear cell carcinoma [@report_id:OH2203828|2022-04-18; @pubmed:33758607].\",\n    \"oncologist\": \"- Urgently optimize supportive care: investigate/transfuse severe anemia [@20230103|2023-01-03], assess ECOG, pain, comorbidities, and clarify goals of care.  \\n\\n- Obtain updated contrast CT chest/abdomen/pelvis for current extent, then plan palliative radiation to sacral/right iliac lesions and systemic strategy. [@guideline:nccn_ovariancancer_v3_2025__v00000000|15]  \\n\\n- Arrange comprehensive tumor profiling (MSI, TMB, PD‑L1, broad somatic panel) on recent tissue/ctDNA to inform non‑platinum and trial options.\",\n    \"radiologist\": \"- Obtain updated contrast CT chest/abdomen/pelvis to reassess burden since progression on 2022-12-29/30 imaging [@2022-12-29|CT][@2022-12-29|MR].  \\n\\n- Reserve PET/CT for unresolved questions about sacral/right iliac bone or splenic involvement that would directly modify radiation fields [@2022-12-29|CT].  \\n\\n- Use updated imaging to guide palliative RT planning for painful presacral/sacral/right iliac lesions, aligning with symptom-directed management in recurrence [@guideline:nccn_ovariancancer_v3_2025__v00000000|22].\",\n    \"pathologist\": \"- Urgently document ECOG, detailed symptoms, comorbidities, and evaluate/transfuse for severe anemia before defining any new systemic strategy [@guideline:nccn_ovariancancer_v3_2025__v00000000|14].  \\n\\n- Obtain updated contrast CT chest/abdomen/pelvis to reassess pelvic, hepatic, bone, and splenic disease before radiation or systemic decisions [@report_id_unknown|unknown].  \\n\\n- Arrange comprehensive tumor profiling on recent tissue or ctDNA (MSI, TMB, PD-L1, broad somatic panel) to inform future options [@OH2203828|2022-04-18].\",\n    \"nuclear\": \"- Prioritize supportive care: document ECOG, symptoms, comorbidities; investigate/transfuse for severe anemia before systemic decisions (Hgb 74 g/L, labs otherwise unknown).  \\n\\n- Obtain updated contrast CT chest/abdomen/pelvis to reassess pelvic, hepatic, sacral/right iliac, and splenic disease before radiation planning [@2022-12-29|MR][@2022-12-29|CT].  \\n\\n- Reserve PET/CT for situations where CT leaves uncertainty that would meaningfully alter radiation fields or local interventions [@guideline:nccn_ovariancancer_v3_2025__v00000000|22].\"\n  },\n  \"Round 2\": {\n    \"chair\": \"- Prioritize second-line systemic therapy for platinum-resistant clear cell ovarian carcinoma with visceral and bone metastases; deem surgery/radiation palliative only [@guideline:nccn_ovariancancer_v3_2025__v00000000|14; @report_id:2022-12-29|CT].  \\n\\n- Before finalizing regimen, urgently optimize anemia, assess ECOG, symptoms, and clarify goals; obtain full chemistry, coagulation, and updated pain/thromboembolism status [@report_id:20230103|5600862].  \\n\\n- Arrange comprehensive survivorship and trial-focused review including prior HRD-negative, BRCA‑wildtype status to consider non‑platinum, anti‑angiogenic, immunotherapy, or trial options in sequencing [@guideline:esmo_cpg_epithelialovarian_2023__v00000000|10; @report_id:OH2203828].\",\n    \"oncologist\": \"- Urgently correct anemia (transfusion, iron/B12 workup), complete full labs, document ECOG, symptoms, comorbidities, and goals of care. [@20230103|2023-01-03]  \\n\\n- Restage with contrast CT chest/abdomen/pelvis, then coordinate palliative radiation for painful pelvic/sacral/right iliac disease and integrate palliative care. [@guideline:nccn_ovariancancer_v3_2025__v00000000|15]  \\n\\n- Send comprehensive molecular profiling (MSI, TMB, PD‑L1, broad panel/ctDNA); after optimization, select non‑platinum systemic/clinical‑trial strategy for platinum‑resistant clear cell disease. [@pubmed:33758607]\",\n    \"radiologist\": \"- Obtain updated contrast-enhanced CT chest/abdomen/pelvis to restage since documented progression on Dec 2022 imaging [@2022-12-29|CT][@2022-12-29|MR].  \\n\\n- Use CT as primary tool for palliative RT planning to presacral/sacral/right iliac lesions; reserve PET/CT for equivocal sites [@guideline:nccn_ovariancancer_v3_2025__v00000000|22].  \\n\\n- Reassess splenic low-density lesion on new CT to distinguish evolving infarct from alternative pathology and guide need for further imaging [@2022-12-29|CT].\",\n    \"pathologist\": \"- Proceed with comprehensive tumor profiling (MSI, TMB, PD‑L1, broad somatic panel) on recent tissue/ctDNA to expand options [@guideline:nccn_ovariancancer_v3_2025__v00000000|15].  \\n\\n- Maintain diagnosis of ovarian clear cell carcinoma with intact MMR and HRD-/BRCA1/2‑wild type status; ATM p.Y316C remains VUS [@HISTOLOGY_AND_IHC|2022-03-28].  \\n\\n- Ensure pathology–radiology correlation on new contrast CT (pelvis, sacrum/right iliac, spleen) to confirm sites for palliative radiation (report_id unknown|unknown).\",\n    \"nuclear\": \"- Continue with updated contrast CT chest/abdomen/pelvis as primary restaging tool to guide palliative radiation planning [@2022-12-29|CT][@2022-12-29|MR].  \\n\\n- Reserve PET/CT for CT‑equivocal bone or splenic lesions where metabolic clarification would change radiation fields or local procedures [@guideline:nccn_ovariancancer_v3_2025__v00000000|22].  \\n\\n- No current evidence that PET/CT would alter systemic therapy choice in this established platinum‑resistant, widely metastatic setting [@guideline:nccn_ovariancancer_v3_2025__v00000000|22].\"\n  }\n}\n\nSTRICT RULES:\n- Any factual statement about past tests/treatments must include [@report_id|date] or say unknown.\n- Any statement derived from guideline or PubMed literature must include [@guideline:doc_id|page] or [@pubmed:PMID].\n- If you cite guideline/PubMed evidence in Core Treatment Strategy or Change Triggers, include at least one tag in that bullet.\n- If experts disagree, pick the safest plan and state the key uncertainty.\n- You MUST consider the MDT discussion summary and interactions above when making your decision.\n\n# Response Format\nFinal Assessment:\n<1–3 sentences: summarize histology/biology, current disease status, and key uncertainties>\n\nCore Treatment Strategy:\n- < ≤20 words concrete decision >\n- < ≤20 words concrete decision >\n- < ≤20 words concrete decision >\n- < ≤20 words concrete decision >\n\nChange Triggers:\n- < ≤20 words \"if X, then adjust management from A to B\" >\n- < ≤20 words \"if X, then adjust management from A to B\" >\n", "assistant_reply": "- Confirm ECOG status, symptoms, goals; if ECOG ≥3 or patient declines systemic therapy, then adjust management from active treatment to best supportive care. [@guideline:nccn_ovariancancer_v3_2025__v00000000|22]\n\n- Clarify current bleeding, pain, anemia and HGB 74 g/L; if symptomatic or hemodynamically unstable, then adjust management from outpatient planning to urgent transfusion/stabilization. [@20230103|5600862]\n\n- Obtain full molecular/biomarker profile and trial options; if actionable alteration or suitable trial available, then adjust management from standard empiric therapy to biomarker- or trial-driven strategy.", "timestamp": "2026-01-19T08:07:06.807898"}], "oncologist": [{"role": "oncologist", "user_message": "Give INITIAL opinion (use ONLY your system-provided patient facts).\nReturn up to 3 bullets, each ≤20 words.\nIf key data missing, say exactly what needs updating.\nAt least ONE bullet must be evidence-based and include [@guideline:doc_id|page] or [@pubmed:PMID].\nIf you reference treatment strategy categories, guidelines, trials, or literature evidence, include tags [@guideline:doc_id|page] or [@pubmed:PMID].", "assistant_reply": "- Early biochemical and radiologic relapse (<6 months) after adjuvant platinum suggests platinum-resistant clear cell ovarian carcinoma; consider non‑platinum systemic approach [@guideline:nccn_ovariancancer_v3_2025__v00000000|14].  \n\n- Current severe anemia (Hgb 74 g/L) may limit therapy intensity; optimize transfusion/iron and clarify performance status, symptoms, comorbidities [@20230103|2023-01-03].  \n\n- HRD negative, BRCA1/2 wild-type; need updated imaging for disease burden, ECOG, renal function, and prior maintenance/biologic exposure to choose regimen [@OH2203828|2022-04-18].", "timestamp": "2026-01-19T08:03:00.463747"}, {"role": "oncologist", "user_message": "ROLE: oncologist. VISIT: 2023-01-03 08:53:29.260000\nDefault is NOT to speak. Speak ONLY if: conflict | safety | missing-critical | new-critical.\n\nCONTEXT (latest):\n[MDT_GLOBAL_KNOWLEDGE]\nKey Knowledge:\n- Platinum‑resistant clear cell ovarian carcinoma with rapid systemic progression (pelvis, liver, bone/sacrum) and likely widespread disease.\n- High symptom burden: painful presacral/bony disease and severe anemia (Hgb 74 g/L) limiting treatment options.\n- Pathology: clear cell carcinoma; MMR intact; HRD‑negative; BRCA1/2 wild‑type; germline ATM VUS; no comprehensive somatic profiling.\n- Imaging shows progressive pelvic/hepatic metastases; splenic lesion suspicious for infarct.\n\nControversies:\n- Added value of PET/CT for staging versus limited impact on systemic management in established platinum‑resistant disease.\n- Choice and intensity of non‑platinum systemic therapy given severe anemia and unknown performance status.\n- Significance of germline ATM VUS for trial eligibility/targeted approaches.\n\nMissing Info:\n- ECOG performance status, detailed symptom burden, and patient goals of care.\n- Updated labs (CBC, iron studies, renal/hepatic function) and comorbidities.\n- Most recent imaging overview and prior exposure to maintenance/biologic therapy.\n- Full tumor profiling (MSI, TMB, PD‑L1, broad somatic panel) and palliative care involvement.\n\nWorking Plan:\n- Clarify ECOG, symptoms, and goals; optimize supportive care (transfusion/iron, pain control).\n- Arrange palliative radiation oncology review for pelvic/sacral/right iliac bone disease.\n- Update staging with contrast CT; consider PET/CT if it will guide local interventions.\n- Plan non‑platinum systemic strategy appropriate to status and prior treatments.\n- Obtain comprehensive molecular profiling (tissue or ctDNA) to guide targeted/clinical trial options.\n\nAllowed targets: [chair,radiologist,pathologist,nuclear]\nReturn ONE-LINE JSON only:{\"speak\":\"yes/no\",\"messages\":[{\"target\":\"<role>\",\"message\":\"<1-2 sentences>\",\"why\":\"conflict|safety|missing|new\"}]}", "assistant_reply": "{\"speak\":\"yes\",\"messages\":[{\"target\":\"chair\",\"message\":\"Before committing to a new systemic line, we must urgently document ECOG, detailed symptoms, comorbidities, and transfuse/clarify cause of severe anemia, as these may preclude intensive chemotherapy options.\",\"why\":\"missing\"}]}", "timestamp": "2026-01-19T08:03:26.637394"}, {"role": "oncologist", "user_message": "ROLE: oncologist. VISIT: 2023-01-03 08:53:29.260000\nDefault is NOT to speak. Speak ONLY if: conflict | safety | missing-critical | new-critical.\n\nCONTEXT (latest):\n[MDT_GLOBAL_KNOWLEDGE]\nKey Knowledge:\n- Platinum‑resistant clear cell ovarian carcinoma with rapid systemic progression (pelvis, liver, bone/sacrum) and likely widespread disease.\n- High symptom burden: painful presacral/bony disease and severe anemia (Hgb 74 g/L) limiting treatment options.\n- Pathology: clear cell carcinoma; MMR intact; HRD‑negative; BRCA1/2 wild‑type; germline ATM VUS; no comprehensive somatic profiling.\n- Imaging shows progressive pelvic/hepatic metastases; splenic lesion suspicious for infarct.\n\nControversies:\n- Added value of PET/CT for staging versus limited impact on systemic management in established platinum‑resistant disease.\n- Choice and intensity of non‑platinum systemic therapy given severe anemia and unknown performance status.\n- Significance of germline ATM VUS for trial eligibility/targeted approaches.\n\nMissing Info:\n- ECOG performance status, detailed symptom burden, and patient goals of care.\n- Updated labs (CBC, iron studies, renal/hepatic function) and comorbidities.\n- Most recent imaging overview and prior exposure to maintenance/biologic therapy.\n- Full tumor profiling (MSI, TMB, PD‑L1, broad somatic panel) and palliative care involvement.\n\nWorking Plan:\n- Clarify ECOG, symptoms, and goals; optimize supportive care (transfusion/iron, pain control).\n- Arrange palliative radiation oncology review for pelvic/sacral/right iliac bone disease.\n- Update staging with contrast CT; consider PET/CT if it will guide local interventions.\n- Plan non‑platinum systemic strategy appropriate to status and prior treatments.\n- Obtain comprehensive molecular profiling (tissue or ctDNA) to guide targeted/clinical trial options.\n\n[RECENT_DELTAS]\n[R1T1 DELTA] oncologist->chair(missing): Before committing to a new systemic line, we must urgently document ECOG, detailed symptoms, comorbidities, and transfuse/clarify cause of severe anemia, as these may preclude intensive chemotherapy options. | radiologist->oncologist(missing): Most recent cross-sectional imaging is from 2022-12-29/30 and already shows clear systemic progression; updated contrast CT (chest/abdomen/pelvis) is needed before further systemic or radiation decisions.\n\nAllowed targets: [chair,radiologist,pathologist,nuclear]\nReturn ONE-LINE JSON only:{\"speak\":\"yes/no\",\"messages\":[{\"target\":\"<role>\",\"message\":\"<1-2 sentences>\",\"why\":\"conflict|safety|missing|new\"}]}", "assistant_reply": "{\"speak\":\"no\",\"messages\":[]}", "timestamp": "2026-01-19T08:03:34.742157"}, {"role": "oncologist", "user_message": "Given MDT context:\n[MDT_GLOBAL_KNOWLEDGE]\nKey Knowledge:\n- Platinum‑resistant clear cell ovarian carcinoma with rapid systemic progression (pelvis, liver, bone/sacrum) and likely widespread disease.\n- High symptom burden: painful presacral/bony disease and severe anemia (Hgb 74 g/L) limiting treatment options.\n- Pathology: clear cell carcinoma; MMR intact; HRD‑negative; BRCA1/2 wild‑type; germline ATM VUS; no comprehensive somatic profiling.\n- Imaging shows progressive pelvic/hepatic metastases; splenic lesion suspicious for infarct.\n\nControversies:\n- Added value of PET/CT for staging versus limited impact on systemic management in established platinum‑resistant disease.\n- Choice and intensity of non‑platinum systemic therapy given severe anemia and unknown performance status.\n- Significance of germline ATM VUS for trial eligibility/targeted approaches.\n\nMissing Info:\n- ECOG performance status, detailed symptom burden, and patient goals of care.\n- Updated labs (CBC, iron studies, renal/hepatic function) and comorbidities.\n- Most recent imaging overview and prior exposure to maintenance/biologic therapy.\n- Full tumor profiling (MSI, TMB, PD‑L1, broad somatic panel) and palliative care involvement.\n\nWorking Plan:\n- Clarify ECOG, symptoms, and goals; optimize supportive care (transfusion/iron, pain control).\n- Arrange palliative radiation oncology review for pelvic/sacral/right iliac bone disease.\n- Update staging with contrast CT; consider PET/CT if it will guide local interventions.\n- Plan non‑platinum systemic strategy appropriate to status and prior treatments.\n- Obtain comprehensive molecular profiling (tissue or ctDNA) to guide targeted/clinical trial options.\n\n[RECENT_DELTAS]\n[R1T1 DELTA] oncologist->chair(missing): Before committing to a new systemic line, we must urgently document ECOG, detailed symptoms, comorbidities, and transfuse/clarify cause of severe anemia, as these may preclude intensive chemotherapy options. | radiologist->oncologist(missing): Most recent cross-sectional imaging is from 2022-12-29/30 and already shows clear systemic progression; updated contrast CT (chest/abdomen/pelvis) is needed before further systemic or radiation decisions.\n[R1T2 DELTA] pathologist->oncologist(unspecified): From a pathology standpoint, comprehensive tumor profiling (MSI, TMB, PD-L1, broad somatic panel) remains outstanding and is important for future options. | nuclear->oncologist(missing): Given rapid progression and planned local interventions, clarify whether PET/CT is intended to change radiation fields or only confirm known lesions. | nuclear->radiologist(missing): If PET/CT is considered, please specify whether CT findings leave uncertainty about sacral/right iliac or splenic involvement that would alter management.\n\nDISCUSSION HISTORY (this round):\nTurn 1: oncologist→chair: Before committing to a new systemic line, we must urgently document ECOG, detailed symptoms, comorbidities, and transfuse/clarify cause of severe anemia, as these may preclude intensive chemotherapy options. | radiologist→oncologist: Most recent cross-sectional imaging is from 2022-12-29/30 and already shows clear systemic progression; updated contrast CT (chest/abdomen/pelvis) is needed before further systemic or radiation decisions.\nTurn 2: pathologist→oncologist: From a pathology standpoint, comprehensive tumor profiling (MSI, TMB, PD-L1, broad somatic panel) remains outstanding and is important for future options. | nuclear→oncologist: Given rapid progression and planned local interventions, clarify whether PET/CT is intended to change radiation fields or only confirm known lesions. | nuclear→radiologist: If PET/CT is considered, please specify whether CT findings leave uncertainty about sacral/right iliac or splenic involvement that would alter management.\n\nProvide FINAL refined plan based on the above context and discussions.\nUp to 3 bullets, each ≤20 words.\nAny factual claim must include [@report_id|date] or say unknown.\nAt least ONE bullet must be evidence-based and include [@guideline:doc_id|page] or [@pubmed:PMID].\nIf you reference treatment strategy categories, guidelines, trials, or literature evidence, include tags [@guideline:doc_id|page] or [@pubmed:PMID].\nIf discussions mentioned specific evidence, you may reference it with appropriate tags.", "assistant_reply": "- Urgently optimize supportive care: investigate/transfuse severe anemia [@20230103|2023-01-03], assess ECOG, pain, comorbidities, and clarify goals of care.  \n\n- Obtain updated contrast CT chest/abdomen/pelvis for current extent, then plan palliative radiation to sacral/right iliac lesions and systemic strategy. [@guideline:nccn_ovariancancer_v3_2025__v00000000|15]  \n\n- Arrange comprehensive tumor profiling (MSI, TMB, PD‑L1, broad somatic panel) on recent tissue/ctDNA to inform non‑platinum and trial options.", "timestamp": "2026-01-19T08:04:30.010192"}, {"role": "oncologist", "user_message": "ROLE: oncologist. VISIT: 2023-01-03 08:53:29.260000\nDefault is NOT to speak. Speak ONLY if: conflict | safety | missing-critical | new-critical.\n\nCONTEXT (latest):\n[MDT_GLOBAL_KNOWLEDGE]\nKey Knowledge:\n- Platinum‑resistant clear cell ovarian carcinoma with rapid progression and widespread involvement (pelvis, liver, sacrum/right iliac bone).\n- High symptom burden: painful pelvic/bony disease and severe anemia (Hgb 74 g/L) restricting systemic options.\n- Pathology: clear cell carcinoma; MMR intact; HRD‑negative; BRCA1/2 wild‑type; germline ATM VUS; comprehensive somatic profiling not yet completed.\n- Last imaging (Dec 2022 CT/MR) shows progressive pelvic/hepatic disease, sacral/right iliac involvement, and splenic lesion suspicious for infarct.\n\nControversies:\n- Need for PET/CT beyond contrast CT, given likely limited impact on systemic therapy and its role mainly in refining radiation fields.\n- Optimal non‑platinum systemic regimen and intensity in the context of severe anemia and yet‑uncertain ECOG/comorbidities.\n- Relevance of ATM VUS for targeted therapy or trial eligibility.\n\nMissing Info:\n- ECOG performance status, detailed symptoms (including pain control), comorbidities, and patient goals of care.\n- Updated comprehensive labs (CBC, iron/B12, renal, hepatic, coagulation).\n- New contrast CT chest/abdomen/pelvis and record of prior maintenance/biologic treatments.\n- Completed comprehensive tumor profiling (MSI, TMB, PD‑L1, broad somatic panel).\n- Confirmation of palliative care involvement and a formal symptom management plan.\n\nWorking Plan:\n- Optimize supportive care urgently: investigate/manage severe anemia, obtain full labs, document ECOG, symptoms, comorbidities, and clarify goals of care.\n- Obtain updated contrast CT chest/abdomen/pelvis to reassess disease and plan palliative radiation to presacral/sacral/right iliac lesions.\n- Reserve PET/CT for CT‑equivocal bone/splenic findings that would alter radiation fields/local interventions.\n- Arrange palliative radiation oncology review for symptomatic pelvic/bone disease.\n- Perform multidisciplinary review of existing molecular data and send comprehensive profiling (MSI, TMB, PD‑L1, broad somatic panel) on recent tissue/ctDNA.\n- After optimization and restaging, select an evidence‑based non‑platinum systemic approach and assess eligibility for clear‑cell, platinum‑resistant clinical trials.\n\nAllowed targets: [chair,radiologist,pathologist,nuclear]\nReturn ONE-LINE JSON only:{\"speak\":\"yes/no\",\"messages\":[{\"target\":\"<role>\",\"message\":\"<1-2 sentences>\",\"why\":\"conflict|safety|missing|new\"}]}", "assistant_reply": "{\"speak\":\"no\",\"messages\":[]}", "timestamp": "2026-01-19T08:04:58.529996"}, {"role": "oncologist", "user_message": "Given MDT context:\n[MDT_GLOBAL_KNOWLEDGE]\nKey Knowledge:\n- Platinum‑resistant clear cell ovarian carcinoma with rapid progression and widespread involvement (pelvis, liver, sacrum/right iliac bone).\n- High symptom burden: painful pelvic/bony disease and severe anemia (Hgb 74 g/L) restricting systemic options.\n- Pathology: clear cell carcinoma; MMR intact; HRD‑negative; BRCA1/2 wild‑type; germline ATM VUS; comprehensive somatic profiling not yet completed.\n- Last imaging (Dec 2022 CT/MR) shows progressive pelvic/hepatic disease, sacral/right iliac involvement, and splenic lesion suspicious for infarct.\n\nControversies:\n- Need for PET/CT beyond contrast CT, given likely limited impact on systemic therapy and its role mainly in refining radiation fields.\n- Optimal non‑platinum systemic regimen and intensity in the context of severe anemia and yet‑uncertain ECOG/comorbidities.\n- Relevance of ATM VUS for targeted therapy or trial eligibility.\n\nMissing Info:\n- ECOG performance status, detailed symptoms (including pain control), comorbidities, and patient goals of care.\n- Updated comprehensive labs (CBC, iron/B12, renal, hepatic, coagulation).\n- New contrast CT chest/abdomen/pelvis and record of prior maintenance/biologic treatments.\n- Completed comprehensive tumor profiling (MSI, TMB, PD‑L1, broad somatic panel).\n- Confirmation of palliative care involvement and a formal symptom management plan.\n\nWorking Plan:\n- Optimize supportive care urgently: investigate/manage severe anemia, obtain full labs, document ECOG, symptoms, comorbidities, and clarify goals of care.\n- Obtain updated contrast CT chest/abdomen/pelvis to reassess disease and plan palliative radiation to presacral/sacral/right iliac lesions.\n- Reserve PET/CT for CT‑equivocal bone/splenic findings that would alter radiation fields/local interventions.\n- Arrange palliative radiation oncology review for symptomatic pelvic/bone disease.\n- Perform multidisciplinary review of existing molecular data and send comprehensive profiling (MSI, TMB, PD‑L1, broad somatic panel) on recent tissue/ctDNA.\n- After optimization and restaging, select an evidence‑based non‑platinum systemic approach and assess eligibility for clear‑cell, platinum‑resistant clinical trials.\n\nDISCUSSION HISTORY (this round):\nNo direct discussions in this round.\n\nProvide FINAL refined plan based on the above context and discussions.\nUp to 3 bullets, each ≤20 words.\nAny factual claim must include [@report_id|date] or say unknown.\nAt least ONE bullet must be evidence-based and include [@guideline:doc_id|page] or [@pubmed:PMID].\nIf you reference treatment strategy categories, guidelines, trials, or literature evidence, include tags [@guideline:doc_id|page] or [@pubmed:PMID].\nIf discussions mentioned specific evidence, you may reference it with appropriate tags.", "assistant_reply": "- Urgently correct anemia (transfusion, iron/B12 workup), complete full labs, document ECOG, symptoms, comorbidities, and goals of care. [@20230103|2023-01-03]  \n\n- Restage with contrast CT chest/abdomen/pelvis, then coordinate palliative radiation for painful pelvic/sacral/right iliac disease and integrate palliative care. [@guideline:nccn_ovariancancer_v3_2025__v00000000|15]  \n\n- Send comprehensive molecular profiling (MSI, TMB, PD‑L1, broad panel/ctDNA); after optimization, select non‑platinum systemic/clinical‑trial strategy for platinum‑resistant clear cell disease. [@pubmed:33758607]", "timestamp": "2026-01-19T08:06:07.954153"}], "radiologist": [{"role": "radiologist", "user_message": "Give INITIAL opinion (use ONLY your system-provided patient facts).\nReturn up to 3 bullets, each ≤20 words.\nIf key data missing, say exactly what needs updating.\nAt least ONE bullet must be evidence-based and include [@guideline:doc_id|page] or [@pubmed:PMID].\nIf you reference treatment strategy categories, guidelines, trials, or literature evidence, include tags [@guideline:doc_id|page] or [@pubmed:PMID].", "assistant_reply": "- Progressive presacral pelvic mass with sacral and right iliac bone involvement, plus multiple pelvic mesenteric nodules consistent with recurrent/metastatic disease [@2022-12-29|MR].  \n\n- Increasing number and size of multiple hepatic metastatic nodules; stable hepatic cysts [@2022-12-29|CT].  \n\n- Splenic patchy low-density lesion suspicious for infarct; recommend imaging follow‑up for evolution and complications [@2022-12-29|CT][@pubmed:33758607].", "timestamp": "2026-01-19T08:03:02.717893"}, {"role": "radiologist", "user_message": "ROLE: radiologist. VISIT: 2023-01-03 08:53:29.260000\nDefault is NOT to speak. Speak ONLY if: conflict | safety | missing-critical | new-critical.\n\nCONTEXT (latest):\n[MDT_GLOBAL_KNOWLEDGE]\nKey Knowledge:\n- Platinum‑resistant clear cell ovarian carcinoma with rapid systemic progression (pelvis, liver, bone/sacrum) and likely widespread disease.\n- High symptom burden: painful presacral/bony disease and severe anemia (Hgb 74 g/L) limiting treatment options.\n- Pathology: clear cell carcinoma; MMR intact; HRD‑negative; BRCA1/2 wild‑type; germline ATM VUS; no comprehensive somatic profiling.\n- Imaging shows progressive pelvic/hepatic metastases; splenic lesion suspicious for infarct.\n\nControversies:\n- Added value of PET/CT for staging versus limited impact on systemic management in established platinum‑resistant disease.\n- Choice and intensity of non‑platinum systemic therapy given severe anemia and unknown performance status.\n- Significance of germline ATM VUS for trial eligibility/targeted approaches.\n\nMissing Info:\n- ECOG performance status, detailed symptom burden, and patient goals of care.\n- Updated labs (CBC, iron studies, renal/hepatic function) and comorbidities.\n- Most recent imaging overview and prior exposure to maintenance/biologic therapy.\n- Full tumor profiling (MSI, TMB, PD‑L1, broad somatic panel) and palliative care involvement.\n\nWorking Plan:\n- Clarify ECOG, symptoms, and goals; optimize supportive care (transfusion/iron, pain control).\n- Arrange palliative radiation oncology review for pelvic/sacral/right iliac bone disease.\n- Update staging with contrast CT; consider PET/CT if it will guide local interventions.\n- Plan non‑platinum systemic strategy appropriate to status and prior treatments.\n- Obtain comprehensive molecular profiling (tissue or ctDNA) to guide targeted/clinical trial options.\n\nAllowed targets: [chair,oncologist,pathologist,nuclear]\nReturn ONE-LINE JSON only:{\"speak\":\"yes/no\",\"messages\":[{\"target\":\"<role>\",\"message\":\"<1-2 sentences>\",\"why\":\"conflict|safety|missing|new\"}]}", "assistant_reply": "{\"speak\":\"yes\",\"messages\":[{\"target\":\"oncologist\",\"message\":\"Most recent cross-sectional imaging is from 2022-12-29/30 and already shows clear systemic progression; updated contrast CT (chest/abdomen/pelvis) is needed before further systemic or radiation decisions.\",\"why\":\"missing\"}]}", "timestamp": "2026-01-19T08:03:28.384852"}, {"role": "radiologist", "user_message": "ROLE: radiologist. VISIT: 2023-01-03 08:53:29.260000\nDefault is NOT to speak. Speak ONLY if: conflict | safety | missing-critical | new-critical.\n\nCONTEXT (latest):\n[MDT_GLOBAL_KNOWLEDGE]\nKey Knowledge:\n- Platinum‑resistant clear cell ovarian carcinoma with rapid systemic progression (pelvis, liver, bone/sacrum) and likely widespread disease.\n- High symptom burden: painful presacral/bony disease and severe anemia (Hgb 74 g/L) limiting treatment options.\n- Pathology: clear cell carcinoma; MMR intact; HRD‑negative; BRCA1/2 wild‑type; germline ATM VUS; no comprehensive somatic profiling.\n- Imaging shows progressive pelvic/hepatic metastases; splenic lesion suspicious for infarct.\n\nControversies:\n- Added value of PET/CT for staging versus limited impact on systemic management in established platinum‑resistant disease.\n- Choice and intensity of non‑platinum systemic therapy given severe anemia and unknown performance status.\n- Significance of germline ATM VUS for trial eligibility/targeted approaches.\n\nMissing Info:\n- ECOG performance status, detailed symptom burden, and patient goals of care.\n- Updated labs (CBC, iron studies, renal/hepatic function) and comorbidities.\n- Most recent imaging overview and prior exposure to maintenance/biologic therapy.\n- Full tumor profiling (MSI, TMB, PD‑L1, broad somatic panel) and palliative care involvement.\n\nWorking Plan:\n- Clarify ECOG, symptoms, and goals; optimize supportive care (transfusion/iron, pain control).\n- Arrange palliative radiation oncology review for pelvic/sacral/right iliac bone disease.\n- Update staging with contrast CT; consider PET/CT if it will guide local interventions.\n- Plan non‑platinum systemic strategy appropriate to status and prior treatments.\n- Obtain comprehensive molecular profiling (tissue or ctDNA) to guide targeted/clinical trial options.\n\n[RECENT_DELTAS]\n[R1T1 DELTA] oncologist->chair(missing): Before committing to a new systemic line, we must urgently document ECOG, detailed symptoms, comorbidities, and transfuse/clarify cause of severe anemia, as these may preclude intensive chemotherapy options. | radiologist->oncologist(missing): Most recent cross-sectional imaging is from 2022-12-29/30 and already shows clear systemic progression; updated contrast CT (chest/abdomen/pelvis) is needed before further systemic or radiation decisions.\n\nAllowed targets: [chair,oncologist,pathologist,nuclear]\nReturn ONE-LINE JSON only:{\"speak\":\"yes/no\",\"messages\":[{\"target\":\"<role>\",\"message\":\"<1-2 sentences>\",\"why\":\"conflict|safety|missing|new\"}]}", "assistant_reply": "{\"speak\":\"no\",\"messages\":[]}", "timestamp": "2026-01-19T08:03:47.671100"}, {"role": "radiologist", "user_message": "Given MDT context:\n[MDT_GLOBAL_KNOWLEDGE]\nKey Knowledge:\n- Platinum‑resistant clear cell ovarian carcinoma with rapid systemic progression (pelvis, liver, bone/sacrum) and likely widespread disease.\n- High symptom burden: painful presacral/bony disease and severe anemia (Hgb 74 g/L) limiting treatment options.\n- Pathology: clear cell carcinoma; MMR intact; HRD‑negative; BRCA1/2 wild‑type; germline ATM VUS; no comprehensive somatic profiling.\n- Imaging shows progressive pelvic/hepatic metastases; splenic lesion suspicious for infarct.\n\nControversies:\n- Added value of PET/CT for staging versus limited impact on systemic management in established platinum‑resistant disease.\n- Choice and intensity of non‑platinum systemic therapy given severe anemia and unknown performance status.\n- Significance of germline ATM VUS for trial eligibility/targeted approaches.\n\nMissing Info:\n- ECOG performance status, detailed symptom burden, and patient goals of care.\n- Updated labs (CBC, iron studies, renal/hepatic function) and comorbidities.\n- Most recent imaging overview and prior exposure to maintenance/biologic therapy.\n- Full tumor profiling (MSI, TMB, PD‑L1, broad somatic panel) and palliative care involvement.\n\nWorking Plan:\n- Clarify ECOG, symptoms, and goals; optimize supportive care (transfusion/iron, pain control).\n- Arrange palliative radiation oncology review for pelvic/sacral/right iliac bone disease.\n- Update staging with contrast CT; consider PET/CT if it will guide local interventions.\n- Plan non‑platinum systemic strategy appropriate to status and prior treatments.\n- Obtain comprehensive molecular profiling (tissue or ctDNA) to guide targeted/clinical trial options.\n\n[RECENT_DELTAS]\n[R1T1 DELTA] oncologist->chair(missing): Before committing to a new systemic line, we must urgently document ECOG, detailed symptoms, comorbidities, and transfuse/clarify cause of severe anemia, as these may preclude intensive chemotherapy options. | radiologist->oncologist(missing): Most recent cross-sectional imaging is from 2022-12-29/30 and already shows clear systemic progression; updated contrast CT (chest/abdomen/pelvis) is needed before further systemic or radiation decisions.\n[R1T2 DELTA] pathologist->oncologist(unspecified): From a pathology standpoint, comprehensive tumor profiling (MSI, TMB, PD-L1, broad somatic panel) remains outstanding and is important for future options. | nuclear->oncologist(missing): Given rapid progression and planned local interventions, clarify whether PET/CT is intended to change radiation fields or only confirm known lesions. | nuclear->radiologist(missing): If PET/CT is considered, please specify whether CT findings leave uncertainty about sacral/right iliac or splenic involvement that would alter management.\n\nDISCUSSION HISTORY (this round):\nTurn 1: oncologist→chair: Before committing to a new systemic line, we must urgently document ECOG, detailed symptoms, comorbidities, and transfuse/clarify cause of severe anemia, as these may preclude intensive chemotherapy options. | radiologist→oncologist: Most recent cross-sectional imaging is from 2022-12-29/30 and already shows clear systemic progression; updated contrast CT (chest/abdomen/pelvis) is needed before further systemic or radiation decisions.\nTurn 2: pathologist→oncologist: From a pathology standpoint, comprehensive tumor profiling (MSI, TMB, PD-L1, broad somatic panel) remains outstanding and is important for future options. | nuclear→oncologist: Given rapid progression and planned local interventions, clarify whether PET/CT is intended to change radiation fields or only confirm known lesions. | nuclear→radiologist: If PET/CT is considered, please specify whether CT findings leave uncertainty about sacral/right iliac or splenic involvement that would alter management.\n\nProvide FINAL refined plan based on the above context and discussions.\nUp to 3 bullets, each ≤20 words.\nAny factual claim must include [@report_id|date] or say unknown.\nAt least ONE bullet must be evidence-based and include [@guideline:doc_id|page] or [@pubmed:PMID].\nIf you reference treatment strategy categories, guidelines, trials, or literature evidence, include tags [@guideline:doc_id|page] or [@pubmed:PMID].\nIf discussions mentioned specific evidence, you may reference it with appropriate tags.", "assistant_reply": "- Obtain updated contrast CT chest/abdomen/pelvis to reassess burden since progression on 2022-12-29/30 imaging [@2022-12-29|CT][@2022-12-29|MR].  \n\n- Reserve PET/CT for unresolved questions about sacral/right iliac bone or splenic involvement that would directly modify radiation fields [@2022-12-29|CT].  \n\n- Use updated imaging to guide palliative RT planning for painful presacral/sacral/right iliac lesions, aligning with symptom-directed management in recurrence [@guideline:nccn_ovariancancer_v3_2025__v00000000|22].", "timestamp": "2026-01-19T08:04:32.486616"}, {"role": "radiologist", "user_message": "ROLE: radiologist. VISIT: 2023-01-03 08:53:29.260000\nDefault is NOT to speak. Speak ONLY if: conflict | safety | missing-critical | new-critical.\n\nCONTEXT (latest):\n[MDT_GLOBAL_KNOWLEDGE]\nKey Knowledge:\n- Platinum‑resistant clear cell ovarian carcinoma with rapid progression and widespread involvement (pelvis, liver, sacrum/right iliac bone).\n- High symptom burden: painful pelvic/bony disease and severe anemia (Hgb 74 g/L) restricting systemic options.\n- Pathology: clear cell carcinoma; MMR intact; HRD‑negative; BRCA1/2 wild‑type; germline ATM VUS; comprehensive somatic profiling not yet completed.\n- Last imaging (Dec 2022 CT/MR) shows progressive pelvic/hepatic disease, sacral/right iliac involvement, and splenic lesion suspicious for infarct.\n\nControversies:\n- Need for PET/CT beyond contrast CT, given likely limited impact on systemic therapy and its role mainly in refining radiation fields.\n- Optimal non‑platinum systemic regimen and intensity in the context of severe anemia and yet‑uncertain ECOG/comorbidities.\n- Relevance of ATM VUS for targeted therapy or trial eligibility.\n\nMissing Info:\n- ECOG performance status, detailed symptoms (including pain control), comorbidities, and patient goals of care.\n- Updated comprehensive labs (CBC, iron/B12, renal, hepatic, coagulation).\n- New contrast CT chest/abdomen/pelvis and record of prior maintenance/biologic treatments.\n- Completed comprehensive tumor profiling (MSI, TMB, PD‑L1, broad somatic panel).\n- Confirmation of palliative care involvement and a formal symptom management plan.\n\nWorking Plan:\n- Optimize supportive care urgently: investigate/manage severe anemia, obtain full labs, document ECOG, symptoms, comorbidities, and clarify goals of care.\n- Obtain updated contrast CT chest/abdomen/pelvis to reassess disease and plan palliative radiation to presacral/sacral/right iliac lesions.\n- Reserve PET/CT for CT‑equivocal bone/splenic findings that would alter radiation fields/local interventions.\n- Arrange palliative radiation oncology review for symptomatic pelvic/bone disease.\n- Perform multidisciplinary review of existing molecular data and send comprehensive profiling (MSI, TMB, PD‑L1, broad somatic panel) on recent tissue/ctDNA.\n- After optimization and restaging, select an evidence‑based non‑platinum systemic approach and assess eligibility for clear‑cell, platinum‑resistant clinical trials.\n\nAllowed targets: [chair,oncologist,pathologist,nuclear]\nReturn ONE-LINE JSON only:{\"speak\":\"yes/no\",\"messages\":[{\"target\":\"<role>\",\"message\":\"<1-2 sentences>\",\"why\":\"conflict|safety|missing|new\"}]}", "assistant_reply": "{\"speak\":\"no\",\"messages\":[]}", "timestamp": "2026-01-19T08:05:08.847419"}, {"role": "radiologist", "user_message": "Given MDT context:\n[MDT_GLOBAL_KNOWLEDGE]\nKey Knowledge:\n- Platinum‑resistant clear cell ovarian carcinoma with rapid progression and widespread involvement (pelvis, liver, sacrum/right iliac bone).\n- High symptom burden: painful pelvic/bony disease and severe anemia (Hgb 74 g/L) restricting systemic options.\n- Pathology: clear cell carcinoma; MMR intact; HRD‑negative; BRCA1/2 wild‑type; germline ATM VUS; comprehensive somatic profiling not yet completed.\n- Last imaging (Dec 2022 CT/MR) shows progressive pelvic/hepatic disease, sacral/right iliac involvement, and splenic lesion suspicious for infarct.\n\nControversies:\n- Need for PET/CT beyond contrast CT, given likely limited impact on systemic therapy and its role mainly in refining radiation fields.\n- Optimal non‑platinum systemic regimen and intensity in the context of severe anemia and yet‑uncertain ECOG/comorbidities.\n- Relevance of ATM VUS for targeted therapy or trial eligibility.\n\nMissing Info:\n- ECOG performance status, detailed symptoms (including pain control), comorbidities, and patient goals of care.\n- Updated comprehensive labs (CBC, iron/B12, renal, hepatic, coagulation).\n- New contrast CT chest/abdomen/pelvis and record of prior maintenance/biologic treatments.\n- Completed comprehensive tumor profiling (MSI, TMB, PD‑L1, broad somatic panel).\n- Confirmation of palliative care involvement and a formal symptom management plan.\n\nWorking Plan:\n- Optimize supportive care urgently: investigate/manage severe anemia, obtain full labs, document ECOG, symptoms, comorbidities, and clarify goals of care.\n- Obtain updated contrast CT chest/abdomen/pelvis to reassess disease and plan palliative radiation to presacral/sacral/right iliac lesions.\n- Reserve PET/CT for CT‑equivocal bone/splenic findings that would alter radiation fields/local interventions.\n- Arrange palliative radiation oncology review for symptomatic pelvic/bone disease.\n- Perform multidisciplinary review of existing molecular data and send comprehensive profiling (MSI, TMB, PD‑L1, broad somatic panel) on recent tissue/ctDNA.\n- After optimization and restaging, select an evidence‑based non‑platinum systemic approach and assess eligibility for clear‑cell, platinum‑resistant clinical trials.\n\nDISCUSSION HISTORY (this round):\nNo direct discussions in this round.\n\nProvide FINAL refined plan based on the above context and discussions.\nUp to 3 bullets, each ≤20 words.\nAny factual claim must include [@report_id|date] or say unknown.\nAt least ONE bullet must be evidence-based and include [@guideline:doc_id|page] or [@pubmed:PMID].\nIf you reference treatment strategy categories, guidelines, trials, or literature evidence, include tags [@guideline:doc_id|page] or [@pubmed:PMID].\nIf discussions mentioned specific evidence, you may reference it with appropriate tags.", "assistant_reply": "- Obtain updated contrast-enhanced CT chest/abdomen/pelvis to restage since documented progression on Dec 2022 imaging [@2022-12-29|CT][@2022-12-29|MR].  \n\n- Use CT as primary tool for palliative RT planning to presacral/sacral/right iliac lesions; reserve PET/CT for equivocal sites [@guideline:nccn_ovariancancer_v3_2025__v00000000|22].  \n\n- Reassess splenic low-density lesion on new CT to distinguish evolving infarct from alternative pathology and guide need for further imaging [@2022-12-29|CT].", "timestamp": "2026-01-19T08:06:10.800984"}], "pathologist": [{"role": "pathologist", "user_message": "Give INITIAL opinion (use ONLY your system-provided patient facts).\nReturn up to 3 bullets, each ≤20 words.\nIf key data missing, say exactly what needs updating.\nAt least ONE bullet must be evidence-based and include [@guideline:doc_id|page] or [@pubmed:PMID].\nIf you reference treatment strategy categories, guidelines, trials, or literature evidence, include tags [@guideline:doc_id|page] or [@pubmed:PMID].", "assistant_reply": "- Histology and IHC support diagnosis of ovarian clear cell carcinoma involving rectosigmoid, retroperitoneum, and vagina; grade not specified [@HISTOLOGY_AND_IHC|2022-03-28].  \n\n- MMR proteins intact; HRD and BRCA1/2 pathogenic variants not detected; germline ATM p.Y316C reported, clinical significance unclear [@OH2203828|2022-04-18].  \n\n- For future care, comprehensive tumor profiling (MSI, TMB, PD-L1, broader somatic panel) is missing and should be updated [@guideline:nccn_ovariancancer_v3_2025__v00000000|15].", "timestamp": "2026-01-19T08:03:05.472003"}, {"role": "pathologist", "user_message": "ROLE: pathologist. VISIT: 2023-01-03 08:53:29.260000\nDefault is NOT to speak. Speak ONLY if: conflict | safety | missing-critical | new-critical.\n\nCONTEXT (latest):\n[MDT_GLOBAL_KNOWLEDGE]\nKey Knowledge:\n- Platinum‑resistant clear cell ovarian carcinoma with rapid systemic progression (pelvis, liver, bone/sacrum) and likely widespread disease.\n- High symptom burden: painful presacral/bony disease and severe anemia (Hgb 74 g/L) limiting treatment options.\n- Pathology: clear cell carcinoma; MMR intact; HRD‑negative; BRCA1/2 wild‑type; germline ATM VUS; no comprehensive somatic profiling.\n- Imaging shows progressive pelvic/hepatic metastases; splenic lesion suspicious for infarct.\n\nControversies:\n- Added value of PET/CT for staging versus limited impact on systemic management in established platinum‑resistant disease.\n- Choice and intensity of non‑platinum systemic therapy given severe anemia and unknown performance status.\n- Significance of germline ATM VUS for trial eligibility/targeted approaches.\n\nMissing Info:\n- ECOG performance status, detailed symptom burden, and patient goals of care.\n- Updated labs (CBC, iron studies, renal/hepatic function) and comorbidities.\n- Most recent imaging overview and prior exposure to maintenance/biologic therapy.\n- Full tumor profiling (MSI, TMB, PD‑L1, broad somatic panel) and palliative care involvement.\n\nWorking Plan:\n- Clarify ECOG, symptoms, and goals; optimize supportive care (transfusion/iron, pain control).\n- Arrange palliative radiation oncology review for pelvic/sacral/right iliac bone disease.\n- Update staging with contrast CT; consider PET/CT if it will guide local interventions.\n- Plan non‑platinum systemic strategy appropriate to status and prior treatments.\n- Obtain comprehensive molecular profiling (tissue or ctDNA) to guide targeted/clinical trial options.\n\nAllowed targets: [chair,oncologist,radiologist,nuclear]\nReturn ONE-LINE JSON only:{\"speak\":\"yes/no\",\"messages\":[{\"target\":\"<role>\",\"message\":\"<1-2 sentences>\",\"why\":\"conflict|safety|missing|new\"}]}", "assistant_reply": "{\"speak\":\"no\",\"messages\":[]}", "timestamp": "2026-01-19T08:03:29.694499"}, {"role": "pathologist", "user_message": "ROLE: pathologist. VISIT: 2023-01-03 08:53:29.260000\nDefault is NOT to speak. Speak ONLY if: conflict | safety | missing-critical | new-critical.\n\nCONTEXT (latest):\n[MDT_GLOBAL_KNOWLEDGE]\nKey Knowledge:\n- Platinum‑resistant clear cell ovarian carcinoma with rapid systemic progression (pelvis, liver, bone/sacrum) and likely widespread disease.\n- High symptom burden: painful presacral/bony disease and severe anemia (Hgb 74 g/L) limiting treatment options.\n- Pathology: clear cell carcinoma; MMR intact; HRD‑negative; BRCA1/2 wild‑type; germline ATM VUS; no comprehensive somatic profiling.\n- Imaging shows progressive pelvic/hepatic metastases; splenic lesion suspicious for infarct.\n\nControversies:\n- Added value of PET/CT for staging versus limited impact on systemic management in established platinum‑resistant disease.\n- Choice and intensity of non‑platinum systemic therapy given severe anemia and unknown performance status.\n- Significance of germline ATM VUS for trial eligibility/targeted approaches.\n\nMissing Info:\n- ECOG performance status, detailed symptom burden, and patient goals of care.\n- Updated labs (CBC, iron studies, renal/hepatic function) and comorbidities.\n- Most recent imaging overview and prior exposure to maintenance/biologic therapy.\n- Full tumor profiling (MSI, TMB, PD‑L1, broad somatic panel) and palliative care involvement.\n\nWorking Plan:\n- Clarify ECOG, symptoms, and goals; optimize supportive care (transfusion/iron, pain control).\n- Arrange palliative radiation oncology review for pelvic/sacral/right iliac bone disease.\n- Update staging with contrast CT; consider PET/CT if it will guide local interventions.\n- Plan non‑platinum systemic strategy appropriate to status and prior treatments.\n- Obtain comprehensive molecular profiling (tissue or ctDNA) to guide targeted/clinical trial options.\n\n[RECENT_DELTAS]\n[R1T1 DELTA] oncologist->chair(missing): Before committing to a new systemic line, we must urgently document ECOG, detailed symptoms, comorbidities, and transfuse/clarify cause of severe anemia, as these may preclude intensive chemotherapy options. | radiologist->oncologist(missing): Most recent cross-sectional imaging is from 2022-12-29/30 and already shows clear systemic progression; updated contrast CT (chest/abdomen/pelvis) is needed before further systemic or radiation decisions.\n\nAllowed targets: [chair,oncologist,radiologist,nuclear]\nReturn ONE-LINE JSON only:{\"speak\":\"yes/no\",\"messages\":[{\"target\":\"<role>\",\"message\":\"<1-2 sentences>\",\"why\":\"conflict|safety|missing|new\"}]}", "assistant_reply": "{\"speak\":\"yes\",\"messages\":[{\"target\":\"oncologist\",\"message\":\"From a pathology standpoint, comprehensive tumor profiling (MSI, TMB, PD-L1, broad somatic panel) remains outstanding and is important for future options.\",\"why\":\"missing-critical\"}]}", "timestamp": "2026-01-19T08:03:57.662159"}, {"role": "pathologist", "user_message": "Given MDT context:\n[MDT_GLOBAL_KNOWLEDGE]\nKey Knowledge:\n- Platinum‑resistant clear cell ovarian carcinoma with rapid systemic progression (pelvis, liver, bone/sacrum) and likely widespread disease.\n- High symptom burden: painful presacral/bony disease and severe anemia (Hgb 74 g/L) limiting treatment options.\n- Pathology: clear cell carcinoma; MMR intact; HRD‑negative; BRCA1/2 wild‑type; germline ATM VUS; no comprehensive somatic profiling.\n- Imaging shows progressive pelvic/hepatic metastases; splenic lesion suspicious for infarct.\n\nControversies:\n- Added value of PET/CT for staging versus limited impact on systemic management in established platinum‑resistant disease.\n- Choice and intensity of non‑platinum systemic therapy given severe anemia and unknown performance status.\n- Significance of germline ATM VUS for trial eligibility/targeted approaches.\n\nMissing Info:\n- ECOG performance status, detailed symptom burden, and patient goals of care.\n- Updated labs (CBC, iron studies, renal/hepatic function) and comorbidities.\n- Most recent imaging overview and prior exposure to maintenance/biologic therapy.\n- Full tumor profiling (MSI, TMB, PD‑L1, broad somatic panel) and palliative care involvement.\n\nWorking Plan:\n- Clarify ECOG, symptoms, and goals; optimize supportive care (transfusion/iron, pain control).\n- Arrange palliative radiation oncology review for pelvic/sacral/right iliac bone disease.\n- Update staging with contrast CT; consider PET/CT if it will guide local interventions.\n- Plan non‑platinum systemic strategy appropriate to status and prior treatments.\n- Obtain comprehensive molecular profiling (tissue or ctDNA) to guide targeted/clinical trial options.\n\n[RECENT_DELTAS]\n[R1T1 DELTA] oncologist->chair(missing): Before committing to a new systemic line, we must urgently document ECOG, detailed symptoms, comorbidities, and transfuse/clarify cause of severe anemia, as these may preclude intensive chemotherapy options. | radiologist->oncologist(missing): Most recent cross-sectional imaging is from 2022-12-29/30 and already shows clear systemic progression; updated contrast CT (chest/abdomen/pelvis) is needed before further systemic or radiation decisions.\n[R1T2 DELTA] pathologist->oncologist(unspecified): From a pathology standpoint, comprehensive tumor profiling (MSI, TMB, PD-L1, broad somatic panel) remains outstanding and is important for future options. | nuclear->oncologist(missing): Given rapid progression and planned local interventions, clarify whether PET/CT is intended to change radiation fields or only confirm known lesions. | nuclear->radiologist(missing): If PET/CT is considered, please specify whether CT findings leave uncertainty about sacral/right iliac or splenic involvement that would alter management.\n\nDISCUSSION HISTORY (this round):\nTurn 1: oncologist→chair: Before committing to a new systemic line, we must urgently document ECOG, detailed symptoms, comorbidities, and transfuse/clarify cause of severe anemia, as these may preclude intensive chemotherapy options. | radiologist→oncologist: Most recent cross-sectional imaging is from 2022-12-29/30 and already shows clear systemic progression; updated contrast CT (chest/abdomen/pelvis) is needed before further systemic or radiation decisions.\nTurn 2: pathologist→oncologist: From a pathology standpoint, comprehensive tumor profiling (MSI, TMB, PD-L1, broad somatic panel) remains outstanding and is important for future options. | nuclear→oncologist: Given rapid progression and planned local interventions, clarify whether PET/CT is intended to change radiation fields or only confirm known lesions. | nuclear→radiologist: If PET/CT is considered, please specify whether CT findings leave uncertainty about sacral/right iliac or splenic involvement that would alter management.\n\nProvide FINAL refined plan based on the above context and discussions.\nUp to 3 bullets, each ≤20 words.\nAny factual claim must include [@report_id|date] or say unknown.\nAt least ONE bullet must be evidence-based and include [@guideline:doc_id|page] or [@pubmed:PMID].\nIf you reference treatment strategy categories, guidelines, trials, or literature evidence, include tags [@guideline:doc_id|page] or [@pubmed:PMID].\nIf discussions mentioned specific evidence, you may reference it with appropriate tags.", "assistant_reply": "- Urgently document ECOG, detailed symptoms, comorbidities, and evaluate/transfuse for severe anemia before defining any new systemic strategy [@guideline:nccn_ovariancancer_v3_2025__v00000000|14].  \n\n- Obtain updated contrast CT chest/abdomen/pelvis to reassess pelvic, hepatic, bone, and splenic disease before radiation or systemic decisions [@report_id_unknown|unknown].  \n\n- Arrange comprehensive tumor profiling on recent tissue or ctDNA (MSI, TMB, PD-L1, broad somatic panel) to inform future options [@OH2203828|2022-04-18].", "timestamp": "2026-01-19T08:04:36.641364"}, {"role": "pathologist", "user_message": "ROLE: pathologist. VISIT: 2023-01-03 08:53:29.260000\nDefault is NOT to speak. Speak ONLY if: conflict | safety | missing-critical | new-critical.\n\nCONTEXT (latest):\n[MDT_GLOBAL_KNOWLEDGE]\nKey Knowledge:\n- Platinum‑resistant clear cell ovarian carcinoma with rapid progression and widespread involvement (pelvis, liver, sacrum/right iliac bone).\n- High symptom burden: painful pelvic/bony disease and severe anemia (Hgb 74 g/L) restricting systemic options.\n- Pathology: clear cell carcinoma; MMR intact; HRD‑negative; BRCA1/2 wild‑type; germline ATM VUS; comprehensive somatic profiling not yet completed.\n- Last imaging (Dec 2022 CT/MR) shows progressive pelvic/hepatic disease, sacral/right iliac involvement, and splenic lesion suspicious for infarct.\n\nControversies:\n- Need for PET/CT beyond contrast CT, given likely limited impact on systemic therapy and its role mainly in refining radiation fields.\n- Optimal non‑platinum systemic regimen and intensity in the context of severe anemia and yet‑uncertain ECOG/comorbidities.\n- Relevance of ATM VUS for targeted therapy or trial eligibility.\n\nMissing Info:\n- ECOG performance status, detailed symptoms (including pain control), comorbidities, and patient goals of care.\n- Updated comprehensive labs (CBC, iron/B12, renal, hepatic, coagulation).\n- New contrast CT chest/abdomen/pelvis and record of prior maintenance/biologic treatments.\n- Completed comprehensive tumor profiling (MSI, TMB, PD‑L1, broad somatic panel).\n- Confirmation of palliative care involvement and a formal symptom management plan.\n\nWorking Plan:\n- Optimize supportive care urgently: investigate/manage severe anemia, obtain full labs, document ECOG, symptoms, comorbidities, and clarify goals of care.\n- Obtain updated contrast CT chest/abdomen/pelvis to reassess disease and plan palliative radiation to presacral/sacral/right iliac lesions.\n- Reserve PET/CT for CT‑equivocal bone/splenic findings that would alter radiation fields/local interventions.\n- Arrange palliative radiation oncology review for symptomatic pelvic/bone disease.\n- Perform multidisciplinary review of existing molecular data and send comprehensive profiling (MSI, TMB, PD‑L1, broad somatic panel) on recent tissue/ctDNA.\n- After optimization and restaging, select an evidence‑based non‑platinum systemic approach and assess eligibility for clear‑cell, platinum‑resistant clinical trials.\n\nAllowed targets: [chair,oncologist,radiologist,nuclear]\nReturn ONE-LINE JSON only:{\"speak\":\"yes/no\",\"messages\":[{\"target\":\"<role>\",\"message\":\"<1-2 sentences>\",\"why\":\"conflict|safety|missing|new\"}]}", "assistant_reply": "{\"speak\":\"no\",\"messages\":[]}", "timestamp": "2026-01-19T08:05:10.450941"}, {"role": "pathologist", "user_message": "Given MDT context:\n[MDT_GLOBAL_KNOWLEDGE]\nKey Knowledge:\n- Platinum‑resistant clear cell ovarian carcinoma with rapid progression and widespread involvement (pelvis, liver, sacrum/right iliac bone).\n- High symptom burden: painful pelvic/bony disease and severe anemia (Hgb 74 g/L) restricting systemic options.\n- Pathology: clear cell carcinoma; MMR intact; HRD‑negative; BRCA1/2 wild‑type; germline ATM VUS; comprehensive somatic profiling not yet completed.\n- Last imaging (Dec 2022 CT/MR) shows progressive pelvic/hepatic disease, sacral/right iliac involvement, and splenic lesion suspicious for infarct.\n\nControversies:\n- Need for PET/CT beyond contrast CT, given likely limited impact on systemic therapy and its role mainly in refining radiation fields.\n- Optimal non‑platinum systemic regimen and intensity in the context of severe anemia and yet‑uncertain ECOG/comorbidities.\n- Relevance of ATM VUS for targeted therapy or trial eligibility.\n\nMissing Info:\n- ECOG performance status, detailed symptoms (including pain control), comorbidities, and patient goals of care.\n- Updated comprehensive labs (CBC, iron/B12, renal, hepatic, coagulation).\n- New contrast CT chest/abdomen/pelvis and record of prior maintenance/biologic treatments.\n- Completed comprehensive tumor profiling (MSI, TMB, PD‑L1, broad somatic panel).\n- Confirmation of palliative care involvement and a formal symptom management plan.\n\nWorking Plan:\n- Optimize supportive care urgently: investigate/manage severe anemia, obtain full labs, document ECOG, symptoms, comorbidities, and clarify goals of care.\n- Obtain updated contrast CT chest/abdomen/pelvis to reassess disease and plan palliative radiation to presacral/sacral/right iliac lesions.\n- Reserve PET/CT for CT‑equivocal bone/splenic findings that would alter radiation fields/local interventions.\n- Arrange palliative radiation oncology review for symptomatic pelvic/bone disease.\n- Perform multidisciplinary review of existing molecular data and send comprehensive profiling (MSI, TMB, PD‑L1, broad somatic panel) on recent tissue/ctDNA.\n- After optimization and restaging, select an evidence‑based non‑platinum systemic approach and assess eligibility for clear‑cell, platinum‑resistant clinical trials.\n\nDISCUSSION HISTORY (this round):\nNo direct discussions in this round.\n\nProvide FINAL refined plan based on the above context and discussions.\nUp to 3 bullets, each ≤20 words.\nAny factual claim must include [@report_id|date] or say unknown.\nAt least ONE bullet must be evidence-based and include [@guideline:doc_id|page] or [@pubmed:PMID].\nIf you reference treatment strategy categories, guidelines, trials, or literature evidence, include tags [@guideline:doc_id|page] or [@pubmed:PMID].\nIf discussions mentioned specific evidence, you may reference it with appropriate tags.", "assistant_reply": "- Proceed with comprehensive tumor profiling (MSI, TMB, PD‑L1, broad somatic panel) on recent tissue/ctDNA to expand options [@guideline:nccn_ovariancancer_v3_2025__v00000000|15].  \n\n- Maintain diagnosis of ovarian clear cell carcinoma with intact MMR and HRD-/BRCA1/2‑wild type status; ATM p.Y316C remains VUS [@HISTOLOGY_AND_IHC|2022-03-28].  \n\n- Ensure pathology–radiology correlation on new contrast CT (pelvis, sacrum/right iliac, spleen) to confirm sites for palliative radiation (report_id unknown|unknown).", "timestamp": "2026-01-19T08:06:13.418649"}], "nuclear": [{"role": "nuclear", "user_message": "Give INITIAL opinion (use ONLY your system-provided patient facts).\nReturn up to 3 bullets, each ≤20 words.\nIf key data missing, say exactly what needs updating.\nAt least ONE bullet must be evidence-based and include [@guideline:doc_id|page] or [@pubmed:PMID].\nIf you reference treatment strategy categories, guidelines, trials, or literature evidence, include tags [@guideline:doc_id|page] or [@pubmed:PMID].", "assistant_reply": "- No PET/CT available; metabolic burden, sacral/right iliac bone involvement, and splenic lesion characterization remain unknown/needs update.  \n\n- Prior CT/MR show progressive pelvic, hepatic, and possible sacral/right iliac bone metastases, high suspicion for widespread recurrence [@2022-12-29|MR][@2022-12-29|CT].  \n\n- PET/CT could refine current staging, assess extrahepatic/peritoneal/bone disease, and guide radiotherapy or surgery decisions [@guideline:nccn_ovariancancer_v3_2025__v00000000|22].", "timestamp": "2026-01-19T08:03:08.059102"}, {"role": "nuclear", "user_message": "ROLE: nuclear. VISIT: 2023-01-03 08:53:29.260000\nDefault is NOT to speak. Speak ONLY if: conflict | safety | missing-critical | new-critical.\n\nCONTEXT (latest):\n[MDT_GLOBAL_KNOWLEDGE]\nKey Knowledge:\n- Platinum‑resistant clear cell ovarian carcinoma with rapid systemic progression (pelvis, liver, bone/sacrum) and likely widespread disease.\n- High symptom burden: painful presacral/bony disease and severe anemia (Hgb 74 g/L) limiting treatment options.\n- Pathology: clear cell carcinoma; MMR intact; HRD‑negative; BRCA1/2 wild‑type; germline ATM VUS; no comprehensive somatic profiling.\n- Imaging shows progressive pelvic/hepatic metastases; splenic lesion suspicious for infarct.\n\nControversies:\n- Added value of PET/CT for staging versus limited impact on systemic management in established platinum‑resistant disease.\n- Choice and intensity of non‑platinum systemic therapy given severe anemia and unknown performance status.\n- Significance of germline ATM VUS for trial eligibility/targeted approaches.\n\nMissing Info:\n- ECOG performance status, detailed symptom burden, and patient goals of care.\n- Updated labs (CBC, iron studies, renal/hepatic function) and comorbidities.\n- Most recent imaging overview and prior exposure to maintenance/biologic therapy.\n- Full tumor profiling (MSI, TMB, PD‑L1, broad somatic panel) and palliative care involvement.\n\nWorking Plan:\n- Clarify ECOG, symptoms, and goals; optimize supportive care (transfusion/iron, pain control).\n- Arrange palliative radiation oncology review for pelvic/sacral/right iliac bone disease.\n- Update staging with contrast CT; consider PET/CT if it will guide local interventions.\n- Plan non‑platinum systemic strategy appropriate to status and prior treatments.\n- Obtain comprehensive molecular profiling (tissue or ctDNA) to guide targeted/clinical trial options.\n\nAllowed targets: [chair,oncologist,radiologist,pathologist]\nReturn ONE-LINE JSON only:{\"speak\":\"yes/no\",\"messages\":[{\"target\":\"<role>\",\"message\":\"<1-2 sentences>\",\"why\":\"conflict|safety|missing|new\"}]}", "assistant_reply": "{\"speak\":\"no\",\"messages\":[]}", "timestamp": "2026-01-19T08:03:30.838088"}, {"role": "nuclear", "user_message": "ROLE: nuclear. VISIT: 2023-01-03 08:53:29.260000\nDefault is NOT to speak. Speak ONLY if: conflict | safety | missing-critical | new-critical.\n\nCONTEXT (latest):\n[MDT_GLOBAL_KNOWLEDGE]\nKey Knowledge:\n- Platinum‑resistant clear cell ovarian carcinoma with rapid systemic progression (pelvis, liver, bone/sacrum) and likely widespread disease.\n- High symptom burden: painful presacral/bony disease and severe anemia (Hgb 74 g/L) limiting treatment options.\n- Pathology: clear cell carcinoma; MMR intact; HRD‑negative; BRCA1/2 wild‑type; germline ATM VUS; no comprehensive somatic profiling.\n- Imaging shows progressive pelvic/hepatic metastases; splenic lesion suspicious for infarct.\n\nControversies:\n- Added value of PET/CT for staging versus limited impact on systemic management in established platinum‑resistant disease.\n- Choice and intensity of non‑platinum systemic therapy given severe anemia and unknown performance status.\n- Significance of germline ATM VUS for trial eligibility/targeted approaches.\n\nMissing Info:\n- ECOG performance status, detailed symptom burden, and patient goals of care.\n- Updated labs (CBC, iron studies, renal/hepatic function) and comorbidities.\n- Most recent imaging overview and prior exposure to maintenance/biologic therapy.\n- Full tumor profiling (MSI, TMB, PD‑L1, broad somatic panel) and palliative care involvement.\n\nWorking Plan:\n- Clarify ECOG, symptoms, and goals; optimize supportive care (transfusion/iron, pain control).\n- Arrange palliative radiation oncology review for pelvic/sacral/right iliac bone disease.\n- Update staging with contrast CT; consider PET/CT if it will guide local interventions.\n- Plan non‑platinum systemic strategy appropriate to status and prior treatments.\n- Obtain comprehensive molecular profiling (tissue or ctDNA) to guide targeted/clinical trial options.\n\n[RECENT_DELTAS]\n[R1T1 DELTA] oncologist->chair(missing): Before committing to a new systemic line, we must urgently document ECOG, detailed symptoms, comorbidities, and transfuse/clarify cause of severe anemia, as these may preclude intensive chemotherapy options. | radiologist->oncologist(missing): Most recent cross-sectional imaging is from 2022-12-29/30 and already shows clear systemic progression; updated contrast CT (chest/abdomen/pelvis) is needed before further systemic or radiation decisions.\n\nAllowed targets: [chair,oncologist,radiologist,pathologist]\nReturn ONE-LINE JSON only:{\"speak\":\"yes/no\",\"messages\":[{\"target\":\"<role>\",\"message\":\"<1-2 sentences>\",\"why\":\"conflict|safety|missing|new\"}]}", "assistant_reply": "{\"speak\":\"yes\",\"messages\":[{\"target\":\"oncologist\",\"message\":\"Given rapid progression and planned local interventions, clarify whether PET/CT is intended to change radiation fields or only confirm known lesions.\",\"why\":\"missing\"},{\"target\":\"radiologist\",\"message\":\"If PET/CT is considered, please specify whether CT findings leave uncertainty about sacral/right iliac or splenic involvement that would alter management.\",\"why\":\"missing\"}]}", "timestamp": "2026-01-19T08:04:00.641149"}, {"role": "nuclear", "user_message": "Given MDT context:\n[MDT_GLOBAL_KNOWLEDGE]\nKey Knowledge:\n- Platinum‑resistant clear cell ovarian carcinoma with rapid systemic progression (pelvis, liver, bone/sacrum) and likely widespread disease.\n- High symptom burden: painful presacral/bony disease and severe anemia (Hgb 74 g/L) limiting treatment options.\n- Pathology: clear cell carcinoma; MMR intact; HRD‑negative; BRCA1/2 wild‑type; germline ATM VUS; no comprehensive somatic profiling.\n- Imaging shows progressive pelvic/hepatic metastases; splenic lesion suspicious for infarct.\n\nControversies:\n- Added value of PET/CT for staging versus limited impact on systemic management in established platinum‑resistant disease.\n- Choice and intensity of non‑platinum systemic therapy given severe anemia and unknown performance status.\n- Significance of germline ATM VUS for trial eligibility/targeted approaches.\n\nMissing Info:\n- ECOG performance status, detailed symptom burden, and patient goals of care.\n- Updated labs (CBC, iron studies, renal/hepatic function) and comorbidities.\n- Most recent imaging overview and prior exposure to maintenance/biologic therapy.\n- Full tumor profiling (MSI, TMB, PD‑L1, broad somatic panel) and palliative care involvement.\n\nWorking Plan:\n- Clarify ECOG, symptoms, and goals; optimize supportive care (transfusion/iron, pain control).\n- Arrange palliative radiation oncology review for pelvic/sacral/right iliac bone disease.\n- Update staging with contrast CT; consider PET/CT if it will guide local interventions.\n- Plan non‑platinum systemic strategy appropriate to status and prior treatments.\n- Obtain comprehensive molecular profiling (tissue or ctDNA) to guide targeted/clinical trial options.\n\n[RECENT_DELTAS]\n[R1T1 DELTA] oncologist->chair(missing): Before committing to a new systemic line, we must urgently document ECOG, detailed symptoms, comorbidities, and transfuse/clarify cause of severe anemia, as these may preclude intensive chemotherapy options. | radiologist->oncologist(missing): Most recent cross-sectional imaging is from 2022-12-29/30 and already shows clear systemic progression; updated contrast CT (chest/abdomen/pelvis) is needed before further systemic or radiation decisions.\n[R1T2 DELTA] pathologist->oncologist(unspecified): From a pathology standpoint, comprehensive tumor profiling (MSI, TMB, PD-L1, broad somatic panel) remains outstanding and is important for future options. | nuclear->oncologist(missing): Given rapid progression and planned local interventions, clarify whether PET/CT is intended to change radiation fields or only confirm known lesions. | nuclear->radiologist(missing): If PET/CT is considered, please specify whether CT findings leave uncertainty about sacral/right iliac or splenic involvement that would alter management.\n\nDISCUSSION HISTORY (this round):\nTurn 1: oncologist→chair: Before committing to a new systemic line, we must urgently document ECOG, detailed symptoms, comorbidities, and transfuse/clarify cause of severe anemia, as these may preclude intensive chemotherapy options. | radiologist→oncologist: Most recent cross-sectional imaging is from 2022-12-29/30 and already shows clear systemic progression; updated contrast CT (chest/abdomen/pelvis) is needed before further systemic or radiation decisions.\nTurn 2: pathologist→oncologist: From a pathology standpoint, comprehensive tumor profiling (MSI, TMB, PD-L1, broad somatic panel) remains outstanding and is important for future options. | nuclear→oncologist: Given rapid progression and planned local interventions, clarify whether PET/CT is intended to change radiation fields or only confirm known lesions. | nuclear→radiologist: If PET/CT is considered, please specify whether CT findings leave uncertainty about sacral/right iliac or splenic involvement that would alter management.\n\nProvide FINAL refined plan based on the above context and discussions.\nUp to 3 bullets, each ≤20 words.\nAny factual claim must include [@report_id|date] or say unknown.\nAt least ONE bullet must be evidence-based and include [@guideline:doc_id|page] or [@pubmed:PMID].\nIf you reference treatment strategy categories, guidelines, trials, or literature evidence, include tags [@guideline:doc_id|page] or [@pubmed:PMID].\nIf discussions mentioned specific evidence, you may reference it with appropriate tags.", "assistant_reply": "- Prioritize supportive care: document ECOG, symptoms, comorbidities; investigate/transfuse for severe anemia before systemic decisions (Hgb 74 g/L, labs otherwise unknown).  \n\n- Obtain updated contrast CT chest/abdomen/pelvis to reassess pelvic, hepatic, sacral/right iliac, and splenic disease before radiation planning [@2022-12-29|MR][@2022-12-29|CT].  \n\n- Reserve PET/CT for situations where CT leaves uncertainty that would meaningfully alter radiation fields or local interventions [@guideline:nccn_ovariancancer_v3_2025__v00000000|22].", "timestamp": "2026-01-19T08:04:39.160301"}, {"role": "nuclear", "user_message": "ROLE: nuclear. VISIT: 2023-01-03 08:53:29.260000\nDefault is NOT to speak. Speak ONLY if: conflict | safety | missing-critical | new-critical.\n\nCONTEXT (latest):\n[MDT_GLOBAL_KNOWLEDGE]\nKey Knowledge:\n- Platinum‑resistant clear cell ovarian carcinoma with rapid progression and widespread involvement (pelvis, liver, sacrum/right iliac bone).\n- High symptom burden: painful pelvic/bony disease and severe anemia (Hgb 74 g/L) restricting systemic options.\n- Pathology: clear cell carcinoma; MMR intact; HRD‑negative; BRCA1/2 wild‑type; germline ATM VUS; comprehensive somatic profiling not yet completed.\n- Last imaging (Dec 2022 CT/MR) shows progressive pelvic/hepatic disease, sacral/right iliac involvement, and splenic lesion suspicious for infarct.\n\nControversies:\n- Need for PET/CT beyond contrast CT, given likely limited impact on systemic therapy and its role mainly in refining radiation fields.\n- Optimal non‑platinum systemic regimen and intensity in the context of severe anemia and yet‑uncertain ECOG/comorbidities.\n- Relevance of ATM VUS for targeted therapy or trial eligibility.\n\nMissing Info:\n- ECOG performance status, detailed symptoms (including pain control), comorbidities, and patient goals of care.\n- Updated comprehensive labs (CBC, iron/B12, renal, hepatic, coagulation).\n- New contrast CT chest/abdomen/pelvis and record of prior maintenance/biologic treatments.\n- Completed comprehensive tumor profiling (MSI, TMB, PD‑L1, broad somatic panel).\n- Confirmation of palliative care involvement and a formal symptom management plan.\n\nWorking Plan:\n- Optimize supportive care urgently: investigate/manage severe anemia, obtain full labs, document ECOG, symptoms, comorbidities, and clarify goals of care.\n- Obtain updated contrast CT chest/abdomen/pelvis to reassess disease and plan palliative radiation to presacral/sacral/right iliac lesions.\n- Reserve PET/CT for CT‑equivocal bone/splenic findings that would alter radiation fields/local interventions.\n- Arrange palliative radiation oncology review for symptomatic pelvic/bone disease.\n- Perform multidisciplinary review of existing molecular data and send comprehensive profiling (MSI, TMB, PD‑L1, broad somatic panel) on recent tissue/ctDNA.\n- After optimization and restaging, select an evidence‑based non‑platinum systemic approach and assess eligibility for clear‑cell, platinum‑resistant clinical trials.\n\nAllowed targets: [chair,oncologist,radiologist,pathologist]\nReturn ONE-LINE JSON only:{\"speak\":\"yes/no\",\"messages\":[{\"target\":\"<role>\",\"message\":\"<1-2 sentences>\",\"why\":\"conflict|safety|missing|new\"}]}", "assistant_reply": "{\"speak\":\"no\",\"messages\":[]}", "timestamp": "2026-01-19T08:06:00.100199"}, {"role": "nuclear", "user_message": "Given MDT context:\n[MDT_GLOBAL_KNOWLEDGE]\nKey Knowledge:\n- Platinum‑resistant clear cell ovarian carcinoma with rapid progression and widespread involvement (pelvis, liver, sacrum/right iliac bone).\n- High symptom burden: painful pelvic/bony disease and severe anemia (Hgb 74 g/L) restricting systemic options.\n- Pathology: clear cell carcinoma; MMR intact; HRD‑negative; BRCA1/2 wild‑type; germline ATM VUS; comprehensive somatic profiling not yet completed.\n- Last imaging (Dec 2022 CT/MR) shows progressive pelvic/hepatic disease, sacral/right iliac involvement, and splenic lesion suspicious for infarct.\n\nControversies:\n- Need for PET/CT beyond contrast CT, given likely limited impact on systemic therapy and its role mainly in refining radiation fields.\n- Optimal non‑platinum systemic regimen and intensity in the context of severe anemia and yet‑uncertain ECOG/comorbidities.\n- Relevance of ATM VUS for targeted therapy or trial eligibility.\n\nMissing Info:\n- ECOG performance status, detailed symptoms (including pain control), comorbidities, and patient goals of care.\n- Updated comprehensive labs (CBC, iron/B12, renal, hepatic, coagulation).\n- New contrast CT chest/abdomen/pelvis and record of prior maintenance/biologic treatments.\n- Completed comprehensive tumor profiling (MSI, TMB, PD‑L1, broad somatic panel).\n- Confirmation of palliative care involvement and a formal symptom management plan.\n\nWorking Plan:\n- Optimize supportive care urgently: investigate/manage severe anemia, obtain full labs, document ECOG, symptoms, comorbidities, and clarify goals of care.\n- Obtain updated contrast CT chest/abdomen/pelvis to reassess disease and plan palliative radiation to presacral/sacral/right iliac lesions.\n- Reserve PET/CT for CT‑equivocal bone/splenic findings that would alter radiation fields/local interventions.\n- Arrange palliative radiation oncology review for symptomatic pelvic/bone disease.\n- Perform multidisciplinary review of existing molecular data and send comprehensive profiling (MSI, TMB, PD‑L1, broad somatic panel) on recent tissue/ctDNA.\n- After optimization and restaging, select an evidence‑based non‑platinum systemic approach and assess eligibility for clear‑cell, platinum‑resistant clinical trials.\n\nDISCUSSION HISTORY (this round):\nNo direct discussions in this round.\n\nProvide FINAL refined plan based on the above context and discussions.\nUp to 3 bullets, each ≤20 words.\nAny factual claim must include [@report_id|date] or say unknown.\nAt least ONE bullet must be evidence-based and include [@guideline:doc_id|page] or [@pubmed:PMID].\nIf you reference treatment strategy categories, guidelines, trials, or literature evidence, include tags [@guideline:doc_id|page] or [@pubmed:PMID].\nIf discussions mentioned specific evidence, you may reference it with appropriate tags.", "assistant_reply": "- Continue with updated contrast CT chest/abdomen/pelvis as primary restaging tool to guide palliative radiation planning [@2022-12-29|CT][@2022-12-29|MR].  \n\n- Reserve PET/CT for CT‑equivocal bone or splenic lesions where metabolic clarification would change radiation fields or local procedures [@guideline:nccn_ovariancancer_v3_2025__v00000000|22].  \n\n- No current evidence that PET/CT would alter systemic therapy choice in this established platinum‑resistant, widely metastatic setting [@guideline:nccn_ovariancancer_v3_2025__v00000000|22].", "timestamp": "2026-01-19T08:06:16.241096"}], "assistant": [{"role": "assistant", "user_message": "Summarize expert opinions concisely for MDT.\n{\"chair\":\"- Confirm performance status, symptom burden, and goals of care, then prioritize systemic therapy for platinum‑resistant clear‑cell ovarian carcinoma with rapid progression [@guideline:nccn_ovariancancer_v3_2025__v00000000|22; @pubmed:33758607].  \\n\\n- Obtain updated labs (including iron studies, renal/hepatic function), address severe anemia (Hgb 74 g/L) and bone/sacral pain, and arrange palliative radiation consult for symptomatic pelvic/osseous disease [@20230103|5600862; @2022-12-29|MR].  \\n\\n- Ensure comprehensive molecular profiling using recent tumor (beyond current HRD‑negative, BRCA‑wildtype report) to identify trial/targeted options, and discuss enrollment in studies tailored to clear‑cell, platinum‑resistant ovarian cancer [@OH2203828|2022-04-18; @guideline:nccn_ovariancancer_v3_2025__v00000000|15; @pubmed:33758607].\",\"oncologist\":\"- Early biochemical and radiologic relapse (<6 months) after adjuvant platinum suggests platinum-resistant clear cell ovarian carcinoma; consider non‑platinum systemic approach [@guideline:nccn_ovariancancer_v3_2025__v00000000|14].  \\n\\n- Current severe anemia (Hgb 74 g/L) may limit therapy intensity; optimize transfusion/iron and clarify performance status, symptoms, comorbidities [@20230103|2023-01-03].  \\n\\n- HRD negative, BRCA1/2 wild-type; need updated imaging for disease burden, ECOG, renal function, and prior maintenance/biologic exposure to choose regimen [@OH2203828|2022-04-18].\",\"radiologist\":\"- Progressive presacral pelvic mass with sacral and right iliac bone involvement, plus multiple pelvic mesenteric nodules consistent with recurrent/metastatic disease [@2022-12-29|MR].  \\n\\n- Increasing number and size of multiple hepatic metastatic nodules; stable hepatic cysts [@2022-12-29|CT].  \\n\\n- Splenic patchy low-density lesion suspicious for infarct; recommend imaging follow‑up for evolution and complications [@2022-12-29|CT][@pubmed:33758607].\",\"pathologist\":\"- Histology and IHC support diagnosis of ovarian clear cell carcinoma involving rectosigmoid, retroperitoneum, and vagina; grade not specified [@HISTOLOGY_AND_IHC|2022-03-28].  \\n\\n- MMR proteins intact; HRD and BRCA1/2 pathogenic variants not detected; germline ATM p.Y316C reported, clinical significance unclear [@OH2203828|2022-04-18].  \\n\\n- For future care, comprehensive tumor profiling (MSI, TMB, PD-L1, broader somatic panel) is missing and should be updated [@guideline:nccn_ovariancancer_v3_2025__v00000000|15].\",\"nuclear\":\"- No PET/CT available; metabolic burden, sacral/right iliac bone involvement, and splenic lesion characterization remain unknown/needs update.  \\n\\n- Prior CT/MR show progressive pelvic, hepatic, and possible sacral/right iliac bone metastases, high suspicion for widespread recurrence [@2022-12-29|MR][@2022-12-29|CT].  \\n\\n- PET/CT could refine current staging, assess extrahepatic/peritoneal/bone disease, and guide radiotherapy or surgery decisions [@guideline:nccn_ovariancancer_v3_2025__v00000000|22].\"}\n\nOutput:\nKey Knowledge:\n- ...\nControversies:\n- ...\nMissing Info:\n- ...\nWorking Plan:\n- ...", "assistant_reply": "Key Knowledge:\n- Platinum‑resistant clear cell ovarian carcinoma with early relapse and rapid systemic progression (pelvis, liver, bone/sacrum; likely widespread disease).\n- Severe symptomatic burden: large presacral mass with sacral/right iliac bone involvement causing pain; severe anemia (Hgb 74 g/L) likely limiting treatment intensity.\n- Pathology: clear cell histology; MMR intact, HRD‑negative, BRCA1/2 wild‑type; germline ATM VUS. No current comprehensive somatic profiling (MSI, TMB, PD‑L1, broad panel).\n- Current imaging (CT/MR) shows progressive pelvic and hepatic metastases; splenic low‑density lesion suspicious for infarct.\n\nControversies:\n- Extent and pattern of disease not fully staged metabolically (no PET/CT) vs whether additional staging would change systemic approach in clearly platinum‑resistant disease.\n- Optimal sequencing/intensity of non‑platinum systemic therapy in the context of severe anemia and unclear performance status.\n- Clinical relevance of germline ATM variant and whether it could influence trial eligibility.\n\nMissing Info:\n- Performance status (ECOG), detailed symptom burden, and patient goals of care.\n- Updated labs: full CBC, iron studies, renal/hepatic function, and other treatment‑limiting comorbidities.\n- Most recent cross‑sectional imaging for accurate disease map; any prior maintenance/biologic therapies.\n- Comprehensive tumor profiling (MSI, TMB, PD‑L1, extended somatic panel) from recent tissue or ctDNA.\n- Palliative care involvement and pain management status.\n\nWorking Plan:\n- Clarify ECOG, symptoms, and goals; optimize supportive care including transfusion/iron for anemia and analgesia.\n- Arrange palliative radiation oncology assessment for pelvic/sacral/right iliac bone pain and local control.\n- Obtain updated staging (contrast CT; consider PET/CT if it will influence local treatment planning).\n- Initiate/plan non‑platinum systemic therapy for platinum‑resistant clear cell ovarian carcinoma, tailored to performance status and prior treatments.\n- Send comprehensive molecular profiling on recent tumor (or liquid biopsy) to identify targeted/clinical trial options.", "timestamp": "2026-01-19T08:03:17.902298"}, {"role": "assistant", "user_message": "MDT global knowledge:\nKey Knowledge:\n- Platinum‑resistant clear cell ovarian carcinoma with early relapse and rapid systemic progression (pelvis, liver, bone/sacrum; likely widespread disease).\n- Severe symptomatic burden: large presacral mass with sacral/right iliac bone involvement causing pain; severe anemia (Hgb 74 g/L) likely limiting treatment intensity.\n- Pathology: clear cell histology; MMR intact, HRD‑negative, BRCA1/2 wild‑type; germline ATM VUS. No current comprehensive somatic profiling (MSI, TMB, PD‑L1, broad panel).\n- Current imaging (CT/MR) shows progressive pelvic and hepatic metastases; splenic low‑density lesion suspicious for infarct.\n\nControversies:\n- Extent and pattern of disease not fully staged metabolically (no PET/CT) vs whether additional staging would change systemic approach in clearly platinum‑resistant disease.\n- Optimal sequencing/intensity of non‑platinum systemic therapy in the context of severe anemia and unclear performance status.\n- Clinical relevance of germline ATM variant and whether it could influence trial eligibility.\n\nMissing Info:\n- Performance status (ECOG), detailed symptom burden, and patient goals of care.\n- Updated labs: full CBC, iron studies, renal/hepatic function, and other treatment‑limiting comorbidities.\n- Most recent cross‑sectional imaging for accurate disease map; any prior maintenance/biologic therapies.\n- Comprehensive tumor profiling (MSI, TMB, PD‑L1, extended somatic panel) from recent tissue or ctDNA.\n- Palliative care involvement and pain management status.\n\nWorking Plan:\n- Clarify ECOG, symptoms, and goals; optimize supportive care including transfusion/iron for anemia and analgesia.\n- Arrange palliative radiation oncology assessment for pelvic/sacral/right iliac bone pain and local control.\n- Obtain updated staging (contrast CT; consider PET/CT if it will influence local treatment planning).\n- Initiate/plan non‑platinum systemic therapy for platinum‑resistant clear cell ovarian carcinoma, tailored to performance status and prior treatments.\n- Send comprehensive molecular profiling on recent tumor (or liquid biopsy) to identify targeted/clinical trial options.\n\nRe-summarize concisely. Must include:\nKey Knowledge:\n- ...\nControversies:\n- ...\nMissing Info:\n- ...\nWorking Plan:\n- ...", "assistant_reply": "Key Knowledge:\n- Platinum‑resistant clear cell ovarian carcinoma with rapid systemic progression (pelvis, liver, bone/sacrum) and likely widespread disease.\n- High symptom burden: painful presacral/bony disease and severe anemia (Hgb 74 g/L) limiting treatment options.\n- Pathology: clear cell carcinoma; MMR intact; HRD‑negative; BRCA1/2 wild‑type; germline ATM VUS; no comprehensive somatic profiling.\n- Imaging shows progressive pelvic/hepatic metastases; splenic lesion suspicious for infarct.\n\nControversies:\n- Added value of PET/CT for staging versus limited impact on systemic management in established platinum‑resistant disease.\n- Choice and intensity of non‑platinum systemic therapy given severe anemia and unknown performance status.\n- Significance of germline ATM VUS for trial eligibility/targeted approaches.\n\nMissing Info:\n- ECOG performance status, detailed symptom burden, and patient goals of care.\n- Updated labs (CBC, iron studies, renal/hepatic function) and comorbidities.\n- Most recent imaging overview and prior exposure to maintenance/biologic therapy.\n- Full tumor profiling (MSI, TMB, PD‑L1, broad somatic panel) and palliative care involvement.\n\nWorking Plan:\n- Clarify ECOG, symptoms, and goals; optimize supportive care (transfusion/iron, pain control).\n- Arrange palliative radiation oncology review for pelvic/sacral/right iliac bone disease.\n- Update staging with contrast CT; consider PET/CT if it will guide local interventions.\n- Plan non‑platinum systemic strategy appropriate to status and prior treatments.\n- Obtain comprehensive molecular profiling (tissue or ctDNA) to guide targeted/clinical trial options.", "timestamp": "2026-01-19T08:03:21.628633"}, {"role": "assistant", "user_message": "You are MDT assistant. Update MDT GLOBAL structured memory by integrating ROUND FINAL plans. Keep the same output format with: Key Knowledge / Controversies / Missing Info / Working Plan.\n\nCURRENT_MDT_GLOBAL_KNOWLEDGE:\n[MDT_GLOBAL_KNOWLEDGE]\nKey Knowledge:\n- Platinum‑resistant clear cell ovarian carcinoma with rapid systemic progression (pelvis, liver, bone/sacrum) and likely widespread disease.\n- High symptom burden: painful presacral/bony disease and severe anemia (Hgb 74 g/L) limiting treatment options.\n- Pathology: clear cell carcinoma; MMR intact; HRD‑negative; BRCA1/2 wild‑type; germline ATM VUS; no comprehensive somatic profiling.\n- Imaging shows progressive pelvic/hepatic metastases; splenic lesion suspicious for infarct.\n\nControversies:\n- Added value of PET/CT for staging versus limited impact on systemic management in established platinum‑resistant disease.\n- Choice and intensity of non‑platinum systemic therapy given severe anemia and unknown performance status.\n- Significance of germline ATM VUS for trial eligibility/targeted approaches.\n\nMissing Info:\n- ECOG performance status, detailed symptom burden, and patient goals of care.\n- Updated labs (CBC, iron studies, renal/hepatic function) and comorbidities.\n- Most recent imaging overview and prior exposure to maintenance/biologic therapy.\n- Full tumor profiling (MSI, TMB, PD‑L1, broad somatic panel) and palliative care involvement.\n\nWorking Plan:\n- Clarify ECOG, symptoms, and goals; optimize supportive care (transfusion/iron, pain control).\n- Arrange palliative radiation oncology review for pelvic/sacral/right iliac bone disease.\n- Update staging with contrast CT; consider PET/CT if it will guide local interventions.\n- Plan non‑platinum systemic strategy appropriate to status and prior treatments.\n- Obtain comprehensive molecular profiling (tissue or ctDNA) to guide targeted/clinical trial options.\n\nROUND_1_FINAL_PLANS_JSON:\n{\"chair\":\"- Confirm performance status, symptom burden, and discuss goals; prioritize systemic therapy for platinum‑resistant clear cell histology and rapid metastatic progression [@report_id:2022-12-29|MR; @report_id:2022-12-29|CT; @guideline:nccn_ovariancancer_v3_2025__v00000000|22].  \\n\\n- Obtain updated comprehensive labs (including iron/B12, renal, hepatic, coagulation), manage significant anemia urgently, and rule out contraindications before starting next‑line systemic and bone‑directed/palliative local treatments [@report_id:2023-01-03|5600862].  \\n\\n- Arrange multidisciplinary review of molecular profile (HRD‑negative, BRCA‑WT, ATM variant) and consider repeat/expanded profiling on recent tissue, then prioritize evidence‑based non‑platinum systemic options and clinical trial enrollment for platinum‑resistant ovarian clear cell carcinoma [@report_id:OH2203828|2022-04-18; @pubmed:33758607].\",\"oncologist\":\"- Urgently optimize supportive care: investigate/transfuse severe anemia [@20230103|2023-01-03], assess ECOG, pain, comorbidities, and clarify goals of care.  \\n\\n- Obtain updated contrast CT chest/abdomen/pelvis for current extent, then plan palliative radiation to sacral/right iliac lesions and systemic strategy. [@guideline:nccn_ovariancancer_v3_2025__v00000000|15]  \\n\\n- Arrange comprehensive tumor profiling (MSI, TMB, PD‑L1, broad somatic panel) on recent tissue/ctDNA to inform non‑platinum and trial options.\",\"radiologist\":\"- Obtain updated contrast CT chest/abdomen/pelvis to reassess burden since progression on 2022-12-29/30 imaging [@2022-12-29|CT][@2022-12-29|MR].  \\n\\n- Reserve PET/CT for unresolved questions about sacral/right iliac bone or splenic involvement that would directly modify radiation fields [@2022-12-29|CT].  \\n\\n- Use updated imaging to guide palliative RT planning for painful presacral/sacral/right iliac lesions, aligning with symptom-directed management in recurrence [@guideline:nccn_ovariancancer_v3_2025__v00000000|22].\",\"pathologist\":\"- Urgently document ECOG, detailed symptoms, comorbidities, and evaluate/transfuse for severe anemia before defining any new systemic strategy [@guideline:nccn_ovariancancer_v3_2025__v00000000|14].  \\n\\n- Obtain updated contrast CT chest/abdomen/pelvis to reassess pelvic, hepatic, bone, and splenic disease before radiation or systemic decisions [@report_id_unknown|unknown].  \\n\\n- Arrange comprehensive tumor profiling on recent tissue or ctDNA (MSI, TMB, PD-L1, broad somatic panel) to inform future options [@OH2203828|2022-04-18].\",\"nuclear\":\"- Prioritize supportive care: document ECOG, symptoms, comorbidities; investigate/transfuse for severe anemia before systemic decisions (Hgb 74 g/L, labs otherwise unknown).  \\n\\n- Obtain updated contrast CT chest/abdomen/pelvis to reassess pelvic, hepatic, sacral/right iliac, and splenic disease before radiation planning [@2022-12-29|MR][@2022-12-29|CT].  \\n\\n- Reserve PET/CT for situations where CT leaves uncertainty that would meaningfully alter radiation fields or local interventions [@guideline:nccn_ovariancancer_v3_2025__v00000000|22].\"}", "assistant_reply": "Key Knowledge:\n- Platinum‑resistant clear cell ovarian carcinoma with rapid systemic progression (pelvis, liver, bone/sacrum) and likely widespread disease.\n- High symptom burden: painful presacral/sacral/right iliac bone disease and severe anemia (Hgb 74 g/L) limiting treatment options.\n- Pathology: clear cell carcinoma; MMR intact; HRD‑negative; BRCA1/2 wild‑type; germline ATM VUS; no comprehensive somatic profiling (MSI, TMB, PD‑L1, broad panel) completed yet.\n- Current imaging (Dec 2022 CT/MR) shows progressive pelvic and hepatic metastases, sacral/right iliac involvement, and splenic lesion suspicious for infarct; updated imaging pending.\n\nControversies:\n- Added value of PET/CT for further staging versus limited impact on systemic management, with PET/CT reserved for CT‑equivocal findings that would change radiation fields/local treatment.\n- Optimal choice and intensity of non‑platinum systemic therapy in the context of severe anemia and yet‑to‑be‑documented ECOG and comorbidities.\n- Clinical significance of germline ATM VUS and any implications for targeted therapy or clinical trial eligibility.\n\nMissing Info:\n- ECOG performance status, detailed symptom burden (including pain control), comorbidities, and patient goals of care.\n- Updated comprehensive labs: CBC, iron/B12, renal, hepatic, coagulation profile, and other treatment‑limiting factors.\n- Up‑to‑date contrast CT chest/abdomen/pelvis for current disease extent; documentation of prior maintenance/biologic therapies.\n- Completed comprehensive tumor profiling (MSI, TMB, PD‑L1, broad somatic panel) from recent tissue or ctDNA.\n- Confirmation of palliative care involvement and structured pain/symptom management plan.\n\nWorking Plan:\n- Urgently optimize supportive care: investigate and transfuse/manage severe anemia; obtain full labs; document ECOG, symptoms, comorbidities, and clarify goals of care.\n- Obtain updated contrast CT chest/abdomen/pelvis to reassess pelvic, hepatic, bone, and splenic disease; use this to guide palliative radiation planning for presacral/sacral/right iliac lesions.\n- Reserve PET/CT for cases where CT leaves uncertainty about bone or splenic involvement that would meaningfully alter radiation fields or other local interventions.\n- Arrange palliative radiation oncology review for symptomatic pelvic/sacral/right iliac disease alongside symptom‑directed management.\n- Conduct multidisciplinary review of existing molecular data (HRD‑negative, BRCA‑WT, ATM VUS) and send comprehensive profiling (MSI, TMB, PD‑L1, broad somatic panel) on recent tissue or ctDNA.\n- Following optimization and staging, prioritize an evidence‑based non‑platinum systemic strategy and evaluate for clinical trial enrollment specific to platinum‑resistant clear cell ovarian carcinoma.", "timestamp": "2026-01-19T08:04:46.479025"}, {"role": "assistant", "user_message": "MDT global knowledge:\nKey Knowledge:\n- Platinum‑resistant clear cell ovarian carcinoma with rapid systemic progression (pelvis, liver, bone/sacrum) and likely widespread disease.\n- High symptom burden: painful presacral/sacral/right iliac bone disease and severe anemia (Hgb 74 g/L) limiting treatment options.\n- Pathology: clear cell carcinoma; MMR intact; HRD‑negative; BRCA1/2 wild‑type; germline ATM VUS; no comprehensive somatic profiling (MSI, TMB, PD‑L1, broad panel) completed yet.\n- Current imaging (Dec 2022 CT/MR) shows progressive pelvic and hepatic metastases, sacral/right iliac involvement, and splenic lesion suspicious for infarct; updated imaging pending.\n\nControversies:\n- Added value of PET/CT for further staging versus limited impact on systemic management, with PET/CT reserved for CT‑equivocal findings that would change radiation fields/local treatment.\n- Optimal choice and intensity of non‑platinum systemic therapy in the context of severe anemia and yet‑to‑be‑documented ECOG and comorbidities.\n- Clinical significance of germline ATM VUS and any implications for targeted therapy or clinical trial eligibility.\n\nMissing Info:\n- ECOG performance status, detailed symptom burden (including pain control), comorbidities, and patient goals of care.\n- Updated comprehensive labs: CBC, iron/B12, renal, hepatic, coagulation profile, and other treatment‑limiting factors.\n- Up‑to‑date contrast CT chest/abdomen/pelvis for current disease extent; documentation of prior maintenance/biologic therapies.\n- Completed comprehensive tumor profiling (MSI, TMB, PD‑L1, broad somatic panel) from recent tissue or ctDNA.\n- Confirmation of palliative care involvement and structured pain/symptom management plan.\n\nWorking Plan:\n- Urgently optimize supportive care: investigate and transfuse/manage severe anemia; obtain full labs; document ECOG, symptoms, comorbidities, and clarify goals of care.\n- Obtain updated contrast CT chest/abdomen/pelvis to reassess pelvic, hepatic, bone, and splenic disease; use this to guide palliative radiation planning for presacral/sacral/right iliac lesions.\n- Reserve PET/CT for cases where CT leaves uncertainty about bone or splenic involvement that would meaningfully alter radiation fields or other local interventions.\n- Arrange palliative radiation oncology review for symptomatic pelvic/sacral/right iliac disease alongside symptom‑directed management.\n- Conduct multidisciplinary review of existing molecular data (HRD‑negative, BRCA‑WT, ATM VUS) and send comprehensive profiling (MSI, TMB, PD‑L1, broad somatic panel) on recent tissue or ctDNA.\n- Following optimization and staging, prioritize an evidence‑based non‑platinum systemic strategy and evaluate for clinical trial enrollment specific to platinum‑resistant clear cell ovarian carcinoma.\n\nRe-summarize concisely. Must include:\nKey Knowledge:\n- ...\nControversies:\n- ...\nMissing Info:\n- ...\nWorking Plan:\n- ...", "assistant_reply": "Key Knowledge:\n- Platinum‑resistant clear cell ovarian carcinoma with rapid progression and widespread involvement (pelvis, liver, sacrum/right iliac bone).\n- High symptom burden: painful pelvic/bony disease and severe anemia (Hgb 74 g/L) restricting systemic options.\n- Pathology: clear cell carcinoma; MMR intact; HRD‑negative; BRCA1/2 wild‑type; germline ATM VUS; comprehensive somatic profiling not yet completed.\n- Last imaging (Dec 2022 CT/MR) shows progressive pelvic/hepatic disease, sacral/right iliac involvement, and splenic lesion suspicious for infarct.\n\nControversies:\n- Need for PET/CT beyond contrast CT, given likely limited impact on systemic therapy and its role mainly in refining radiation fields.\n- Optimal non‑platinum systemic regimen and intensity in the context of severe anemia and yet‑uncertain ECOG/comorbidities.\n- Relevance of ATM VUS for targeted therapy or trial eligibility.\n\nMissing Info:\n- ECOG performance status, detailed symptoms (including pain control), comorbidities, and patient goals of care.\n- Updated comprehensive labs (CBC, iron/B12, renal, hepatic, coagulation).\n- New contrast CT chest/abdomen/pelvis and record of prior maintenance/biologic treatments.\n- Completed comprehensive tumor profiling (MSI, TMB, PD‑L1, broad somatic panel).\n- Confirmation of palliative care involvement and a formal symptom management plan.\n\nWorking Plan:\n- Optimize supportive care urgently: investigate/manage severe anemia, obtain full labs, document ECOG, symptoms, comorbidities, and clarify goals of care.\n- Obtain updated contrast CT chest/abdomen/pelvis to reassess disease and plan palliative radiation to presacral/sacral/right iliac lesions.\n- Reserve PET/CT for CT‑equivocal bone/splenic findings that would alter radiation fields/local interventions.\n- Arrange palliative radiation oncology review for symptomatic pelvic/bone disease.\n- Perform multidisciplinary review of existing molecular data and send comprehensive profiling (MSI, TMB, PD‑L1, broad somatic panel) on recent tissue/ctDNA.\n- After optimization and restaging, select an evidence‑based non‑platinum systemic approach and assess eligibility for clear‑cell, platinum‑resistant clinical trials.", "timestamp": "2026-01-19T08:04:52.486359"}, {"role": "assistant", "user_message": "You are MDT assistant. Update MDT GLOBAL structured memory by integrating ROUND FINAL plans. Keep the same output format with: Key Knowledge / Controversies / Missing Info / Working Plan.\n\nCURRENT_MDT_GLOBAL_KNOWLEDGE:\n[MDT_GLOBAL_KNOWLEDGE]\nKey Knowledge:\n- Platinum‑resistant clear cell ovarian carcinoma with rapid progression and widespread involvement (pelvis, liver, sacrum/right iliac bone).\n- High symptom burden: painful pelvic/bony disease and severe anemia (Hgb 74 g/L) restricting systemic options.\n- Pathology: clear cell carcinoma; MMR intact; HRD‑negative; BRCA1/2 wild‑type; germline ATM VUS; comprehensive somatic profiling not yet completed.\n- Last imaging (Dec 2022 CT/MR) shows progressive pelvic/hepatic disease, sacral/right iliac involvement, and splenic lesion suspicious for infarct.\n\nControversies:\n- Need for PET/CT beyond contrast CT, given likely limited impact on systemic therapy and its role mainly in refining radiation fields.\n- Optimal non‑platinum systemic regimen and intensity in the context of severe anemia and yet‑uncertain ECOG/comorbidities.\n- Relevance of ATM VUS for targeted therapy or trial eligibility.\n\nMissing Info:\n- ECOG performance status, detailed symptoms (including pain control), comorbidities, and patient goals of care.\n- Updated comprehensive labs (CBC, iron/B12, renal, hepatic, coagulation).\n- New contrast CT chest/abdomen/pelvis and record of prior maintenance/biologic treatments.\n- Completed comprehensive tumor profiling (MSI, TMB, PD‑L1, broad somatic panel).\n- Confirmation of palliative care involvement and a formal symptom management plan.\n\nWorking Plan:\n- Optimize supportive care urgently: investigate/manage severe anemia, obtain full labs, document ECOG, symptoms, comorbidities, and clarify goals of care.\n- Obtain updated contrast CT chest/abdomen/pelvis to reassess disease and plan palliative radiation to presacral/sacral/right iliac lesions.\n- Reserve PET/CT for CT‑equivocal bone/splenic findings that would alter radiation fields/local interventions.\n- Arrange palliative radiation oncology review for symptomatic pelvic/bone disease.\n- Perform multidisciplinary review of existing molecular data and send comprehensive profiling (MSI, TMB, PD‑L1, broad somatic panel) on recent tissue/ctDNA.\n- After optimization and restaging, select an evidence‑based non‑platinum systemic approach and assess eligibility for clear‑cell, platinum‑resistant clinical trials.\n\nROUND_2_FINAL_PLANS_JSON:\n{\"chair\":\"- Prioritize second-line systemic therapy for platinum-resistant clear cell ovarian carcinoma with visceral and bone metastases; deem surgery/radiation palliative only [@guideline:nccn_ovariancancer_v3_2025__v00000000|14; @report_id:2022-12-29|CT].  \\n\\n- Before finalizing regimen, urgently optimize anemia, assess ECOG, symptoms, and clarify goals; obtain full chemistry, coagulation, and updated pain/thromboembolism status [@report_id:20230103|5600862].  \\n\\n- Arrange comprehensive survivorship and trial-focused review including prior HRD-negative, BRCA‑wildtype status to consider non‑platinum, anti‑angiogenic, immunotherapy, or trial options in sequencing [@guideline:esmo_cpg_epithelialovarian_2023__v00000000|10; @report_id:OH2203828].\",\"oncologist\":\"- Urgently correct anemia (transfusion, iron/B12 workup), complete full labs, document ECOG, symptoms, comorbidities, and goals of care. [@20230103|2023-01-03]  \\n\\n- Restage with contrast CT chest/abdomen/pelvis, then coordinate palliative radiation for painful pelvic/sacral/right iliac disease and integrate palliative care. [@guideline:nccn_ovariancancer_v3_2025__v00000000|15]  \\n\\n- Send comprehensive molecular profiling (MSI, TMB, PD‑L1, broad panel/ctDNA); after optimization, select non‑platinum systemic/clinical‑trial strategy for platinum‑resistant clear cell disease. [@pubmed:33758607]\",\"radiologist\":\"- Obtain updated contrast-enhanced CT chest/abdomen/pelvis to restage since documented progression on Dec 2022 imaging [@2022-12-29|CT][@2022-12-29|MR].  \\n\\n- Use CT as primary tool for palliative RT planning to presacral/sacral/right iliac lesions; reserve PET/CT for equivocal sites [@guideline:nccn_ovariancancer_v3_2025__v00000000|22].  \\n\\n- Reassess splenic low-density lesion on new CT to distinguish evolving infarct from alternative pathology and guide need for further imaging [@2022-12-29|CT].\",\"pathologist\":\"- Proceed with comprehensive tumor profiling (MSI, TMB, PD‑L1, broad somatic panel) on recent tissue/ctDNA to expand options [@guideline:nccn_ovariancancer_v3_2025__v00000000|15].  \\n\\n- Maintain diagnosis of ovarian clear cell carcinoma with intact MMR and HRD-/BRCA1/2‑wild type status; ATM p.Y316C remains VUS [@HISTOLOGY_AND_IHC|2022-03-28].  \\n\\n- Ensure pathology–radiology correlation on new contrast CT (pelvis, sacrum/right iliac, spleen) to confirm sites for palliative radiation (report_id unknown|unknown).\",\"nuclear\":\"- Continue with updated contrast CT chest/abdomen/pelvis as primary restaging tool to guide palliative radiation planning [@2022-12-29|CT][@2022-12-29|MR].  \\n\\n- Reserve PET/CT for CT‑equivocal bone or splenic lesions where metabolic clarification would change radiation fields or local procedures [@guideline:nccn_ovariancancer_v3_2025__v00000000|22].  \\n\\n- No current evidence that PET/CT would alter systemic therapy choice in this established platinum‑resistant, widely metastatic setting [@guideline:nccn_ovariancancer_v3_2025__v00000000|22].\"}", "assistant_reply": "Key Knowledge:\n- Platinum‑resistant clear cell ovarian carcinoma with rapid progression and widespread involvement (pelvis, liver, sacrum/right iliac bone); surgery and radiation regarded as palliative only.\n- High symptom burden from painful pelvic/bony disease and severe anemia (Hgb 74 g/L), constraining systemic therapy intensity.\n- Pathology: ovarian clear cell carcinoma; MMR intact; HRD‑negative; BRCA1/2 wild‑type; germline ATM p.Y316C VUS; comprehensive somatic profiling (MSI, TMB, PD‑L1, broad panel) still pending.\n- Last imaging (Dec 2022 CT/MR) shows progressive pelvic/hepatic disease, sacral/right iliac involvement, and a splenic lesion suspicious for infarct; restaging CT planned as primary imaging tool.\n\nControversies:\n- Need for PET/CT beyond contrast CT, with consensus leaning to limit PET/CT to CT‑equivocal lesions that would change radiation fields/local interventions, as PET/CT is unlikely to alter systemic therapy.\n- Optimal selection and sequencing of non‑platinum systemic therapy (including potential anti‑angiogenic/immunotherapy and trials) given severe anemia and yet‑uncertain ECOG and comorbidities.\n- Clinical relevance of the ATM VUS for targeted approaches and clinical trial eligibility.\n\nMissing Info:\n- ECOG performance status, detailed symptom and pain profile, comorbidities, thromboembolism status, and patient goals of care.\n- Updated comprehensive labs: CBC, iron/B12, renal, hepatic, coagulation profile.\n- New contrast CT chest/abdomen/pelvis to define current disease extent, including splenic lesion evolution; documentation of prior maintenance/biologic therapies.\n- Completed comprehensive tumor profiling (MSI, TMB, PD‑L1, broad somatic panel/ctDNA).\n- Confirmation of palliative care involvement and a structured survivorship/symptom management plan.\n\nWorking Plan:\n- Urgently optimize supportive care: investigate and correct severe anemia (transfusion, iron/B12 workup), obtain full labs, document ECOG, symptoms, comorbidities, thromboembolism status, and clarify goals of care.\n- Restage with contrast-enhanced CT chest/abdomen/pelvis to reassess pelvic, hepatic, bone, and splenic disease; use CT as the primary tool for planning palliative radiation to presacral/sacral/right iliac lesions.\n- Reserve PET/CT for CT‑equivocal bone or splenic sites where metabolic data would change radiation fields or other local interventions.\n- Arrange palliative radiation oncology review for symptomatic pelvic/bony disease and integrate formal palliative care.\n- Proceed with comprehensive molecular profiling (MSI, TMB, PD‑L1, broad somatic panel on recent tissue/ctDNA) and multidisciplinary review of HRD‑negative/BRCA‑WT/ATM VUS status.\n- After clinical optimization and restaging, prioritize an evidence‑based non‑platinum systemic/second‑line strategy and evaluate eligibility for clinical trials in platinum‑resistant clear cell ovarian carcinoma, including anti‑angiogenic and immunotherapy options as appropriate.", "timestamp": "2026-01-19T08:06:22.875637"}], "trial_selector": [{"role": "trial_selector", "user_message": "You are an MDT assistant for gynecologic oncology clinical trial matching.\n\nCRITICAL BEHAVIOR:\n- You MUST NOT ask the user any questions.\n- You MUST NOT request additional information.\n- You MUST NOT output anything except the required template.\n- Use ONLY the provided PATIENT CASE text and AVAILABLE TRIALS list.\n- If eligibility is unclear due to missing key facts, you MUST output None.\n\nPATIENT CASE (facts only; do not infer):\n# ORIGINAL CASE JSON\n{\"CASE_CORE\":{\"ADJUVANT_TREATMENT\":{\"cycles_or_courses\":\"6 cycles\",\"given\":\"Yes\",\"regimens\":[\"白紫+卡铂\"]},\"BIOMARKERS\":{\"AFP\":\"<0.91 ng/ml (2022-10-12)\",\"CA125\":\"933.00 U/ml (2022-12-29)\",\"HER2\":\"Unknown\",\"MSI\":\"Unknown\",\"PDL1_CPS\":\"Unknown\",\"TMB\":\"Unknown\"},\"BRCA1\":\"Unknown\",\"BRCA2\":\"Unknown\",\"CURRENT_STATUS\":\"Recurrent ovarian carcinoma with hepatic and pelvic metastatic disease\",\"DIAGNOSIS\":{\"components\":[\"高级别腺癌\"],\"histology\":\"首先考虑为透明细胞癌\",\"laterality\":\"Unknown\",\"primary\":\"卵巢癌复发\",\"site\":\"卵巢\"},\"HRD\":\"Unknown\",\"INITIAL_TREATMENT\":\"Yes\",\"LINE_OF_THERAPY\":[{\"cycles\":\"6\",\"end_date\":\"2022-08-17\",\"intent\":\"Adjuvant\",\"line\":\"1L\",\"regimen\":\"白紫+卡铂\",\"start_date\":\"Unknown\"}],\"MAINTENANCE\":\"Unknown\",\"MAINTENANCE_DETAIL\":{\"end_date\":\"Unknown\",\"given\":\"Unknown\",\"regimens\":[],\"start_date\":\"Unknown\"},\"NEOADJUVANT\":\"Unknown\",\"PFI_days\":\"56\",\"PLATINUM_HISTORY\":[{\"PFI_days\":\"56\",\"end_date\":\"2022-08-17\",\"evidence\":\"CA125:89.60U/ml (2022-10-12)\",\"evidence_type\":\"Biochemical\",\"first_relapse_date\":\"2022-10-12\",\"line\":\"1L\",\"start_date\":\"Unknown\",\"status\":\"Resistant\"}],\"PLATINUM_PFI_CURRENT\":\"56\",\"PLATINUM_STATUS\":\"Resistant\",\"PLATINUM_STATUS_CURRENT\":\"Resistant\",\"RELAPSE\":\"Yes\",\"RELAPSE_DATE\":{\"date\":\"2022-10-12\",\"evidence\":\"CA125:89.60U/ml\",\"type\":\"Biochemical\"},\"SCENE\":\"Platinum_resistant_relapse\",\"STAGE\":{\"stage_basis\":\"Unknown\",\"stage_system\":\"Unknown\",\"stage_text\":\"Unknown\"},\"SURGERY_DONE\":{\"date\":\"2022-03-28\",\"performed\":\"Yes\",\"procedure\":\"Debulking surgery + partial rectosigmoid resection + partial vaginectomy + retroperitoneal lesion resection + complex adhesiolysis + left ureteral stent placement + bladder repair\"},\"TIMELINE\":{\"constraints\":{\"max_events\":30,\"min_events\":3,\"must_include\":[\"first diagnostic imaging or pathology confirmation (if available)\"],\"ordering_rules\":{\"prioritize_last_event\":true}},\"events\":[{\"date\":\"2022-03-28\",\"description\":\"Debulking surgery with multiple procedures (partial rectosigmoid resection, partial vaginectomy, retroperitoneal lesion resection, left ureteral stent, bladder repair)\",\"event_type\":\"Surgery\",\"key_result\":\"Tumor ~7*4*2.5cm; full-thickness intestinal wall high-grade adenocarcinoma; consider clear cell carcinoma\",\"regimen_or_test\":\"Surgery\"},{\"date\":\"2022-08-17\",\"description\":\"Postoperative chemotherapy completed: 白紫+卡铂, 6 cycles\",\"event_type\":\"Chemo\",\"key_result\":\"Last administration recorded 2022-08-17\",\"regimen_or_test\":\"白紫+卡铂\"},{\"date\":\"2022-10-12\",\"description\":\"Tumor markers rising after chemotherapy\",\"event_type\":\"Lab\",\"key_result\":\"CA19-9:77.20U/ml; CA125:89.60U/ml; AFP:<0.91ng/ml\",\"regimen_or_test\":\"CA125, CA19-9, HE4, AFP\"},{\"date\":\"2022-10-24\",\"description\":\"MRI: pelvic post-op, presacral mass increased; pelvic mesenteric enhancing nodules\",\"event_type\":\"Imaging\",\"key_result\":\"Consider recurrence with adjacent sacral involvement; pelvic mesenteric nodules suggest metastases\",\"regimen_or_test\":\"MRI pelvis\"},{\"date\":\"2022-10-25\",\"description\":\"CT: multiple hepatic nodules, some new, likely metastases\",\"event_type\":\"Imaging\",\"key_result\":\"Multiple liver lesions, consider metastases\",\"regimen_or_test\":\"CT abdomen\"},{\"date\":\"2022-12-29\",\"description\":\"Tumor markers markedly elevated\",\"event_type\":\"Lab\",\"key_result\":\"CA19-9:229.00U/ml; CA125:933.00U/ml; HE4:111.00pmol/L\",\"regimen_or_test\":\"CA125, CA19-9, HE4, CA15-3\"},{\"date\":\"2022-12-30\",\"description\":\"MRI and CT show progression: increased presacral mass, new right iliac bone lesion, more hepatic metastases\",\"event_type\":\"Imaging\",\"key_result\":\"Pelvic presacral mass increased; right iliac bone enhancing nodule; hepatic metastases increased\",\"regimen_or_test\":\"MRI pelvis, CT abdomen\"}]},\"VISIT_DATE\":\"2023-01-03\",\"first_relapse_date\":\"2022-10-12\",\"last_platinum_end_date\":\"2022-08-17\"},\"LAB_TRENDS\":{\"labs\":[{\"analyte\":\"CA125\",\"history\":[{\"date\":\"Unknown\",\"flag\":\"Unknown\",\"value\":\"45.7\"},{\"date\":\"2022-08-15\",\"flag\":\"Unknown\",\"value\":\"14.90\"},{\"date\":\"2022-10-12\",\"flag\":\"↑\",\"value\":\"89.60\"},{\"date\":\"2022-11-17\",\"flag\":\"Unknown\",\"value\":\"403\"},{\"date\":\"2022-12-29\",\"flag\":\"↑\",\"value\":\"933.00\"}],\"latest\":{\"date\":\"2022-12-29\",\"flag\":\"↑\",\"value\":\"933.00\"},\"reference_range\":\"Unknown\",\"unit\":\"U/ml\"},{\"analyte\":\"CA19-9\",\"history\":[{\"date\":\"Unknown\",\"flag\":\"Unknown\",\"value\":\"161\"},{\"date\":\"2022-08-15\",\"flag\":\"Unknown\",\"value\":\"7.16\"},{\"date\":\"2022-10-12\",\"flag\":\"↑\",\"value\":\"77.20\"},{\"date\":\"2022-12-29\",\"flag\":\"↑\",\"value\":\"229.00\"}],\"latest\":{\"date\":\"2022-12-29\",\"flag\":\"↑\",\"value\":\"229.00\"},\"reference_range\":\"Unknown\",\"unit\":\"U/ml\"},{\"analyte\":\"HE4\",\"history\":[{\"date\":\"Unknown\",\"flag\":\"Unknown\",\"value\":\"562\"},{\"date\":\"2022-08-15\",\"flag\":\"↑\",\"value\":\"87.90\"},{\"date\":\"2022-10-12\",\"flag\":\"Unknown\",\"value\":\"59.70\"},{\"date\":\"2022-12-29\",\"flag\":\"↑\",\"value\":\"111.00\"}],\"latest\":{\"date\":\"2022-12-29\",\"flag\":\"↑\",\"value\":\"111.00\"},\"reference_range\":\"Unknown\",\"unit\":\"pmol/L\"},{\"analyte\":\"AFP\",\"history\":[{\"date\":\"2022-10-12\",\"flag\":\"Unknown\",\"value\":\"<0.91\"}],\"latest\":{\"date\":\"2022-10-12\",\"flag\":\"Unknown\",\"value\":\"<0.91\"},\"reference_range\":\"Unknown\",\"unit\":\"ng/ml\"},{\"analyte\":\"Hb\",\"history\":[{\"date\":\"2022-11-10\",\"flag\":\"Unknown\",\"value\":\"97\"},{\"date\":\"2022-11-30\",\"flag\":\"Unknown\",\"value\":\"94\"}],\"latest\":{\"date\":\"2022-11-30\",\"flag\":\"Unknown\",\"value\":\"94\"},\"reference_range\":\"Unknown\",\"unit\":\"g/L\"}],\"milestones\":[{\"date\":\"2022-03-28\",\"description\":\"Primary debulking surgery\",\"type\":\"Surgery\"},{\"date\":\"2022-08-17\",\"description\":\"Completed 6 cycles of 白紫+卡铂\",\"type\":\"ChemoEnd\"},{\"date\":\"2022-10-12\",\"description\":\"Biochemical relapse with rising CA125\",\"type\":\"Relapse\"}]},\"MED_ONC\":{\"current_regimen\":{\"cycle_info\":\"Unknown\",\"last_admin_date\":\"Unknown\",\"name\":\"Unknown\"},\"genetic_testing\":{\"germline\":[],\"somatic\":[]},\"monitoring_points\":[],\"planned_next_regimen\":\"Unknown\",\"prior_systemic_therapies\":[\"白紫+卡铂 (6 cycles)\"]},\"NUC_MED\":{\"studies\":[]},\"PATHOLOGY\":{\"specimens\":[{\"components\":[\"高级别腺癌\"],\"date\":\"2022-03-28\",\"diagnosis\":\"部分直乙结肠+左侧腹膜后肿瘤+部分阴道: 肠壁全层见高级别腺癌，结合T2022-04771首先考虑为透明细胞癌；可符合卵巢透明细胞癌累及。\",\"grade\":\"Unknown\",\"ihc\":[{\"marker\":\"MLH1\",\"result\":\"(+)\"},{\"marker\":\"MSH6\",\"result\":\"(+)\"},{\"marker\":\"MSH2\",\"result\":\"(+)\"},{\"marker\":\"PMS2\",\"result\":\"(+)\"},{\"marker\":\"ER\",\"result\":\"(部分+)\"},{\"marker\":\"PR\",\"result\":\"(少弱+)\"},{\"marker\":\"P53\",\"result\":\"(+/-)\"},{\"marker\":\"WT1\",\"result\":\"(-)\"},{\"marker\":\"Ki-67\",\"result\":\"(60%+)\"},{\"marker\":\"HNF1B\",\"result\":\"(+)\"},{\"marker\":\"NapsinA\",\"result\":\"(灶+)\"},{\"marker\":\"P16\",\"result\":\"(+)\"},{\"marker\":\"PAX8\",\"result\":\"(+)\"},{\"marker\":\"SALL4\",\"result\":\"(-)\"},{\"marker\":\"ZBTB16\",\"result\":\"(-)\"}],\"involvement_sites\":[\"intestinal wall full thickness\",\"peritoneum (left retroperitoneal tumor)\",\"vagina (partial)\"],\"laterality\":\"Unknown\",\"molecular\":[],\"raw_text\":\"2022.03.28在全麻下行“瘤体减灭术+直肠乙状结肠部分切除术+阴道部分切除术+腹膜后病损切除术+复杂肠粘连松解术+左输尿管支架置管术+膀胱修补术。（部分直乙结肠+左侧腹膜后肿瘤+部分阴道）肠壁全层见高级别腺癌，结合T2022-04771首先考虑为透明细胞癌，正在加做免疫组化进一步明确。肿块大小约7*4*2.5cm。双侧切缘阴性，肠周淋巴结（4/15）见癌转移，伴癌结节1枚。（膀胱后壁肿瘤）纤维脂肪组织，局灶纤维组织增生、含铁血黄素沉积、泡沫样组织反应，未见癌累及。补充诊断1：【补充报告】（部分直乙结肠+左侧腹膜后肿瘤+部分阴道）可符合卵巢透明细胞癌累及。免疫组化（HI22-06789）瘤细胞：MLH1(ES05)（+），MSH6（+），MSH2（+），PMS2（+），ER（部分+），PR（少弱+），P53（+/-），WT1（-），Ki-67（60%+），HNF1B（+），NapsinA（灶+），P16（+），PAX8（+），SALL4（-），ZBTB16（-）\",\"sample_type\":\"Surgical resection\",\"site\":\"partial rectosigmoid + left retroperitoneal tumor + partial vagina\",\"tumor_size\":\"7*4*2.5cm\",\"uncertainty_or_missing\":[\"Molecular/genetic testing not reported\",\"Definitive origin laterality not specified\"]}]},\"RADIOLOGY\":{\"next_imaging_plan\":{\"modality\":\"Unknown\",\"timing\":\"Unknown\"},\"studies\":[{\"anatomic_sites\":[\"pelvis\",\"sacrum\"],\"date\":\"2022-10-24\",\"findings\":[\"Pelvis post-op changes\",\"presacral mass, consider recurrence with adjacent sacral involvement\",\"multiple enhancing small mesenteric nodules in pelvis, suggest metastases\"],\"impression\":\"Recurrence with possible sacral involvement and pelvic mesenteric metastases\",\"modality\":\"MRI\",\"trend_vs_prior\":\"Worse\"},{\"anatomic_sites\":[\"liver\"],\"date\":\"2022-10-25\",\"findings\":[\"Multiple hepatic nodules, some new compared to prior\",\"hepatic cysts unchanged\"],\"impression\":\"Multiple liver lesions, consider metastases\",\"modality\":\"CT\",\"trend_vs_prior\":\"Worse\"},{\"anatomic_sites\":[\"pelvis\",\"right iliac bone\",\"sacrum\",\"rectum\"],\"date\":\"2022-12-30\",\"findings\":[\"Presacral mass increased in range with heterogeneous enhancement\",\"new enhancing nodule in right iliac bone\",\"multiple pelvic mesenteric enhancing nodules\",\"rectal local bowel wall thickening with enhancement\"],\"impression\":\"Progressive pelvic recurrence with possible peritoneal and sacral involvement; new right iliac bone lesion\",\"modality\":\"MRI\",\"trend_vs_prior\":\"Worse\"},{\"anatomic_sites\":[\"liver\",\"spleen\"],\"date\":\"2022-12-30\",\"findings\":[\"Multiple hepatic metastatic nodules increased in number and size\",\"patchy splenic shadow, possible splenic infarct\"],\"impression\":\"Progressive hepatic metastases; splenic abnormality noted, follow-up suggested\",\"modality\":\"CT\",\"trend_vs_prior\":\"Worse\"}]},\"TIMELINE\":{\"constraints\":{\"max_events\":30,\"min_events\":3,\"must_include\":[\"first diagnostic imaging or pathology confirmation (if available)\"],\"ordering_rules\":{\"prioritize_last_event\":true}},\"events\":[{\"date\":\"2022-03-28\",\"description\":\"Debulking surgery with multiple procedures (partial rectosigmoid resection, partial vaginectomy, retroperitoneal lesion resection, left ureteral stent, bladder repair)\",\"event_type\":\"Surgery\",\"key_result\":\"Tumor ~7*4*2.5cm; full-thickness intestinal wall high-grade adenocarcinoma; consider clear cell carcinoma\",\"regimen_or_test\":\"Surgery\"},{\"date\":\"2022-08-17\",\"description\":\"Postoperative chemotherapy completed: 白紫+卡铂, 6 cycles\",\"event_type\":\"Chemo\",\"key_result\":\"Last administration recorded 2022-08-17\",\"regimen_or_test\":\"白紫+卡铂\"},{\"date\":\"2022-10-12\",\"description\":\"Tumor markers rising after chemotherapy\",\"event_type\":\"Lab\",\"key_result\":\"CA19-9:77.20U/ml; CA125:89.60U/ml; AFP:<0.91ng/ml\",\"regimen_or_test\":\"CA125, CA19-9, HE4, AFP\"},{\"date\":\"2022-10-24\",\"description\":\"MRI: pelvic post-op, presacral mass increased; pelvic mesenteric enhancing nodules\",\"event_type\":\"Imaging\",\"key_result\":\"Consider recurrence with adjacent sacral involvement; pelvic mesenteric nodules suggest metastases\",\"regimen_or_test\":\"MRI pelvis\"},{\"date\":\"2022-10-25\",\"description\":\"CT: multiple hepatic nodules, some new, likely metastases\",\"event_type\":\"Imaging\",\"key_result\":\"Multiple liver lesions, consider metastases\",\"regimen_or_test\":\"CT abdomen\"},{\"date\":\"2022-12-29\",\"description\":\"Tumor markers markedly elevated\",\"event_type\":\"Lab\",\"key_result\":\"CA19-9:229.00U/ml; CA125:933.00U/ml; HE4:111.00pmol/L\",\"regimen_or_test\":\"CA125, CA19-9, HE4, CA15-3\"},{\"date\":\"2022-12-30\",\"description\":\"MRI and CT show progression: increased presacral mass, new right iliac bone lesion, more hepatic metastases\",\"event_type\":\"Imaging\",\"key_result\":\"Pelvic presacral mass increased; right iliac bone enhancing nodule; hepatic metastases increased\",\"regimen_or_test\":\"MRI pelvis, CT abdomen\"}]}}\n\n# MUTATION / GENETIC REPORTS (Full Text for Trial Matching)\n## Mutation Report 1 (ID: OH2203828, Date: 2022-04-18)\nATM NM_000051:exon8:c.A947G:p.Y316C（胚系）；HRD 阴性；BRCA1 胚系和体系未检出致病突变（视为阴性）；BRCA2 胚系和体系未检出致病突变（视为阴性）；TP53 胚系和体系未检出致病突变（视为阴性）；ARID1A 胚系和体系未检出致病突变（视为阴性）；PTEN 胚系和体系未检出致病突变（视为阴性）；PIK3CA 胚系和体系未检出致病突变（视为阴性）；PALB2 胚系和体系未检出致病突变（视为阴性）；RAD51D 胚系和体系未检出致病突变（视为阴性）；BRIP1 胚系和体系未检出致病突变（视为阴性）；BARD1 胚系和体系未检出致病突变（视为阴性）\n\n\nAVAILABLE TRIALS (compact; use id/name exactly as shown):\n[\n  {\n    \"id\": \"340\",\n    \"name\": \"阿得贝利单抗联合贝伐珠单抗新辅助治疗宫颈癌的单中心、单臂的探索性临床研究\",\n    \"phase\": \"Ⅱ\",\n    \"conditions\": null,\n    \"line_of_therapy\": \"NACT\",\n    \"biomarker\": null,\n    \"doctor\": \"裴 璇\",\n    \"sponsor\": \"IIT 复旦大学附属肿瘤医院\",\n    \"lead_or_participation\": \"牵头\",\n    \"treatment\": \"单臂研究\\n\\n阿得贝利单抗注射液（抗PD-L1 单抗）\\n\\n+贝伐珠单抗注射液\",\n    \"key_inclusion\": \"1、T1b3/T2a2/T2bNxM0期宫颈鳞癌、腺癌、腺鳞癌的患者\\n\\n2. 未接受过针对宫颈癌的系统性或局部抗肿瘤治疗，包括放疗、化疗、免疫治疗、生物制剂、小分子靶向治疗等\\n\\n3. 同意接受根治性子宫切除术治疗，且研究者判断无手术禁忌的患者\",\n    \"key_exclusion\": \"\",\n    \"contacts\": [\n      \"周 琳\"\n    ],\n    \"phones\": [\n      \"15202340966\"\n    ],\n    \"_raw\": {\n      \"id\": \"340\",\n      \"项目名称\": \"阿得贝利单抗联合贝伐珠单抗新辅助治疗宫颈癌的单中心、单臂的探索性临床研究\",\n      \"医生\": \"裴 璇\",\n      \"试验治疗/用药\": \"单臂研究<br />\\r\\n阿得贝利单抗注射液（抗PD-L1 单抗）<br />\\r\\n+贝伐珠单抗注射液<br />\",\n      \"期别\": \"Ⅱ\",\n      \"申请单位\": \"IIT 复旦大学附属肿瘤医院\",\n      \"牵头/参与\": \"牵头\",\n      \"目标受试者治疗线数\": \"NACT\",\n      \"入组排除标准\": \"1、T1b3/T2a2/T2bNxM0期宫颈鳞癌、腺癌、腺鳞癌的患者<br />\\r\\n2. 未接受过针对宫颈癌的系统性或局部抗肿瘤治疗，包括放疗、化疗、免疫治疗、生物制剂、小分子靶向治疗等<br />\\r\\n3. 同意接受根治性子宫切除术治疗，且研究者判断无手术禁忌的患者<br />\",\n      \"联系人\": [\n        \"周 琳\"\n      ],\n      \"联系电话\": [\n        \"15202340966\"\n      ]\n    }\n  },\n  {\n    \"id\": \"341\",\n    \"name\": \"一项Volrustomig治疗含铂类同步放化疗后未进展的高风险局部晚期宫颈癌女性的随机、双盲、安慰剂对照、多中心、全球III期研究\",\n    \"phase\": \"Ⅲ\",\n    \"conditions\": null,\n    \"line_of_therapy\": \" 适宜接受CCRT治疗 IIIA至IVA期，M0的CC患者\",\n    \"biomarker\": null,\n    \"doctor\": \"朱 俊\",\n    \"sponsor\": \"阿斯利康全球研发（中国）有限公司\",\n    \"lead_or_participation\": \"全球协调 （国内组长单位：重庆省肿瘤医院）\",\n    \"treatment\": \"Volrustomig（MEDI5752）（抗PD-1/CTLA-4双抗）750 mg/安慰剂，IV，q3w\",\n    \"key_inclusion\": \"1、组织学确诊的宫颈鳞癌、腺癌、腺鳞癌\\n\\n2、适宜接受CCRT治疗，影像学分期：FIGO 2018 IIIA至IVA期，M0\",\n    \"key_exclusion\": \"\",\n    \"contacts\": [\n      \"江文艳\"\n    ],\n    \"phones\": [\n      \"15664735519\"\n    ],\n    \"_raw\": {\n      \"id\": \"341\",\n      \"项目名称\": \"一项Volrustomig治疗含铂类同步放化疗后未进展的高风险局部晚期宫颈癌女性的随机、双盲、安慰剂对照、多中心、全球III期研究\",\n      \"医生\": \"朱 俊\",\n      \"试验治疗/用药\": \"Volrustomig（MEDI5752）（抗PD-1/CTLA-4双抗）750 mg/安慰剂，IV，q3w\",\n      \"期别\": \"Ⅲ\",\n      \"申请单位\": \"阿斯利康全球研发（中国）有限公司\",\n      \"牵头/参与\": \"全球协调 （国内组长单位：重庆省肿瘤医院）\",\n      \"目标受试者治疗线数\": \" 适宜接受CCRT治疗 IIIA至IVA期，M0的CC患者\",\n      \"入组排除标准\": \"1、组织学确诊的宫颈鳞癌、腺癌、腺鳞癌<br />\\r\\n2、适宜接受CCRT治疗，影像学分期：FIGO 2018 IIIA至IVA期，M0<br />\",\n      \"联系人\": [\n        \"江文艳\"\n      ],\n      \"联系电话\": [\n        \"15664735519\"\n      ]\n    }\n  },\n  {\n    \"id\": \"342\",\n    \"name\": \"一项评价SG001注射液加含铂化疗联合/不联合贝伐珠单抗用于一线治疗PD-L1阳性（CPS≥1）的复发或转移性宫颈癌的有效性和安全性的随机、双盲、安慰剂对照、多中心的III期临床研究\",\n    \"phase\": \"Ⅲ\",\n    \"conditions\": null,\n    \"line_of_therapy\": \"1L\",\n    \"biomarker\": null,\n    \"doctor\": \"裴 璇\",\n    \"sponsor\": \" 石药集团中奇制药技术（石家庄）有限公司\",\n    \"lead_or_participation\": \"参与（牵头单位：中国医学科学院肿瘤医院）\",\n    \"treatment\": \"随机双盲对照\\n\\nSG001/安慰剂（抗 PD-1 单抗）\\n\\n+紫杉醇\\n\\n+顺铂/卡铂\\n\\n±贝伐珠单抗注射液\",\n    \"key_inclusion\": \"1、病理类型：宫颈鳞癌、腺癌、腺鳞癌\\n\\n2、复发或转移性（既往化疗不能超过4周期，末次化疗时间到复发或转移时间大于12个月）及未接受过任何针对复发或转移性宫颈癌的全身系统性抗肿瘤治疗\\n\\n3、PD-L1 表达阳性（CPS≥1）（知情后检测）\",\n    \"key_exclusion\": \"\",\n    \"contacts\": [\n      \"肖含笑\"\n    ],\n    \"phones\": [\n      \"15956367593\"\n    ],\n    \"_raw\": {\n      \"id\": \"342\",\n      \"项目名称\": \"一项评价SG001注射液加含铂化疗联合/不联合贝伐珠单抗用于一线治疗PD-L1阳性（CPS≥1）的复发或转移性宫颈癌的有效性和安全性的随机、双盲、安慰剂对照、多中心的III期临床研究\",\n      \"医生\": \"裴 璇\",\n      \"试验治疗/用药\": \"随机双盲对照<br />\\r\\nSG001/安慰剂（抗 PD-1 单抗）<br />\\r\\n+紫杉醇<br />\\r\\n+顺铂/卡铂<br />\\r\\n±贝伐珠单抗注射液<br />\",\n      \"期别\": \"Ⅲ\",\n      \"申请单位\": \" 石药集团中奇制药技术（石家庄）有限公司\",\n      \"牵头/参与\": \"参与（牵头单位：中国医学科学院肿瘤医院）\",\n      \"目标受试者治疗线数\": \"1L\",\n      \"入组排除标准\": \"1、病理类型：宫颈鳞癌、腺癌、腺鳞癌<br />\\r\\n2、复发或转移性（既往化疗不能超过4周期，末次化疗时间到复发或转移时间大于12个月）及未接受过任何针对复发或转移性宫颈癌的全身系统性抗肿瘤治疗<br />\\r\\n3、PD-L1 表达阳性（CPS≥1）（知情后检测）<br />\\r\\n<div>\\r\\n\\t<br />\\r\\n</div>\",\n      \"联系人\": [\n        \"肖含笑\"\n      ],\n      \"联系电话\": [\n        \"15956367593\"\n      ]\n    }\n  },\n  {\n    \"id\": \"343\",\n    \"name\": \"信迪利单抗联合贝伐珠单抗治疗复发或转移性宫颈癌的单臂、开放、单中心的II期临床研究\",\n    \"phase\": \"Ⅱ\",\n    \"conditions\": null,\n    \"line_of_therapy\": \"≥2线\",\n    \"biomarker\": null,\n    \"doctor\": \"黄 妍\",\n    \"sponsor\": \"IIT 复旦大学附属肿瘤医院\",\n    \"lead_or_participation\": \"牵头\",\n    \"treatment\": \"信迪利单抗注射液\\n\\n+贝伐珠单抗注射液\",\n    \"key_inclusion\": \"1、病理类型：宫颈鳞癌、腺癌、腺鳞癌\\n\\n2、不适宜手术/根治性放疗的患者\",\n    \"key_exclusion\": \"\",\n    \"contacts\": [\n      \"黄 妍\"\n    ],\n    \"phones\": [\n      \"18017317141\"\n    ],\n    \"_raw\": {\n      \"id\": \"343\",\n      \"项目名称\": \"信迪利单抗联合贝伐珠单抗治疗复发或转移性宫颈癌的单臂、开放、单中心的II期临床研究\",\n      \"医生\": \"黄 妍\",\n      \"试验治疗/用药\": \"信迪利单抗注射液<br />\\r\\n+贝伐珠单抗注射液<br />\",\n      \"期别\": \"Ⅱ\",\n      \"申请单位\": \"IIT 复旦大学附属肿瘤医院\",\n      \"牵头/参与\": \"牵头\",\n      \"目标受试者治疗线数\": \"≥2线\",\n      \"入组排除标准\": \"1、病理类型：宫颈鳞癌、腺癌、腺鳞癌<br />\\r\\n2、不适宜手术/根治性放疗的患者<br />\",\n      \"联系人\": [\n        \"黄 妍\"\n      ],\n      \"联系电话\": [\n        \"18017317141\"\n      ]\n    }\n  },\n  {\n    \"id\": \"344\",\n    \"name\": \"9MW2821对比研究者选择的化疗治疗含铂化疗失败的复发或转移性宫颈癌的随机、开放、对照、多中心Ⅲ期临床研究\",\n    \"phase\": \"Ⅲ\",\n    \"conditions\": null,\n    \"line_of_therapy\": \"2线\",\n    \"biomarker\": null,\n    \"doctor\": \"裴 璇\",\n    \"sponsor\": \"迈威（上海）生物科技股份有限公司\",\n    \"lead_or_participation\": \"共同牵头（医学科学院肿瘤吴令英）\",\n    \"treatment\": \"随机对照研究\\n\\n试验组：9MW2821（ADC，靶向Nectin-4，毒性分子：MMAE）\\n\\n对照组：研究者可选择的化疗方案\\n\\n吉西他滨、培美曲塞、拓扑替康\",\n    \"key_inclusion\": \"1、经标准治疗失败的且细胞学或组织病理学诊断明确的宫颈鳞癌、腺癌、腺鳞癌；\",\n    \"key_exclusion\": \"\",\n    \"contacts\": [\n      \"龚珊珊\"\n    ],\n    \"phones\": [\n      \"17373726445\"\n    ],\n    \"_raw\": {\n      \"id\": \"344\",\n      \"项目名称\": \"9MW2821对比研究者选择的化疗治疗含铂化疗失败的复发或转移性宫颈癌的随机、开放、对照、多中心Ⅲ期临床研究\",\n      \"医生\": \"裴 璇\",\n      \"试验治疗/用药\": \"随机对照研究<br />\\r\\n试验组：9MW2821（ADC，靶向Nectin-4，毒性分子：MMAE）<br />\\r\\n对照组：研究者可选择的化疗方案<br />\\r\\n吉西他滨、培美曲塞、拓扑替康<br />\",\n      \"期别\": \"Ⅲ\",\n      \"申请单位\": \"迈威（上海）生物科技股份有限公司\",\n      \"牵头/参与\": \"共同牵头（医学科学院肿瘤吴令英）\",\n      \"目标受试者治疗线数\": \"2线\",\n      \"入组排除标准\": \"1、经标准治疗失败的且细胞学或组织病理学诊断明确的宫颈鳞癌、腺癌、腺鳞癌；\",\n      \"联系人\": [\n        \"龚珊珊\"\n      ],\n      \"联系电话\": [\n        \"17373726445\"\n      ]\n    }\n  },\n  {\n    \"id\": \"345\",\n    \"name\": \" 评估JSKN003在中国晚期恶性实体瘤受试者中的安全性、耐受性、药代动力学/药效学以及抗肿瘤活性的I/II期临床研究\",\n    \"phase\": \"II期\",\n    \"conditions\": null,\n    \"line_of_therapy\": \"2、3、4L\",\n    \"biomarker\": null,\n    \"doctor\": \"李佳佳\",\n    \"sponsor\": \"江苏康宁杰瑞生物制药有限公司\",\n    \"lead_or_participation\": \"牵头\",\n    \"treatment\": \"JSKN003-102（ADC，靶向HER2，毒性分子：拓扑异构酶I 抑制剂）\",\n    \"key_inclusion\": \"1、HER2 表达（IHC≥1+）\\n\\n2、经标准治疗失败、不能耐受标准治疗\\n\\n或缺乏有效治疗手段的受试者；\",\n    \"key_exclusion\": \"\",\n    \"contacts\": [\n      \"王 涛\"\n    ],\n    \"phones\": [\n      \"18721569326\"\n    ],\n    \"_raw\": {\n      \"id\": \"345\",\n      \"项目名称\": \" 评估JSKN003在中国晚期恶性实体瘤受试者中的安全性、耐受性、药代动力学/药效学以及抗肿瘤活性的I/II期临床研究\",\n      \"医生\": \"李佳佳\",\n      \"试验治疗/用药\": \"JSKN003-102（ADC，靶向HER2，毒性分子：拓扑异构酶I 抑制剂）\",\n      \"期别\": \"II期\",\n      \"申请单位\": \"江苏康宁杰瑞生物制药有限公司\",\n      \"牵头/参与\": \"牵头\",\n      \"目标受试者治疗线数\": \"2、3、4L\",\n      \"入组排除标准\": \"1、HER2 表达（IHC≥1+）<br />\\r\\n2、经标准治疗失败、不能耐受标准治疗<br />\\r\\n或缺乏有效治疗手段的受试者；<br />\",\n      \"联系人\": [\n        \"王 涛\"\n      ],\n      \"联系电话\": [\n        \"18721569326\"\n      ]\n    }\n  },\n  {\n    \"id\": \"346\",\n    \"name\": \"一项评价Trastuzumab Deruxtecan (T-DXd DS-8201a）治疗选定 HER2过表达肿瘤患者的有效性和安全性的多中心、开放性 II期研究（ DESTINY-PanTumor03)\",\n    \"phase\": \"II期\",\n    \"conditions\": null,\n    \"line_of_therapy\": \"＞1线\",\n    \"biomarker\": null,\n    \"doctor\": \"朱 俊\",\n    \"sponsor\": \"阿斯利康投资（中国）有限公司\",\n    \"lead_or_participation\": \"牵头\",\n    \"treatment\": \"Trastuzumab Deruxtecan（ADC，靶向HER2，毒性分子：拓扑异构酶I 抑制剂）\",\n    \"key_inclusion\": \"1、可预筛检测HER2 要求HER2 过表达（IHC≥1+）\\n\\n2、经标准治疗失败、不能耐受标准治疗\\n\\n或缺乏有效治疗手段的受试者；\",\n    \"key_exclusion\": \"\",\n    \"contacts\": [\n      \"江文燕\"\n    ],\n    \"phones\": [\n      \"15664735519\"\n    ],\n    \"_raw\": {\n      \"id\": \"346\",\n      \"项目名称\": \"一项评价Trastuzumab Deruxtecan (T-DXd DS-8201a）治疗选定 HER2过表达肿瘤患者的有效性和安全性的多中心、开放性 II期研究（ DESTINY-PanTumor03)\",\n      \"医生\": \"朱 俊\",\n      \"试验治疗/用药\": \"Trastuzumab Deruxtecan（ADC，靶向HER2，毒性分子：拓扑异构酶I 抑制剂）\",\n      \"期别\": \"II期\",\n      \"申请单位\": \"阿斯利康投资（中国）有限公司\",\n      \"牵头/参与\": \"牵头\",\n      \"目标受试者治疗线数\": \"＞1线\",\n      \"入组排除标准\": \"1、可预筛检测HER2 要求HER2 过表达（IHC≥1+）<br />\\r\\n2、经标准治疗失败、不能耐受标准治疗<br />\\r\\n或缺乏有效治疗手段的受试者；<br />\",\n      \"联系人\": [\n        \"江文燕\"\n      ],\n      \"联系电话\": [\n        \"15664735519\"\n      ]\n    }\n  },\n  {\n    \"id\": \"347\",\n    \"name\": \"一项在晚期/转移性实体瘤患者中评价LB1410联合LB4330的Ib/II期、开放、剂量递增和扩展研究\",\n    \"phase\": \"II期\",\n    \"conditions\": null,\n    \"line_of_therapy\": \"2L、3L\",\n    \"biomarker\": null,\n    \"doctor\": \"郭勤浩\",\n    \"sponsor\": \"上海健信生物医药科技有限公司\",\n    \"lead_or_participation\": \"参与（组长单位：上海市东方医院）\",\n    \"treatment\": \"LB1410注射液（抗PD-1和TIM-3的人源化双特异抗体）\\n\\n+LB4330（抗CLDN18.2抗体/人IL-10的融合蛋白）\",\n    \"key_inclusion\": \"1、经组织学确诊的宫颈鳞癌；\\n\\n2、仅接受过1个治疗线的ICI治疗；\\n\\n3、接受ICI治疗后6月内进展，要求PD-L1表达阳性，CPS≥1/IPS≥1%/TPS≥1%\",\n    \"key_exclusion\": \"\",\n    \"contacts\": [\n      \"吴菡雨\"\n    ],\n    \"phones\": [\n      \"17638320253\"\n    ],\n    \"_raw\": {\n      \"id\": \"347\",\n      \"项目名称\": \"一项在晚期/转移性实体瘤患者中评价LB1410联合LB4330的Ib/II期、开放、剂量递增和扩展研究\",\n      \"医生\": \"郭勤浩\",\n      \"试验治疗/用药\": \"LB1410注射液（抗PD-1和TIM-3的人源化双特异抗体）<br />\\r\\n+LB4330（抗CLDN18.2抗体/人IL-10的融合蛋白）<br />\",\n      \"期别\": \"II期\",\n      \"申请单位\": \"上海健信生物医药科技有限公司\",\n      \"牵头/参与\": \"参与（组长单位：上海市东方医院）\",\n      \"目标受试者治疗线数\": \"2L、3L\",\n      \"入组排除标准\": \"1、经组织学确诊的宫颈鳞癌；<br />\\r\\n2、仅接受过1个治疗线的ICI治疗；<br />\\r\\n3、接受ICI治疗后6月内进展，要求PD-L1表达阳性，CPS≥1/IPS≥1%/TPS≥1%<br />\",\n      \"联系人\": [\n        \"吴菡雨\"\n      ],\n      \"联系电话\": [\n        \"17638320253\"\n      ]\n    }\n  },\n  {\n    \"id\": \"348\",\n    \"name\": \"一项评估MRG004A在组织因子阳性的晚期或转移性实体瘤患者中的安全性、耐受性、有效性和药代动力学的开放、多中心、I/II期剂量递增和扩展临床研究\",\n    \"phase\": \"I期\",\n    \"conditions\": null,\n    \"line_of_therapy\": \"2L、3L\",\n    \"biomarker\": null,\n    \"doctor\": \"郭勤浩、 Ⅰ期： 刘汝娇、 高水平、 陈 阳\",\n    \"sponsor\": \" 上海美雅珂生物技术有限责任公司\",\n    \"lead_or_participation\": \"牵头\",\n    \"treatment\": \"MRG004A（ADC，靶向组织因子（tissue factor，TF））\",\n    \"key_inclusion\": \"1、必须有组织学或细胞学证实的不切除或转移性肿瘤，标准治疗期间进展或经治后复发、进展。\",\n    \"key_exclusion\": \"\",\n    \"contacts\": [\n      \"杨 珂\"\n    ],\n    \"phones\": [\n      \"17774582517\"\n    ],\n    \"_raw\": {\n      \"id\": \"348\",\n      \"项目名称\": \"一项评估MRG004A在组织因子阳性的晚期或转移性实体瘤患者中的安全性、耐受性、有效性和药代动力学的开放、多中心、I/II期剂量递增和扩展临床研究\",\n      \"医生\": \"郭勤浩、 Ⅰ期： 刘汝娇、 高水平、 陈 阳\",\n      \"试验治疗/用药\": \"MRG004A（ADC，靶向组织因子（tissue factor，TF））\",\n      \"期别\": \"I期\",\n      \"申请单位\": \" 上海美雅珂生物技术有限责任公司\",\n      \"牵头/参与\": \"牵头\",\n      \"目标受试者治疗线数\": \"2L、3L\",\n      \"入组排除标准\": \"1、必须有组织学或细胞学证实的不切除或转移性肿瘤，标准治疗期间进展或经治后复发、进展。\",\n      \"联系人\": [\n        \"杨 珂\"\n      ],\n      \"联系电话\": [\n        \"17774582517\"\n      ]\n    }\n  },\n  {\n    \"id\": \"349\",\n    \"name\": \"评价自体肿瘤浸润淋巴细胞（C-TIL052A）联合IL-2（C-TIL052A细胞疗法）治疗转移或复发、持续性宫颈癌患者的安全性和有效性的I期临床研究\",\n    \"phase\": \"Ⅰ期\",\n    \"conditions\": null,\n    \"line_of_therapy\": \"≥2线\",\n    \"biomarker\": null,\n    \"doctor\": \"温 灏 、冯 征\",\n    \"sponsor\": \" 复旦大学附属肿瘤医院\",\n    \"lead_or_participation\": \"牵头\",\n    \"treatment\": \"C-TIL052A（自体肿瘤浸润淋巴细胞）\\n\\n+白细胞介素-2（IL-2）\",\n    \"key_inclusion\": \"1、标准治疗失败的转移或复发、持续性宫颈鳞癌患者\\n\\n2、经研究者评估可取得 1.0g 及以上的肿瘤组织样本（淋巴结除外）\",\n    \"key_exclusion\": \"\",\n    \"contacts\": [\n      \"郜兴云、郑成小\"\n    ],\n    \"phones\": [\n      \"17803905925、18301939758\"\n    ],\n    \"_raw\": {\n      \"id\": \"349\",\n      \"项目名称\": \"评价自体肿瘤浸润淋巴细胞（C-TIL052A）联合IL-2（C-TIL052A细胞疗法）治疗转移或复发、持续性宫颈癌患者的安全性和有效性的I期临床研究\",\n      \"医生\": \"温 灏 、冯 征\",\n      \"试验治疗/用药\": \"C-TIL052A（自体肿瘤浸润淋巴细胞）<br />\\r\\n+白细胞介素-2（IL-2）<br />\",\n      \"期别\": \"Ⅰ期\",\n      \"申请单位\": \" 复旦大学附属肿瘤医院\",\n      \"牵头/参与\": \"牵头\",\n      \"目标受试者治疗线数\": \"≥2线\",\n      \"入组排除标准\": \"1、标准治疗失败的转移或复发、持续性宫颈鳞癌患者<br />\\r\\n2、经研究者评估可取得 1.0g 及以上的肿瘤组织样本（淋巴结除外）<br />\",\n      \"联系人\": [\n        \"郜兴云、郑成小\"\n      ],\n      \"联系电话\": [\n        \"17803905925、18301939758\"\n      ]\n    }\n  }\n]\n\nDECISION RULE (be conservative):\nRecommend ONE trial ONLY IF ALL are true:\n1) Cancer type / primary site clearly matches.\n2) Disease setting clearly matches (e.g., recurrent/advanced/metastatic and line is not fundamentally unclear).\n3) Required biomarker/subtype is explicitly present in case text (if trial requires it).\n4) No more than 2 critical eligibility confirmations remain.\n\nIf ANY of the above is not satisfied -> output None.\n\nOUTPUT TEMPLATE (EXACT; no extra text):\n\nTrial Recommendation:\n- id: <trial id or None>\n- name: <trial name or None>\n- Reason: <1 short sentence>\n- Missing eligibility confirmations (0-2 items):\n  - item1 (or \"None\")\n  - item2", "assistant_reply": "Trial Recommendation:\n- id: None\n- name: None\n- Reason: Primary cancer is ovarian clear cell carcinoma, not cervical cancer as required by all available trials.\n- Missing eligibility confirmations (0-2 items):\n  - None\n  - None", "timestamp": "2026-01-19T08:06:26.359743"}]}, "trace_events": [{"ts": "2026-01-19T08:02:10.566313", "event": "pipeline_start", "payload": {"visit_time": "2023-01-03 08:53:29.260000", "meta_info": "340123197709263626"}}, {"ts": "2026-01-19T08:02:10.566765", "event": "case_fingerprint", "payload": {"case_fingerprint": "efe856c0897d"}}, {"ts": "2026-01-19T08:02:10.854067", "event": "reports_loaded", "payload": {"lab_n": 92, "img_n": 10, "path_n": 0, "mut_n": 1, "cutoff_dt": "2023-01-04 08:53:29"}}, {"ts": "2026-01-19T08:02:16.077482", "event": "reports_selected", "payload": {"lab": {"chair": ["20221229|8300002|2022-12-29", "20221229|9703212|2022-12-29", "20230103|5600862|2023-01-03"], "oncologist": ["20221229|8300002|2022-12-29", "20221229|9703212|2022-12-29", "20230103|5600862|2023-01-03"], "radiologist": [], "pathologist": [], "nuclear": []}, "imaging": {"chair": ["2022-10-24|CT|2022-10-24", "2022-12-29|MR|2022-12-29", "2022-12-29|CT|2022-12-29"], "oncologist": [], "radiologist": ["2022-10-24|CT|2022-10-24", "2022-12-29|MR|2022-12-29", "2022-12-29|CT|2022-12-29"], "pathologist": [], "nuclear": ["2022-10-24|CT|2022-10-24", "2022-12-29|MR|2022-12-29", "2022-12-29|CT|2022-12-29"]}, "pathology": {"chair": [], "oncologist": [], "radiologist": [], "pathologist": [], "nuclear": []}, "mutation": {"chair": ["OH2203828|2022-04-18"], "oncologist": ["OH2203828|2022-04-18"], "radiologist": [], "pathologist": ["OH2203828|2022-04-18"], "nuclear": []}}}, {"ts": "2026-01-19T08:02:16.082777", "event": "rag_key_facts", "payload": {"facts": "DIAGNOSIS: primary=卵巢癌复发; histology=首先考虑为透明细胞癌; components=高级别腺癌\nPATHOLOGY: 部分直乙结肠+左侧腹膜后肿瘤+部分阴道: 肠壁全层见高级别腺癌，结合T2022-04771首先考虑为透明细胞癌；可符合卵巢透明细胞癌累及。\nPLATINUM: status=Resistant; pfi_days=56\nGENETICS: HRD=Unknown; BRCA1=Unknown; BRCA2=Unknown\nBIOMARKERS: CA125=933.00 U/ml (2022-12-29); AFP=<0.91 ng/ml (2022-10-12); TMB=Unknown; MSI=Unknown; PDL1_CPS=Unknown\nMUTATION_REPORT: id=OH2203828; date=2022-04-18; note=ATM NM_000051:exon8:c.A947G:p.Y316C（胚系）；HRD 阴性；BRCA1 胚系和体系未检出致病突变（视为阴性）；BRCA2 胚系和体系未检出致病突变（视为阴性）；TP53 胚系和体系未检出致病突变（视为阴性）；ARID1A 胚系和体系未检出致病突变（视为阴性）；PTEN 胚系和体系未检出致病突变（视为阴性）；PIK3CA 胚系和体系未检出致病突变（视为阴性）；PAL…"}}, {"ts": "2026-01-19T08:02:43.918944", "event": "rag_query", "payload": {"query": "Ovarian clear cell carcinoma, platinum-refractory after 6 cycles carboplatin-based chemo; metastatic to liver, pelvic/peritoneal, sacrum/right iliac bone; MMR intact (MLH1/MSH2/MSH6/PMS2+); need systemic options and trial eligibility considering prior debulking and good organ function; histology: clear cell carcinoma"}}, {"ts": "2026-01-19T08:02:43.918949", "event": "rag_hits", "payload": {"source": "guideline", "topk": 5, "n": 5}}, {"ts": "2026-01-19T08:02:43.918951", "event": "rag_hits", "payload": {"source": "pubmed", "topk": 5, "n": 5}}, {"ts": "2026-01-19T08:02:43.918953", "event": "rag_hits_merged", "payload": {"n": 10}}, {"ts": "2026-01-19T08:02:53.245995", "event": "mdt_discussion_start", "payload": {"num_rounds": 2, "num_turns": 2}}, {"ts": "2026-01-19T08:02:53.246048", "event": "mdt_initial_opinion_role_start", "payload": {"role": "chair", "order": 1}}, {"ts": "2026-01-19T08:02:57.137244", "event": "mdt_initial_opinion_role_end", "payload": {"role": "chair", "chars": 835}}, {"ts": "2026-01-19T08:02:57.137326", "event": "mdt_initial_opinion_role_start", "payload": {"role": "oncologist", "order": 2}}, {"ts": "2026-01-19T08:03:00.463768", "event": "mdt_initial_opinion_role_end", "payload": {"role": "oncologist", "chars": 590}}, {"ts": "2026-01-19T08:03:00.463835", "event": "mdt_initial_opinion_role_start", "payload": {"role": "radiologist", "order": 3}}, {"ts": "2026-01-19T08:03:02.717913", "event": "mdt_initial_opinion_role_end", "payload": {"role": "radiologist", "chars": 454}}, {"ts": "2026-01-19T08:03:02.717987", "event": "mdt_initial_opinion_role_start", "payload": {"role": "pathologist", "order": 4}}, {"ts": "2026-01-19T08:03:05.472057", "event": "mdt_initial_opinion_role_end", "payload": {"role": "pathologist", "chars": 518}}, {"ts": "2026-01-19T08:03:05.472182", "event": "mdt_initial_opinion_role_start", "payload": {"role": "nuclear", "order": 5}}, {"ts": "2026-01-19T08:03:08.059129", "event": "mdt_initial_opinion_role_end", "payload": {"role": "nuclear", "chars": 503}}, {"ts": "2026-01-19T08:04:08.354548", "event": "evidence_tag_warning", "payload": {"role": "chair/final_round_1", "preview": "- Confirm performance status, symptom burden, and discuss goals; prioritize systemic therapy for platinum‑resistant clear cell histology and rapid metastatic pr…"}}, {"ts": "2026-01-19T08:06:22.875859", "event": "mdt_discussion_end", "payload": {"merged_chars": 2975}}, {"ts": "2026-01-19T08:06:22.878422", "event": "trial_matching_start", "payload": {"trials_json_path": "files/all_trials_filtered.json"}}, {"ts": "2026-01-19T08:06:26.359770", "event": "trial_matching_end", "payload": {"recommended": false}}, {"ts": "2026-01-19T08:06:26.359783", "event": "final_output_start", "payload": {}}, {"ts": "2026-01-19T08:07:06.807942", "event": "final_output_end", "payload": {"final_output_chars": 628}}], "trace_mermaid": "flowchart TD\n  A[Load Case + Fingerprint] --> B[Load Reports]\n  B --> C[Report Selection per Role]\n  C --> D[Guideline+PubMed RAG]\n  D --> E[Init Specialist Agents]\n  E --> F[MDT Discussion Engine]\n  F --> G[Trial Matching]\n  G --> H[Final Chair Output]\n  H --> I[Save Logs]\n"}
